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Chemokines and chemokine receptors 
The G protein-coupled receptor (GPCR) family has emerged as the most 
important target for therapeutic intervention, as currently more than 60% of all 
known marketed drugs target GPCRs.1 Most of these small-molecule ligands are 
acting on class A biogenic amine receptors, such as the serotonin, histamine, 
adrenoceptors, and the muscarinic acetylcholine and dopamine receptors. 
Currently, also small molecules acting on other classes of the GPCR family are 
developed, especially those of the peptide or protein binding receptor classes.  
The chemokine receptor family is the largest subfamily of peptide-binding GPCRs 
described until now (Figure 1).2 Chemokine receptors play an important role in 
several disease processes, e.g. in cancer,3 acute and chronic inflammation, 
angiogenesis and angiostasis, and as co-receptors for the cellular entry of 
human immunodeficiency virus (HIV).2 These receptors are defined by their 
ability to signal on binding one or more members of the chemokine superfamily 
of small (8-14 kDa) chemotactic cytokines.  
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Figure 1. Topology of a chemokine receptor. The separate amino acids are shown as circles. The N-
terminus and the extracellular loops (EL) are located outside the cell, while the C-terminus resides 
intracellularly. The transmembrane regions (TM) are located in the membrane of the cell. Adapted from 
Fernandez et al.4  
 
Chemokines are classified into two major (CXC and CC) and two minor (C and 
CX3C) groups, dependent on the number and spacing of conserved cysteine 
residues in their amino terminus (Table 1 and 2).5 CXC, CC, and CX3C 
chemokines all have four conserved cysteine residues, whereas C chemokines 
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have only two, corresponding to the second and fourth cysteines in the other 
groups.6 CXC and CX3C chemokines are distinguished by the presence of one 
(CXC) or three (CX3C) amino acids between the first and second cysteine 
residues, whereas the first two cysteines in CC chemokines are adjacent. All 
chemokines consist of three beta sheets and an alpha helix, which separate the 
short N-terminus and the C-terminal domains. Interestingly, the different 
chemokines adopt a similar tertiary folding, even in cases of low overall 
sequence identity (varying from 20 to 95%).6  
 
Table 1. Overview of the CC chemokine receptors and their ligands.2,7 
CC Family of Chemokines and Chemokine Receptors 
Receptor Chemokine ligands Associated diseases 
CCR1 
CCL3 (MIP-1α), CCL5 (RANTES), 
CCL7 (MCP-3), CCL14 (HCC1) 
Rheumatoid arthritis, multiple sclerosis, allograft 
rejection 
CCR2 
CCL2 (MCP-1), CCL8 (MCP-2), 
CCL7, CCL13 (MCP-4), CCL16 
(HCC4) 
Atherosclerosis, rheumatoid arthritis, multiple 
sclerosis, asthma, resistance to intracellular 
pathogens, type 2 diabetes mellitus 
CCR3 
CCL5, CCL7, CCL8, CCL11 
(eotaxin), (MCP-2), CCL13, 
CCL24 
Allergic asthma, rhinitis, contact dermatitis 
CCR4 CCL17 (TARC), CCL22 (MDC) 
Parasitic infection, graft rejection, asthma, contact 
dermatitis, sepsis 
CCR5 
CCL3, CCL4 (MIP-1β), CCL5, 
CCL11, CCL14, CCL16 
HIV-1 co-receptor, allograft rejection, multiple 
sclerosis, rheumatoid arthritis 
CCR6 CCL20 (MIP-3β, LARC) Mucosal humoral immunity, allergic asthma, psoriasis 
CCR7 CCL19 (ELC), CCL21 (SLC) Cancer 
CCR8 CCL1 (1309) Atopic dermatitis, asthma 
CCR9 CCL25 (TECK) Intestinal inflammation, inflammatory bowel disease 
CCR10 CCL27 (CTACK), CCL28 (MEC) 
Skin inflammation and endothelium, dermal skin and 
colon ulcerative colitis. 
 
Currently, approximately 45 chemokines and 19 chemokine receptors have been 
identified in humans.8 These numbers are still growing, because chemokines 
exist for which the receptor has not yet been identified. Morover, there are 
several protein sequences with high homology to chemokine receptors for which 
the ligand is unknown and are thus considered as orphan receptors.9  
 
Binding of chemokines to their cognate receptors is remarkable promiscuous and 
redundant. Most chemokine receptors can bind more than one chemokine and 
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most chemokines can activate several different chemokine receptors.10 
However, binding to chemokine receptors is almost always restricted to a single 
subclass of chemokines, so CC chemokine receptors can only be activated by CC 
chemokines, while CXC chemokines only bind to CXC chemokine receptors.6 
Only the promiscuous chemokine binding proteins D6 and DARC (Duffy antigen 
receptor for chemokines) and the human cytomegalovirus (HCMV) encoded 
receptor US28 have been shown to bind both CC and CXC chemokines with 
equal affinity.11-15 
 
Table 2. Overview of the CXC, CX3C and XC chemokine receptors and their ligands.2,7  
CXC, CX3C and XC Families of Chemokines and Chemokine Receptors 
Receptor Chemokine ligands Associated disease 
CXCR1 CXCL8 (interleukin-8), CXCL6 (GCP2) 
Inflammatory lung disease, COPD 
(chronic obstructive pulmonary disease), 
psoriasis, cancer 
CXCR2 
CXCL8, CXCL1 (GROα), CXCL2 (GROβ), CXCL3 
(GROγ), CXCL5 (ENA-78), CXCL6 
Inflammatory lung disease, COPD, 
psoriasis, cancer, atherosclerosis 
CXCR3-A 
CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-
TAC) 
Inflammatory skin disease, multiple 
sclerosis, allograft rejection 
CXCR3-B CXCL4 (PF4), CXCL9, CXCL10, CXCL11 Cancer 
CXCR4 CXCL12 (SDF-1) HIV-1 co-receptor, cancer 
CXCR5 CXCL13 (BCA-1) Cancer 
CXCR6 CXCL16 (SR-PSOX) 
Inflammatory liver diseas, 
atherosclerosis 
CXCR716 CXCL11, CXCL12 Cancer, HIV-1 co-receptor 
CX3CR1 CX3CL1 (fractalkine) 
Atherosclerosis, allograft rejection, CNS 
(central nervous system) inflammation 
XCR1 CXL1 (lymphotactin), XCL2 
Rheumatoid arthritis, nephropathy, 
cancer 
 
The main role of chemokines is the recruitment of leukocytes, thereby playing a 
key role in the immune system.9,17 There are two different types of chemokines. 
Constitutive chemokines are responsible for the basal leukocyte trafficking and 
the development of normal immune responses, for example in the trafficking of 
lymphocytes to lymphoid tissues. These chemokines are homeostatic in nature 
and are constitutively produced. In contrast, inducible or inflammatory 
chemokines are only secreted during infection or a pro-inflammatory stimulus. 
These chemokines regulate the migration of leukocytes to sites of injury or 
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infection, activate cells to mount an immune response or initiate wound 
healing.4 
 
Inappropriate expression of certain chemokines can lead to excessive leukocyte 
recruitment and activation. If the immune response is inappropriately activated 
and targeted towards normal healthy tissue, this results in autoimmunity and 
disease. Chemokines are suggested to play a role in cancer and a number of 
inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, 
atherosclerosis, asthma and organ transplant rejection (Table 1 and 2). Based 
on the potential role of chemokines and chemokine receptors in the 
pathophysiology of these diseases, chemokine receptor antagonists are 
considered as interesting therapeutics for the treatment of these and other 
proinflammatory diseases.2 As a consequence, a number of companies have 
initiated drug finding programs to discover chemokine receptor antagonists that 
could validate the potential of chemokine receptors as drug targets.  
 
A very important discovery in the chemokine field was the identification of 
chemokine receptors as co-receptors for HIV-1 entry into host cells.18 Human 
and simian immunodeficiency viruses (HIV and SIV) require a chemokine 
receptor in addition to CD4 for efficient entry into cells. HIV enters cells by 
binding to CD4 on the cell surface of the host.19 This induces a conformational 
change in the envelope surface glycoprotein gp120 that allows a secondary 
interaction with a chemokine receptor, thereby acting as a co-receptor for HIV. 
Further structural changes in the envelope transmembrane protein gp41 result 
in membrane fusion and virus entry in the host cell. CCR5 and CXCR4 are the 
most important co-receptors for HIV, but a large number of other seven 
transmembrane (7TM) GPCRs have been shown to act as co-receptors as well, 
including CC, CXC and CX3C chemokine receptors as well as orphan and viral-
encoded GPCRs.20  
 
The most relevant co-receptor in HIV infection appears to be CCR5, since 
individuals with a defective CCR5 allele exhibit resistance to HIV-1 infection. This 
mutant allele of CCR5, CCR5-∆32, is frequent in populations of Caucasian origin 
(about 1% of the population), but was not found in native African, American 
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Indian, and East Asian ethnic groups.21 Individuals homozygous for CCR5-∆32 
cannot produce a complete CCR5 chemokine receptor, resulting in a non-
functional truncated protein that is not transported to the cell surface. Thus, the 
HIV-1 virus cannot attach to the host cells and subsequently enter the cytosol 
resulting in nearly resistance to HIV-1 infection despite repeated exposure. 
Heterozygous individuals of the CCR5-∆32 (about 20% of the population) 
express less functional receptors on the cell surface and display delayed 
progression of 2-3 years to acquired immunodeficiency syndrome (AIDS).21,22 In 
heterozygous carriers the mutant CCR5-∆32 receptor heterocomplexes with 
normal CCR5, so there is only half the amount of the normal CCR5 allele present 
at the cell surface. Moreover, the mutated CCR5-∆32 seems to reduce the 
expression of the normal allele at the cell surface by keeping CCR5 in the 
endoplasmic reticulum. Thus, normal CCR5 can no longer mediate HIV-1 
infection, which can explain the delayed onset of AIDS in CCR5/CCR5-∆32 
individuals.23 
 
In conclusion, the finding that some chemokines and their receptors are 
upregulated in both acute and chronic inflammatory diseases, and the important 
role that they play in the development of AIDS, made them new interesting drug 
targets for therapeutic intervention in these diseases.24  
 
Viral hijacking of the chemokine system 
Viruses exploit the host cell to guarantee their replication and survival. In order 
to take over control from the cell, viruses unleash several strategies upon 
infection. In one of these strategies, host proteins from the chemokine system 
are mimicked to take control of key processes. Several members of the large 
DNA virus families, namely herpesviruses and poxviruses, have incorporated 
chemokines and/or chemokine receptors from their hosts into their own viral 
genome to affect chemokine signaling for their own benefit.25  
 
Currently, there are more than 50 different viral chemokines, chemokine binding 
proteins or chemokine receptors identified in various herpesviruses, poxviruses 
and retroviruses (Figure 2).  
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Figure 2. Three mechanism by which viruses can exploit the host chemokine system. Left: the viral-
encoded chemokines that are able to bind to endogenous chemokine receptors. Middle: the viral-
encoded chemokine receptors. Right: the virus-encoded chemokine-binding proteins (vCKBPs) that act 
as chemokine antagonists. Adapted from Rosenkilde et al.26 
 
Viral chemokines have presumably been acquired through an ancient act of 
molecular piracy from the host genome. It is suggested that these chemokine 
mimics are of biological importance for the viral life cycle, because of the high 
conservation throughout different viral strains.26 They are also suggested to play 
a role in the subversion of the host immune response or the dysregulation of cell 
growth.27 Viral-encoded chemokines show a high degree of complexity in their 
pharmacological profile. They can act selectively on one particular chemokine 
receptor, e.g. MC148 encoded by the poxvirus Molluscum cantagiosum is a 
selective antagonist for the mammalian chemokine receptor CCR8.28 On the 
other hand, a promiscuous binding profile by acting on different chemokine 
receptors is shown for vMIP-2, a CC chemokine encoded by human herpesvirus 
8 (HHV-8), that acts as an antagonist on numerous endogenous and viral-
encoded CC and CXC chemokine receptors.29 Moreover, virus-encoded 
chemokines can have different pharmacological properties on chemokine 
receptors ranging from agonism, antagonism to even inverse agonism.26 
 
Viral-encoded chemokine binding proteins (vCKBPs) are encoded by members of 
the poxviruses and the herpesvirus murine γ-herpesvirus 68 (MHV68). These 
viral chemokine inhibitors are secreted proteins that bind to a broad range of 
chemokines and function as chemokine scavengers.26,30 The vCKBPs are not 
found in the mammalian chemokine system, so they represent an interesting 
class of anti-inflammatory chemokine modulators generated by the virus as 
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antagonists of the endogenous chemokine system. Currently, there are three 
classes of vCKBPs. M-T7, encoded by Myxoma virus, is the only representative 
of the vCKBP1 class. This vCKBP is a low affinity binder of a broad range of 
chemokines at their heparin binding site, thereby inhibiting chemokine action by 
preventing the interaction of these chemokines with the glycosaminoglycan 
(GAG) binding site.31 The vCKBP2 class consists of different chemokine binding 
proteins encoded by poxviruses, which selectively antagonize the action of CC 
chemokines by binding at their receptor binding site.32 To date, M3, encoded by 
murine herpesvirus 68 (MHV68), is the only member of the vCKBP3 group. This 
protein is a broad-spectrum chemokine antagonists and inhibits all four classes 
of chemokines by binding at both the receptor binding site as well as the GAG 
binding site.33 
 
Another strategy used by several large DNA herpesviruses and lentiviruses to 
exploit the host cell is chemokine mimicry.34 Probably the best-known 
employment of GPCRs by viruses is the use of several mammalian chemokine 
receptors as HIV entry factors.35 Yet, viral homologues of chemokine receptors 
have also been identified in several viruses, among which are human, murine 
and rat cytomegalovirus, as well as HHV-6, HHV-7 and the γ-herpesvirus HHV-8. 
Only a couple of these viral GPCRs have so far been demonstrated to be 
functional chemokine receptors with respect to signal transduction and 
chemokine binding properties.25 
 
Although more and more information on the signal transduction pathways and 
chemokine binding properties of viral-encoded GPCRs is elucidated, their exact 
role during the viral life cycle and viral pathogenesis is not known yet. GPCRs 
have key roles in cellular communication and chemokine receptors are important 
in the regulation of the immune system and other important pathophysiological 
conditions. Thus, vGPCRs could play an important role in viral action.36 It can be 
hypothesized that the signaling capacity and chemokine binding profile of viral-
encoded GPCRs have been optimized through an evolutionary selection in favour 
of viral survival and replication. This results in immune evasion by acting as 
scavengers of endogenous chemokines through rapid endocytosis and 
reprogramming of the cellular machinery to help the virus in various parts of the 
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viral life cycle.37 Additional potential roles are cellular activation, tissue targeting 
and cell entry.25 In contrast to their mammalian homologues, a number of viral-
encoded chemokine receptors activate different signaling pathways in a ligand-
independent manner. This constitutive signaling of many vGPCRs and the 
present knowledge that chemokines and their receptors are associated with 
inflammatory diseases and tumour metastasis38 suggests that viral-encoded 
chemokine receptors play an important role in virus-associated diseases.37 
In summary, it has been demonstrated that chemokine mimicry is common and 
important for the pathology of various herpes- and poxvirus infections, but the 
reason why has not been elucidated yet. Nevertheless, viral mimicry of 
chemokines and chemokine receptors provides us with interesting and 
challenging putative new drug targets for a novel class of anti-viral therapy.  
 
Human cytomegalovirus 
Human cytomegalovirus (HCMV) or human herpesvirus-5 (HHV-5) is a highly 
species-specific β-herpesvirus that establishes lifelong latency in the host.39 The 
virus infects endothelial, epithelial, and smooth muscle cells of the upper 
gastrointestinal, respiratory, and urogenital tract,40 and is spread throughout the 
body by latently infected monocytes.41 Differentiation of these monocytes into 
macrophages is accompanied by reactivation of CMV leading to the release of 
infectious virions. 41 Infection of individuals with HCMV is common and arises 
progressively from early age, reaching a seroprevalence of 30-70% in developed 
countries.42 However, in poor socioeconomic groups, homosexuals and among 
people in developing countries the seroprevalence can reach up to 90% in 
adults.43 The highest infection rates are observed in adolescents and in young 
children attending group day care, where CMV shedding and transmission are 
common.44 HCMV can be transmitted via saliva, sexual contact, placental 
transfer, breastfeeding, blood transfusion, solid-organ transplantation or 
haematopoietic stem-cell transplantation.46 
 
Primary infection in healthy individuals rarely causes a serious illness, but may 
be associated with a mononucleosis-like syndrome. In contrast, the primary 
infection or reactivation of the virus in immunocompromised hosts, such as 
premature neonates, transplant recipients, or HIV-infected people, can cause 
Chapter 1 
10 
serious and even life-threatening conditions.39,45 One of the most important 
clinical manifestations of primary HCMV infection is seen in newborn babies, of 
which the mothers are infected during pregnancy.46 It is estimated that 
congenital CMV transmission occurs in 0.5–2% of all newborns.47 The clinical 
symptoms of congenital CMV infection are quite variable, varying from hearing 
defects or neurodevelopmental problems to irreversible CNS involvement in the 
form of microcephaly, encephalitis, seizures, deafness, upper motor neuron 
disorders, psychomotor retardation or blindness.46 Long-term follow up studies 
revealed that up to 80% of the affected infants display serious life-long 
neurological abnormalities with severe life-threatening organ dysfunction and 
death in 10–20% of patients. 
 
Infection with HCMV is furthermore suggested to be associated with vascular 
diseases, such as arterial restenosis, atherosclerosis and chronic allograft 
rejection,48-51 and increasing evidence indicates that CMV may also contribute to 
inflammatory and autoimmune diseases52 as well as colon cancer53 and 
malignant glioma.54 After bone marrow or hematopoietic stem cell 
transplantations, pneumonia and enteritis are the most common clinical 
manifestations of HCMV disease. However, in solid-organ transplant recipients, 
infection with HCMV has been linked to indirect effects, such as dysfunction or 
rejection of the transplanted organ, an increased risk for bacterial or fungal 
opportunistic infections, and accelerated atherosclerosis in heart transplant 
recipients.55 Moreover, co-infection of human cytomegalovirus with HIV has 
been shown to cause an increased risk of disease progression to AIDS and 
dementia in HIV patients.56 
 
The HCMV-encoded receptor US28 as a potential anti-viral drug target? 
The genome of HCMV encodes at least four GPCRs, which are encoded by the 
open reading frames (ORFs) UL33, UL78, US27, and US28.57 A recent study 
suggests that 11 additional ORFs might encode proteins with seven 
transmembrane regions, but none of these genes seem to have other sequence 
characteristics of members of known GPCR families.58 Recently, it was confirmed 
that cytomegaloviruses of higher primates, including HCMV, encode a complete 
novel family of GPCRs in their genome, namely the US12 family, which consists 
Introduction 
   11
of the ten contiguous genes US12 through US21.59 These viral genes are not 
essential for viral replication in vitro, but it is suggested that they play important 
roles in HCMV biology. 
 
UL33 and UL78 both have counterparts in the genome of all sequenced β-
herpesviruses, including rat CMV (R33 and R78, respectively) and mouse CMV 
(M33 and M78, respectively). The genes of US27 and US28 are located in the 
unique short (US) region of the genome of CMV, which is only present in primate 
CMV, namely in human, chimpanzee, African green monkey and rhesus 
macaque CMV.37 UL33, UL78, US28 and presumably US27 are incorporated in 
the viral envelope,60-64 but expression of these proteins is not essential for viral 
replication in vitro.60,65-69 At present, no chemokines are known to bind to UL33, 
UL78 or US27, so these receptors remain orphan receptors. UL33 shows highest 
amino acid sequence identity to the CC chemokine receptors CCR3 and CCR10, 
while US27 displays a 23% sequence identity to CXCR3.37 UL78 has a limited 
sequence identity to chemokine receptors or other GPCRs, and only shares some 
general conserved GPCR features.70 UL33 constitutively activates multiple 
signaling pathways through various G proteins in both transfected as well as 
infected cells, while no signaling has been found yet for both UL78 and 
US27.71,72  
 
Although the exact roles of UL33 and UL78 are not known yet, in vivo 
experiments clearly illustrate the significance of the UL33 and UL78 family 
members in the pathogenesis of CMV infection. The biological significance of R33 
and M33 has been shown for recombinant rat and murine CMV strains in which 
either the R33 or the M33 genes were deleted. In contrast to their wild type 
counterparts, these mutant viruses were unable to replicate in salivary glands 
and caused a lower mortality rate in infected animals.65,73 Additionally, the R33-
deleted mutant virus showed a reduced RCMV accelerated transplant vascular 
sclerosis and chronic rejection in a rat heart transplantation/chronic rejection 
model.74 Mutant viruses were also generated for the UL78 family members. 
Disruption of the UL78 gene of HCMV did not influence viral replication in vitro.69 
In contrast, in vivo experiments showed that deletion of the R78 gene from the 
genome of rat CMV resulted in a lower replication rate in spleen,75 while 
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replication of the M78-deleted mutant virus was impaired in the salivary glands, 
spleen and liver.62 Additionally, a significant lower mortality rate in infected 
animals was observed compared to animals infected with wildtype virus.62,68 
Currently, not much is known about US27. As mentioned before, no ligands 
have been identified for this receptor. However, it has been shown that US27 is 
present in infected cells and enveloped virus particles, suggesting that this 
receptor could initiate or contribute to signal transduction events during the 
early stages of HCMV infection.60,76,77  
 
US28 is currently the best characterized GPCR encoded by HCMV. The exact role 
of US28 has not been elucidated yet, but many important roles during viral 
infection have been attributed to this receptor (Figure 3).70 The 30% amino acid 
sequence homology with the CC chemokine receptor CCR113 suggests that 
HCMV exploits chemokine signaling pathways to interfere with the host immune 
system through chemokine mimicry.34  
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Figure 3. Schematic presentation of the putative roles of the HCMV-encoded receptor US28. 
Abbreviations: CRE, cAMP response element; FAK, focal adhesion kinase; InsP, inositol phosphate; 
NFAT, nuclear factor of activated T cells; NF-kB, nuclear factor kB. Adapted from Vischer et al.70 
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In contrast to human chemokine receptors, of which most receptors only bind 
one class of chemokines, US28 shows a large spectrum chemokine-binding 
profile and can bind a number of inflammatory CC chemokines, such as CCL2, 
CCL3, CCL4, CCL5, and CCL7, as well as the CX3C chemokine CX3CL1 with high 
affinity.12-14,78 Due to its promiscuous chemokine-binding profile it is suggested 
that US28 could act as a chemokine scavenger by sequestering CC chemokines 
from the extracellular environment and thereby helps to subvert the host 
immune system.67,79 This could be a way of the virus to elude immune 
surveillance due to the important role of chemokines in the regulation of the 
immune response. In addition, it has been shown that HCMV-infected fibroblasts 
are capable of depleting endogenous CCL2 and CCL5 from media in a US28-
dependent manner, emphasizing that the chemokine binding properties of US28 
could be a novel antichemokine mechanism for immune evasion.66,67 
 
US28 activates different signaling pathways, such as phospholipase C, cAMP-
response element binding protein (CREB) and nuclear factor activated T cell 
(NFAT) in an agonist-independent manner in both transiently transfected COS-7 
cells as well as in HCMV-infected cells US28.76,80,81 Next to this, US28 
constitutively activate NF-κB, a transcription factor that plays a critical role in 
the regulation of inducible genes in immune response and inflammatory events 
associated with, for example, atherosclerosis.82 Though the biological relevance 
of constitutive activity of vGPCRs has not been elucidated yet, it is believed to 
play an important role in the pathogenesis of virus infection. This has been 
shown for the HHV-8 or Kaposi’s sarcoma-associated herpesvirus (KSHV) 
encoded GPCR ORF74. This receptor is a viral oncogene that constitutively 
activates multiple intracellular signaling pathways resulting in the production 
and secretion of vascular endothelial growth factor (VEGF), thereby causing 
cellular transformations that can develop into highly vascularized Kaposi’s 
sarcoma-like lesions in transgenic mice.83,84 
 
CC chemokines act as agonists on US28 by inducing an increase in intracellular 
calcium in both transfected and HCMV-infected cells and by activating mitogen-
activated protein kinase (MAPK) and focal adhesion kinase (FAK).41,85 In 
contrast, they do not modulate the constitutive signaling of phospholipase C, 
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NF-κB, or CREB, thereby acting as neutral antagonists on these signaling 
pathways.80,86 The CX3C-chemokine CX3CL1 partially inhibits the constitutive 
signaling of phospholipase C and the transcription factor NF-κB, thereby acting 
as a partial inverse agonist.80 For US28 it has been shown to undergo rapid and 
constitutive endocytosis, so only a fraction of US28 is present on the cell 
surface.87 Interestingly, CX3CL1 is reported to act as (partial) agonist on a C-
terminal truncated US28 receptor (US28∆300), which has a reduced constitutive 
internalization resulting in an increase in the number of receptors on the cell 
surface. Apparently, on wild type US28, CX3CL1 decreases the US28 surface 
levels and consequently the US28-mediated constitutive signaling. Thus, it 
seems that the agonistic properties of CX3CL1 are concealed by the constitutive 
endocytosis of wild type US28.87 CX3CL1 is a membrane-bound chemokine and 
binding of US28 to CX3CL1 is suggested to play a role in the cell to cell transfer 
of HCMV.78 Moreover, it could be hypothesized that US28 plays a role in the 
fusion of the CMV envelope with target cells and CMV entry due to its property 
to enhance cell-cell fusion mediated by different viral proteins.88 
 
Similar to other mammalian chemokine receptors, of which CCR5 and CXCR4 are 
the primary HIV-1 co-receptors in vivo, US28 can act as a co-receptor for HIV-1 
entry into cells in vitro.89 Interestingly, a potential symbiotic relationship 
between the two viruses has been suggested, because HIV-1 establishes the 
immunosuppression needed for the emergence of HCMV from latency and 
maximal HCVM replication, while HCMV facilitates HIV-1 infection through US28 
and provides an additional mechanism for cell entry by HIV-1.27  
 
Another feature that increases the interest of US28 as a drug target is induction 
of the migration of vascular smooth muscle cells upon binding with the 
chemokines CCL2 and CCL5. This could be exploited by HCMV to disseminate the 
virus through the human body.90 Since migration of smooth muscle cells 
towards the vascular intima is a typical characteristic of the formation of 
atherosclerotic and restenotic lesions, this could also provide a possible 
connection between HCMV and the development of vascular diseases.  
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During infection with HCMV different growth factors and cytokines are 
upregulated resulting in enhanced cell survival, proliferation and angiogenesis.91 
Recent experiments demonstrated that expression of US28 in vitro induces a 
transformed and pro-angiogenic phenotype. Additionally, activation of pro-
angiogenic signaling pathways was apparent in HCMV-infected cells and this 
could be partially attributed to US28. In vivo, expression of US28 in NIH-3T3 
cells promotes tumorigenesis in mice, thereby acting as a viral oncogene.92 As 
such, after HCMV infection US28 might act in a concerted manner with other 
HCMV-encoded proteins, which were previously linked to oncogenesis,91 and 
enhance and/or promote tumorigenesis.  
 
Currently, the exact role of US28 in the pathogenesis of HCMV infection has not 
been completely elucidated yet. Because US28 is only present in primate CMV, 
this species-specificity as well as ethical considerations hampers the possibility 
to study the role of this receptor during viral infection in vivo. Consequently, 
more research is needed to further prove a causative link between US28 and 
chronic diseases resulting from infection with HCMV. 
 
Small nonpeptidergic ligands acting on viral-encoded GPCRs 
Because of the involvement of chemokines and chemokine receptors in the 
pathophysiology of numerous diseases, chemokine receptors were discovered as 
interesting new therapeutic targets. Chemokine receptors belong to Class A 
GPCRs, which are characterized by their high homology with rhodopsin. Other 
members of this family are the biogenic amine receptors, that have been 
successfully targeted by small-molecule antagonists and thus constitute a solid 
database of knowledge that should aid the design of novel antagonists for other 
GPCRs.2 Drug development programmes were started in order to find small 
molecules acting on chemokine receptors and high-throughput-screenings 
resulted in several potent and selective antagonists currently entering Phase II 
or III clinical trials.  
 
With the discovery of GPCRs encoded by viruses a new unexplored class of 
potential drug targets has emerged and selective small nonpeptidergic 
compounds that are able to inhibit these receptors can serve as new promising 
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therapeutics for innovative anti-viral intervention. Moreover, these small 
molecules can be used to study the relevance of constitutive signaling during 
viral infection. Currently, the HCMV encoded receptor US28 is the only viral-
encoded GPCR for which small non-peptide molecules have been identified. 
Several classes of ligands that inhibit chemokine binding to US28 have been 
reported in the patent literature. Additionally, a series of inverse agonists acting 
on US28 were published recently by our group.81 
 
In 2002, Chemocentryx Inc. disclosed that dissemination of CMV in a host could 
be inhibited by compounds that reversibly block chemokine binding to US28.93,94 
Among these reported ligands are a series of piperazinyldibenzothiepins, 
represented by the 5-hydroxytryptamine (5-HT) receptor antagonist 
methiothepin (1) and the D2 dopamine/5-HT2 antagonist octoclothepin (2) 
(Figure 4).  
 
I
OH
N
H
O
O
N
S(-) -IBZM (3)
S
N
N
R
Methiothepin (1) R = SCH3
Octoclothepin (2) R = Cl  
 
Figure 4. Chemical structures of the US28 ligands methiothepin, octoclothepin and S(-)-IBZM. 
 
These tricyclic compounds have been shown to specifically inhibit [125I]CX3CL1 
binding to US28-expressing cells in a reversible manner with IC50 values of 0.3 
µM and 0.7 µM, respectively.94 In cytoplasmic calcium mobilization experiments 
in US28-expressing HEK293 cells, CX3CL1 acts as an agonist by inducing a rise 
in intracellular Ca2+. Interestingly, both methiothepin and octoclothepin act as 
agonists in the same assay and are able to desensitize the subsequent Ca2+ 
mobilization by CX3CL1.  
 
A family of benzamides, exemplified by S(-)-IBZM (3) in Figure 4, has been 
reported as ligands interacting with US28.93 S(-)-IBZM is known as a D2 
dopamine receptor ligand, which can be radiolabeled due to the presence of a 
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synthetically accessible iodide substituent in the structure. Radiolabeled 3 is 
used in the clinic to visualize D2-dopamine receptors in vivo in the human brain 
by single photon emission tomography (SPECT).95 As shown for methiothepin 
and octoclothepin, S(-)-IBZM is able to specifically displace [125I]CX3CL1 binding 
from US28 with an IC50 value of 0.6 µM and to act as an agonist in the calcium 
mobilization assay. Due to the observed interaction with US28, it was claimed 
that [123I]IBZM could be used for the in vivo detection, diagnosis and imaging of 
CMV infection in a host using single photon emission computed tomography 
(SPECT) (or positron emission tomografie (PET) if 18F or another positron emitter 
is used). Yet, in view of the relatively low micromolar affinity of S(-)-IBZM on 
US28, the feasibility of this approach seems questionable. 
 
Although in general, caution must be taken when trying to deduce structure-
activity relationships (SAR) from patent literature, we will try to identify general 
trends or remarkable issues, e.g. selectivity, in the following subsections. 
 
A large series of bicyclic compounds, represented by compounds 4-53, were 
reported for the treatment or prevention of viral dissemination from CMV 
infection by inhibiting chemokine binding to US28.96 Bicyclic structures A-D 
(Table 3-6) were reacted with a large series of acid chlorides and these 
derivatives were evaluated for their binding properties by their ability to inhibit 
[125I]CX3CL1 binding to human US28-expressing cells and to rhesus CMV-
infected rhesus dermal fibroblasts. Interestingly, a striking species-selectivity 
between human US28 and rhesus CMV was demonstrated. Several tested 
ligands exhibited IC50 values lower than 1 µM on human US28 or rhesus CMV, 
but only compound 49 showed a binding affinity below 1 µM in both systems. 
Recently, species selectivity has been shown for CCR1 antagonist as well and 
this could be inconvenient if these molecules are tested in animal models of 
disease.97  
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All compounds based on bicyclic structure A are shown in Table 3. In detail, the 
unsubstituted analogue 4 and the different substituted compounds 5-8 have an 
affinity < 1 µM on human US28, while none of these compounds show a similar 
affinity on rhesus CMV. The introduction of a methyl group in 9 or the nitrogen 
atom in 10 causes a drop in affinity for both receptors compared to 
unsubstituted compound 4. The thiophene groups in 11 and 12 are allowed in 
the structure and both compounds have an affinity below 1 µM on hUS28, but 
this substitution results in a significant decrease on rhesus CMV. 
 
Table 3. Chemical structures and pharmacological properties of compounds 4-19 for human US28 and 
rhesus CMV.  
 
N
O
OR
N
H
Bicyclic structure A 
no. R 
hUS28 
IC50 (µM)a 
rhesus CMV 
IC50 (µM)b no. R 
hUS28 
IC50 (µM)a 
rhesus CMV 
IC50 (µM)b 
4 
 
< 1 1 - 10 12 
S  
< 1 10 - 40 
5 
O2N  
< 1 10 - 40 13 
 
1 - 10 10 - 40 
6 
Cl
 
< 1 1 - 10 14 
 
1 - 10 10 - 40 
7 
Cl
Cl  
< 1 1 - 10 15 HN
 
10 - 40 10 - 40 
8 
F
 
< 1 10 - 40 16 HN
 
10 - 40 10 - 40 
9 
 
1 - 10 10 - 40 17 
O
 
1 - 10 1 - 10 
10 
H
N
 
1 - 10 10 - 40 18 
 
< 1 1 - 10 
11 
S  
< 1 10 - 40 19 
 
 
1 - 10 1 - 10 
a Displacement of [125I]CX3CL1 from human US28-expressing cells. b Displacement of [125I]CX3CL1 from 
rhesus CMV-infected rhesus dermal fibroblasts.  
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The introduction of an additional carbon atom in the structure of 13 or the 
unsaturated system of 14 does not positively influence the affinity on hUS28 or 
rhesus CMV, while the substituted amine groups of the enantiomerically pure 
compounds 15 and 16 cause a decrease in affinity compared to 4. The presence 
of the ether linkage between the phenyl ring and bicyclic structure A (17) 
results in an affinity between 1 and 10 µM on both hUS28 as rhesus CMV. The 
same is seen for the introduction of a 1-naphtylgroup (19), while the 2-naphtyl 
group in compound 18 does not influence the affinity on rhesus CMV, but causes 
an increase in binding affinity on hUS28 to a value below 1 µM.  
 
The only difference between the bicyclic structures A (Table 3) and B (Table 4) 
is the presence of a double or single bond in the carbon chain attached to the 3-
position of the piperidine ring. The influence of this small structural change is 
not significant. Both the introduction of a benzyl group (20), a 2-chloro benzyl 
group (21) or a 2-naphtyl group (22) results in similar binding affinities as their 
analogues in Table 3. Moreover, 4-phenyl substitution as in compound 23 was 
allowed to maintain affinity on both human as rhesus CMV. The two methyl 
groups in compound 24 do not positively influence the affinity on hUS28 
(compare to compound 20), and this structural change causes a drop in affinity 
on US28 expressed by rhesus CMV. 
 
An interesting series with different cycloalkyl groups attached to the benzylic 
carbon atom was synthesized and tested. On human US28, there are no 
differences in binding affinity between the cyclopentyl group in 25, the 
cyclopropyl group in 26 or the cyclohexyl group in 27, while the last substituent 
is preferred on rhesus CMV. Replacement of one of the phenyl rings in 28 by a 
cyclohexyl ring as in 29 causes a small decrease in affinity on both hUS28 as 
rhesus CMV, while the tricyclic systems in compounds 30 and 31 result in 
binding affinities between 1 and 10 µM on both receptors. 
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Table 4. Chemical structures and pharmacological properties of compounds 20-31 for human US28 
and rhesus CMV.  
 
N
O
OR
N
H
Bicyclic structure B 
no. R 
hUS28 
IC50 (µM)a 
rhesus CMV 
IC50 (µM)b no.       R 
hUS28 
IC50 (µM)a 
rhesus CMV 
IC50 (µM)b 
20 
 
< 1 10 - 40 26 
 
1 - 10 10 - 40 
21 
Cl
 
< 1 1 - 10 27 
 
1 - 10 1 - 10 
22 
 
< 1 1 - 10 28 
 
< 1 1 - 10 
23 
 
< 1 1 - 10 29 
 
1-10 10 - 40 
24 
 
1 - 10 10 - 40 30 
 
1-10 1 - 10 
25 
 
1 - 10 10 - 40 31 
O
 
 
1-10 1 - 10 
a Displacement of [125I]CX3CL1 from human US28-expressing cells. b Displacement of [125I]CX3CL1 from 
rhesus CMV-infected rhesus dermal fibroblasts.  
 
Compounds 32-41 are based on bicyclic structure C (Table 5). Changing the 
substitution in the phenyl ring from a 4-methyl group to 2-chloro or 2-chloro-4-
nitro substitution (compare compounds 33 and 34 with 32) causes a small drop 
in affinity on hUS28, while this structural change increases the IC50 value on 
rhesus CMV from a value between 1-10 µM to a value below 1 µM. In contrast to 
ligands 4-8 in Table 3, which all have affinities below 1 µM, the compounds with 
a benzyl group in 35 or the substituted benzyl groups in 36-38 have affinities 
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on hUS28 between 1-10 µM. On rhesus CMV, the unsubstituted benzyl group in 
compound 35 or the 2-chloro and 2,2-dichloro substituted analogues 37 and 38 
are preferred above the 2-fluoro substituted benzyl group in compound 36. 
Introduction of the nitrogen linker in 40 or the ether linker as in compound 41 
does not increase the affinities on human or rhesus CMV. 
 
Table 5. Chemical structures and pharmacological properties of compounds 32-41 for human US28 
and rhesus CMV.  
 
N
O
OR
N
H
Bicyclic structure C 
no. R 
hUS28 
IC50 (µM)a 
rhesus CMV 
IC50 (µM)b no. R 
hUS28 
IC50 (µM)a 
rhesus CMV 
IC50 (µM)b 
32 
H3C
 
< 1 1 - 10 37 
Cl
 
1 - 10 < 1 
33 
Cl  
1 - 10 < 1 38 
Cl
Cl  
1 - 10 < 1 
34 
Cl
O2N
 
1 - 10 < 1 39 
S  
< 1 1 - 10 
35 
 
1 - 10 < 1 40 
H
N
 
1 - 10 10 - 40 
36 
F
 
 
1 - 10 1 - 10 41 
O
 
1 - 10 1 - 10 
a Displacement of [125I]CX3CL1 from human US28-expressing cells. b Displacement of [125I]CX3CL1 from 
rhesus CMV-infected rhesus dermal fibroblasts.  
 
Interestingly, small changes in affinity are seen if the double bond in bicyclic 
structure C is replaced by a single C-C bond as in scaffold D (Table 5 and 6). 
Analogue 42 has a comparable affinity on hUS28 as compound 33, but the 
presence of the single bond in bicyclic structure D causes a small decrease in 
binding affinity on rhesus CMV. As shown for analogues 4 and 20, the benzyl 
group in compound 43 results in a binding affinity lower than 1 µM on hUS28. 
The introduction of a 2-chloro substituent (44), a 4-phenyl group (45) or a 
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methyl group at the benzylic position (46) are allowed to maintain for an affinity 
between 1-10 µM on human US28 and rhesus CMV.  
 
Table 6. Chemical structures and pharmacological properties of compounds 42-53 for human US28 
and rhesus CMV.  
 
N
O
OR
N
H
Bicyclic structure D 
no.           R 
hUS28 
IC50 
(µM)a 
rhesus 
CMV 
IC50 (µM)b 
no.             R 
hUS28 
IC50 
(µM)a 
rhesus 
CMV 
IC50 (µM)b 
42 
Cl  
1 - 10 1 - 10 48 
 
1 - 10 < 1 
43 
 
< 1 1 - 10 49 
 
< 1 < 1 
44 
Cl
 
1-10 1 - 10 50 
 
1 - 10 < 1 
45 
 
1 - 10 1 - 10 51 
 
1 - 10 < 1 
46 
 
1 - 10 1 - 10 52 
 
1 - 10 < 1 
47 
 
< 1 1 - 10 53 
O
 
1 - 10 < 1 
a Displacement of [125I]CX3CL1 from human US28-expressing cells. b Displacement of [125I]CX3CL1 from 
rhesus CMV-infected rhesus dermal fibroblasts. 
 
If the results of compounds 25 and 27 (bicyclic structure B) are compared with 
the binding affinities of compounds 47 and 48, it is interesting to notice that in 
bicyclic structure D the introduction of a cyclopropyl group (47) results in an 
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affinity lower than 1µM on hUS28, while the cyclohexyl group of 48 is preferred 
on rhesus CMV.  
 
As mentioned before, compound 49 is the only compound that has an affinity 
lower than 1 µM on both human US28 as rhesus CMV. Replacement of one of the 
phenyl rings of 49 by a cyclohexyl group as in 50 results in a small drop of 
affinity on only hUS28, and this is also seen for compound 51. The same 
tricyclic systems as in compounds 30 and 31 (bicyclic structure B) were 
introduced on bicyclic structure D to afford compounds 52 and 53. Interestingly, 
in bicyclic structure B these substitutions result in affinities between 1-10 µM on 
both receptors, while in bicyclic structure D the tricyclic substitutions show a 
slight preference for US28 encoded by rhesus CMV.  
 
The last group of compounds disclosed by Chemocentryx Inc. as inhibitors of 
chemokine binding to US28 is exemplified by compounds 54-65 (Table 7).98 The 
activities of these arylamines were determined by their ability to inhibit 
[125I]CX3CL1 binding to US28-expressing cells. As for the bicyclic compounds, 
the most active compounds were claimed to have IC50 values lower than 1 µM, 
but specific IC50 values and functional data were not reported. A more detailed 
look into the SAR of these arylamines reveals that two small alkyl groups on the 
nitrogen atom attached to the phenoxy linker, like shown for 54-55, is 
preferred. Monosubstitution of the nitrogen atom as in compound 56 or the 
introduction of a more bulky t-butyl group as in 57 makes the affinity drop 
slightly. Incorporation of the nitrogen atom into a ring system, e.g. in a 
pyrrolidine (58) or piperidine ring (59), makes the binding affinity drop slightly 
as well, while introduction of a morpholine ring in compound 60 causes a more 
significant drop in IC50 value. Interestingly, the NO2 group of compound 54 
seems to be essential in the structure, because replacement by a CF3 group 
results in a decrease in binding affinity to 1–10 µM, and introduction of a NH2 or 
a COOCH3 moiety even causes the IC50 values to drop between 10-40 µM 
(structures not shown).  
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Table 7. Chemical structures and pharmacological properties of compounds 54-65 for the HCMV-
encoded receptor US28. 
 
R2
NO2
O R1
OH
 
 
no. R1 R2 IC50 (µM)a no. R1 R2 IC50 (µM)a 
54 N
 
N
 
< 1 60 N O
 
N
 
10 – 40 
55 N
 
N
 
< 1 61 N
 N  
< 1 
56 
NH  
N
 
1 - 10 62 N
 
N O
 
10 – 40 
57 N
 
N
 
1 - 10 63 N
 NH  
< 1 
58 N
 
N
 
1 - 10 64 N
 
N
 
10 - 40 
59 N
 
N
 
1 - 10 65 N  
 
H  
10 – 40 
a Displacement of [125I]CX3CL1. 
 
Introduction of a methyl substituent into the ring system attached to the phenyl 
ring (61) is allowed, but replacement of the pyrrolidine ring into a morpholine 
ring as in compound 62 results in a drop in affinity. An isopropyl group attached 
to the aniline nitrogen atom in 63 results in an IC50 value below 1 µM, while two 
methyl substituents in compound 64 make the affinity drop to a value between 
10 and 40 µM. Removal of any substituent in that position of the molecule in 65 
shows the same drop in IC50 value.  
 
Previously, VUF2274 (66) was identified as the first small non peptide molecule 
acting as an inverse agonist on US28 (Table 8).81 This molecule has been 
previously reported as an antagonist on the human chemokine receptor CCR199 
and was screened on US28 because of the sequence homology of this viral 
receptor with CCR1 (33% identity). Compound 66 has been shown to displace 
[125I]CCL5 binding to US28-expressing COS-7 cells with an IC50 value of 9.3 µM. 
In previous studies it was shown that in transiently transfected COS-7 cells as 
well as in HCMV-infected cells US28 constitutively activates phospholipase C and 
the transcription factor NF-κB in an agonist-independent manner.80,81 
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Constitutive signaling of US28 could be completely blocked by 66 with an EC50 
value of 3.2 µM. VUF2274 does not only dose-dependently inhibit the US28-
mediated constitutive activation of PLC in both transiently transfected cells and 
HCMV-infected fibroblasts, but also inhibits the US28-mediated HIV entry in cells 
cotransfected with CD4.81  
 
To investigate the binding sites of US28 an in silico model was generated based 
on homology with bovine rhodopsin (Figure 5).81 A glutamic acid residue in TM-7 
(Glu277) was identified as an important amino acid for binding of 66 to the 
receptor, because mutation into glutamine to eliminate the charge but to 
maintain the hydrogen bonding potential of the side chain, and into alanine to 
eliminate both the charge as well as the hydrogen bonding potential, 
significantly reduced the binding affinity of 66. The importance of a glutamate 
residue in TM-7 for binding and action of nonpeptidergic chemokine antagonists 
has been shown for the human CCR1, CCR2 and CCR5 chemokine receptors as 
well.100,101 Moreover, it has been suggested for human chemokine receptors in 
general that this residue serves as an important anchor point for the positively 
charged nitrogen atom, which is frequently found in small molecule inhibitors 
acting on these receptors.102  
 
Figure 5. In silico model of US28. Left: Proposed binding site of CCL5 (cyan) with US28. Right: 
Proposed binding site of 66 within the transmembrane helices of US28. 
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As expected, it was shown that 66 and the relatively large chemokine CCL5 do 
not share the same binding site on US28. Firstly, Glu277 was not important for 
CCL5 binding to the receptor. Secondly, mutation of the N-terminus of US28 
(∆(2-22)-US28) resulted in a complete loss of binding affinity of all the tested 
chemokines, but the constitutive signaling of this mutant receptor could still be 
inhibited by 66 with a potency similar to that of wild type US28. Thus, 
compound 66 and CCL5 do not share the same binding site on US28, but the 
small molecule acts as an allosteric modulator and displacement of CCL5 binding 
results from a conformational change induced by 66.81 
 
Table 8. Chemical structures and pharmacological properties of compounds 66-72 for the HCMV-
encoded receptor US28. 
 
no. Code Structure IC50 (µM)a EC50 (µM)b 
66 2274 
N
OH
Cl
CN
 
8.4 3.5 
67 5713 
N
CN
OH
Cl
 
9.6 5.3 
68 (±)-5715 
N
OH
Cl
OH
 
n.a n.a. 
69 5667 
N
OH
Cl
 
5.9 4.2 
70 5658 
N N Cl
CN
 
n.a n.a. 
71 5662 
N Cl
CN
 
10.5 14 
72 5660 
N
OH
CN
 
 
35 29 
a Displacement of [125I]CCL5. b Inhibition of [3H]inositol phosphate production. n.a.= not active. 
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A limited series of analogues of 66 was synthesized to investigate some 
preliminary structure-activity relationships for inverse agonism on US28 (Table 
7).81 Some flexibility was tolerated in the diphenylacetonitrile group, because 
insertion of an ethylene group as in VUF5713 (67) or a thiomethylene group 
(structure not shown) was tolerated and did not influence the affinity and 
efficacy of the compounds. In contrast, replacement of one of the two phenyl 
rings by a more hydrophilic hydroxy group as in compound 68 resulted in a 
complete loss of activity, suggesting that a bulky lypophilic moiety is of 
importance. The nitrile group was not essential in the structure, because its 
removal in VUF5667 (69) did not affect the affinity and efficacy of the 
compound. Interestingly, replacement of the piperidine ring of 66 into a 
piperazine ring in VUF5658 (70) resulted in a complete loss of activity. Finally, 
removal of the hydroxy group attached to the piperidine ring in VUF5662 (71) or 
the chloride substituent in VUF5660 (72) resulted in a 5-10 fold loss of affinity 
and efficacy.  
 
At present, no low molecular weight ligands are known to act on other vGPCRs, 
but this could be only a matter of time. Previously, it was shown that ORF74, a 
constitutively active GPCR encoded by HHV-8, was susceptible to non-peptide 
inverse agonists by inhibition of the constitutive signaling of the viral receptor by 
a Zn2+ ion.29 To this end, a silent metal ion site was constructed by His-
substitution of Arg208 and Arg212 and the signaling of this ORF74 mutant receptor 
was blocked by Zn2+, which acted as an inverse agonist with an EC50 around 1 
µM. This was suggested to be a proof of concept that it is possible to identify 
small nonpeptidergic inverse agonists targeted towards the extracellular part of 
this viral-encoded GPCR. 
 
In summary, the search for small ligands acting on vGPCRs is still an unexplored 
but fascinating research field. The identification of these nonpeptidergic 
molecules is essential to investigate the role of vGPCRs in the pathogenesis of 
viral infection and these molecules can be considered as promising therapeutics 
for clinical anti-viral intervention. 
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Aim of this thesis 
As outlined above, HCMV infection has been linked to numerous pathological 
disorders, such as vascular diseases, transplant rejection, several inflammatory 
and autoimmune diseases, as well as cancer. Furthermore, HIV patients co-
infected with HCMV have an increased risk of rapid disease progression. US28 is 
one of at least four chemokine receptors encoded by HCMV and this receptor is 
suggested to play a significant role in virus-associated diseases. US28 binds 
several inflammatory chemokines and displays a high level of constitutive 
(ligand-independent) signaling by activating various signaling pathways. 
Aberrant activation of signaling pathways by GPCRs has been recognized as a 
potential cause of numerous human pathologies. Inverse agonists are able to 
inhibit this constitutive activation. The identification of such molecules for viral-
encoded GPCRs can be an important tool to investigate the significance of 
constitutive activity and the role of these receptors in viral infection. 
 
The aim of this thesis is to elucidate the first structure-activity relationships for 
inverse agonism on the viral-encoded receptor US28 by the design, synthesis 
and pharmacological evaluation of novel nonpeptidergic ligands. These insights 
will result in a better understanding of the structural requirements important for 
inverse agonism and ultimately lead to compounds with an improved activity 
and selectivity profile on US28. Moreover, these new molecules may serve as 
important tools to investigate the role of US28-mediated constitutive activity 
during viral infection.  
 
Chapter 2 and 3 describe the synthesis and pharmacological characterization of 
an extensive series of analogues of compound 1, identified in our lab as the first 
nonpeptidergic ligand acting on US28. This comprehensive study describes the 
synthesis of several series of compounds and the very first SAR of 
nonpeptidergic ligands acting on a viral GPCR (US28). 
Chapter 4 shows an interesting approach using molecular design techniques to 
identify novel ligands for US28. The design of a focused virtual library around 4-
(4-chlorophenyl)piperidin-4-ol will be shown and how drug-like descriptors were 
applied to compose a diverse subset of 50 compounds. These molecules were 
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synthesized using parallel chemistry approaches and subsequently evaluated 
pharmacologically on US28.  
Chapter 5 discloses the results of our quest for novel chemotypes interacting 
with US28 by screening a selection of compounds from our own in-house 
compound collection. In this study, several interesting ligands have been found, 
of which some are selected as new starting points for further lead optimization 
programs. Interestingly, two of these compounds were classified as a neutral 
antagonist, providing us with a new pharmacological tool.  
Chapter 6 shows the synthesis of a hybrid compound that contains important 
structural features of both compound 1 and one of the neutral antagonists. This 
hybrid molecule led to the discovery of a molecular determinant that leads to 
neutral antagonism or inverse agonism. These compounds give us a better 
understanding of the structural requirements necessary for inverse agonism and 
neutral antagonism and the possibility to modulate the functional activity of 
US28.  
Chapter 7 describes the hit to lead optimization of one of the novel inverse 
agonists that was identified by our in-house database screening. We describe 
some interesting new structure-activity relationships of this completely novel 
class of inverse agonists acting on US28.  
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Abstract 
US28 is a human cytomegalovirus (HCMV) encoded G protein-coupled receptor 
that signals in a constitutively active manner. Recently, we identified 1 {5-(4-
(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile} as the 
first reported nonpeptidergic inverse agonist for a viral-encoded chemokine 
receptor. Interestingly, this compound is able to partially inhibit the viral entry 
of HIV-1. In this study we describe the synthesis of 1 and several of its 
analogues and unique structure-activity relationships for this first class of small-
molecule ligands for the chemokine receptor US28. Moreover, the compounds 
have been pharmacologically characterized as inverse agonists on US28. By 
modification of lead structure 1, it is shown that a 4-phenylpiperidine moiety is 
essential for affinity and activity. Other structural features of 1 are shown to be 
of less importance. These compounds define the first SAR of ligands on a viral 
GPCR (US28) and may therefore serve as important tools to investigate the 
significance of US28-mediated constitutive activity during viral infection. 
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Introduction 
Human cytomegalovirus (HCMV) is a widespread β-herpesvirus that, like other 
herpes viruses, persists during the lifetime of the host.1 Infection of individuals 
with HCMV is common, reaching a seroprevalence of 50-90% in adults, and is 
normally without clinical symptoms.2 However, in immunologically immature or 
immunocompromised hosts, like premature neonates, acquired 
immunodeficiency syndrome (AIDS) patients, and transplant recipients, the 
virus can cause serious and even life-threatening disease.1 Infection with HCMV 
is furthermore suggested to be associated with vascular diseases such as arterial 
restenosis, atherosclerosis and chronic allograft rejection.3-5 
 
The genome of human cytomegalovirus encodes four G protein-coupled 
receptors (GPCRs), namely the open reading frames (ORFs) UL33, UL78, US27, 
and US28.6 Two of these GPCRs, UL33 and UL78, have counterparts in the 
genome of both rat CMV (R33 and R78, respectively) and mouse CMV (M33 and 
M78, respectively), whereas US27 and US28 are specific for HCMV.7 US28 shows 
high homology with β mammalian chemokine receptors, binds several CC 
chemokines with high affinity,8-10 and is able to sequester CC chemokines from 
the extracellular environment via endocytosis.11,12 This feature appears to be a 
putative strategy of the virus to escape immune surveillance by reducing the 
immune response to sites of HCMV infection.13 US28 is able to bind not only CC 
chemokines but also the membrane-bound CX3C chemokine CX3CL1/fractalkine, 
which has been suggested to play a role in the cell to cell transfer of HCMV.14 
Furthermore, upon binding with the CC chemokines CCL2/MCP-1 and 
CCL5/RANTES, US28 induces migration of vascular smooth muscle cells, which 
could provide the molecular basis of the role of HCMV in vascular diseases. The 
migration of smooth muscle cells can also be exploited by HCMV to enhance 
dissemination of the virus through the body.15 Similar to other chemokine 
receptors, such as CCR5 and CXCR4, US28 can act as a co-receptor for human 
immunodeficiency virus-1 (HIV-1) entry when coexpressed with CD4.16 Taken 
together, US28 is considered as an interesting drug target. 
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In previous studies we have shown that in transiently transfected COS-7 cells as 
well as in HCMV-infected cells US28 constitutively activates phospholipase C and 
the transcription factor NF-κB in an agonist-independent manner.17,18 
Interestingly, the CC chemokines CCL2 and CCL5 do not affect the basal US28 
signaling and act as neutral antagonists, whereas the CX3C-chemokine CX3CL1 
partially inhibits the constitutive signaling and acts as a partial inverse agonist. 
Constitutive activity is suggested to be a general characteristic of viral-encoded 
GPCRs. Besides the HCMV-encoded receptor US28, other viral-encoded 
receptors also signal in the absence of any ligand, namely the HHV-8 or Kaposi’s 
sarcoma-associated herpesvirus (KSHV) encoded GPCR ORF7419 and the M33 
gene family members encoded by MCMV, HCMV, and RCMV.18,20,21 Although the 
biological relevance of constitutive activity has not been completely elucidated 
yet, it is believed to play an important role in the pathogenesis of virus infection. 
This is demonstrated for ORF74, which is a viral oncogene resulting in the 
development of Kaposi’s sarcoma-like lesions in transgenic mice.22,23 
 
Inverse agonists are able to inhibit the constitutive activation of GPCRs. The 
identification of such molecules for viral-encoded GPCRs can be an important 
tool to investigate the significance of constitutive activity and the influence of 
these receptors in viral infection. Recently, we identified 1 as a small 
nonpeptidergic molecule that acts as a full inverse agonist on US28. 
Furthermore, this compound is able to inhibit 60% of the US28-mediated HIV 
entry in cells at a concentration of 1 µM.18 This molecule has been previously 
reported as an antagonist on the human chemokine receptor CCR124 and was 
screened on US28 because of the sequence homology of this viral receptor with 
CCR1 (33% identity).10 In this study, the synthesis of 1 and various analogues is 
reported and we present the first structure-activity relationships for the 
interaction of these ligands with US28. 
 
Chemistry 
For the synthesis of compounds 1-20 the following synthetic routes were applied 
(Schemes 1 and 2). 2,2-Diphenylacetonitrile 21 was deprotonated with NaH at 0 
°C followed by a reaction with the appropriate 1,ω-dihalopropanes to yield 
intermediates 22a or 22b.24,25 Compounds 2, 13, 17, and 18 were synthesized 
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by stirring intermediate 22a in DMF at 90 °C in the presence of the 
corresponding amine and an excess of K2CO3 (method A).
24 The yields after 
purification were in the range of 15-50%. The reaction conditions were 
optimized by reacting intermediate 22a or 22b with the corresponding 
piperidine 23 in the presence of NaI, Na2CO3, and CH3CN at reflux temperature 
(method B)26 to give the desired products in yields ranging from 23% to 79%. 
 
CN a,b
CN
X c,d
CN
N
OHN
O
O
21 22a X = Cl
22b X = Br
25
CN
N
HN
1-15
CN
N+
16 R1 = OH; R2 = 4-Cl-Ph
e
f
24
23
R2
R1
R2
R1
R2
R1
 
 
Scheme 1. Synthetic pathway for the synthesis of 1-16. Reagents and conditions: (a) NaH, DMF, 0 °C; 
(b) 1,ω-Dihalopropane; (c) DMF, K2CO3, 90 °C or NaI, Na2CO3, CH3CN, reflux; (d) 6 N HCl, MeOH; (e) 
R2MgBr, THF, 0 °C or n-BuLi, THF, 0 °C for R2 = n-butyl; (f) MeI, DCM. 
 
For compounds 5-10 the appropriate piperidines were not commercially 
available. Consequently, 5-10 were synthesized according to literature 
procedures (Scheme 1, method C).25 Intermediate 22 was reacted with 
protected piperidone 24, followed by the deprotection with HCl to give ketone 
25. This was treated with the appropriate Grignard reagents to yield compounds 
5-9, whereas the reaction with n-BuLi afforded compound 10.25 The yields of 
products 5-10 were moderate to low, ranging from 5% to 42%, because of low 
yields in the recrystallization step.  
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CN
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Scheme 2. Synthetic pathway for the synthesis of 17-20. Reagents and conditions: (a) DMF, K2CO3, 
90 °C or NaI, Na2CO3, CH3CN, reflux; (b) 2M NaOH, MeOH, reflux. 
 
4-(Diphenylmethylene)piperidine, which was used for the synthesis of compound 
15, was obtained by an acid-catalyzed dehydratation of diphenyl(piperidin-4-
yl)methanol with TFA.27 The quaternary ammonium salt 16 was synthesized by 
the methylation of the piperidine nitrogen atom of 1 with methyl iodide.25 Target 
compound 19 was synthesized following method B. The ethyl ester moiety of 19 
was hydrolyzed in high yield with 2 M NaOH, resulting in the carboxylic acid 
derivative 20 (Scheme 2). Compounds 26 and 27 were prepared via the 
reaction of intermediates 28 and 29 with 4-(4-chlorophenyl)-4-piperidinol 30 
(Scheme 3).  
 
X
28 X = O; Y = Br
29 X = CH2 ; Y = Cl
HN
OH
Cl
Y X N OH
Cl
26 X = O
27 X = CH2
30
a
 
 
Scheme 3. Synthetic pathway for the synthesis of 26-27. Reagents and conditions: (a) NaI, Na2CO3, 
CH3CN, reflux. 
Chapter 2 
40 
Compounds 31 and 32 were synthesized as depicted in Scheme 4. 
Butyrophenone derivative 31 was synthesized from commercially available 
reagents as earlier described.28 The carbonyl group of 33 was ketalized with 
ethylene glycol in the presence of p-toluenesulphonic acid to afford the 
protected intermediate 34. Alkylation of piperidine 30 with 34 and deprotection 
of the carbonyl group with HCl resulted in product 31. For the synthesis of 
compound 32 4-chloro-1-phenylbutan-1-one 33 was reduced with NaBH4, 
resulting in alcohol 36. Subsequently, the alcohol group was protected with 
acetyl chloride to give intermediate 37, which was reacted with 4-(4-
chlorophenyl)-4-piperidinol 30 resulting in compound 38. Deprotection with 
NaOH afforded target compound 32.  
 
ClCl
O O O
Cl
OH
Cl
O
O
N
O
OH
Cl
N
OH
Cl
O O N
OH
Cl
O
O
N
OH
OH
Cl
31 32
3334
35
36 37
38
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b
c
d e
b
f
 
 
Scheme 4. Synthetic pathway for the synthesis of 31-32. Reagents and conditions: (a) Ethylene 
glycol, p-toluene sulphonic acid monohydrate, toluene, reflux; (b) 30, DMF, K2CO3, 90 °C or 30, NaI, 
Na2CO3, CH3CN, reflux; (c) HCl, MeOH, reflux; (d) NaBH4, EtOH, 0 °C; (e) acetylchloride, Et3N, Et2O; (f) 
10% NaOH, MeOH, reflux. 
 
Compounds 39-47 were synthesized according to the procedure shown in 
Scheme 5 (method D). Diphenylmethanes, which were not commercially 
available, were obtained from benzophenones 48 in the presence of AlCl3 as a 
Lewis acid and a hydride donor (NaBH4 or tert-butylamineborane).
29,30 
Intermediates 49 were deprotonated with n-BuLi in THF, and the resulting 
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lithium salts reacted with 1,3-dibromopropane to afford bromides 50 in low 
yields.31,32 The conversion of 4-methoxydiphenylmethane (49, R1 = 4-OCH3; R2 
= H) and 3,4-dichlorodiphenylmethane (49, R1 = 3,4-Cl2; R2 = H) into the 
corresponding sodium salts or lithium salts with, respectively, NaNH2 in liquid 
NH3 or n-BuLi in THF was not successful. However, deprotonation of 3,4-
dichlorodiphenylmethane was achieved with LDA in the presence of HMPA. For 
the deprotonation of 4-methoxydiphenylmethane the base strength of n-BuLi 
was not sufficient and a mixture of n-BuLi and potassium tert-butoxide in THF 
was used. Piperidine 30 was alkylated with intermediate 50 in CH3CN in the 
presence of NaI and Na2CO3 to give the desired products 39-47. 
 
O
R1 R2
a
R1 R2 R1 R2
Br
b,c
d
N
OH
Cl
R1
R2
39-47
48 49 50
 
 
Scheme 5. Synthetic pathway for the synthesis of 39-47. Reagents and conditions: (a) AlCl3, NaBH4, 
THF, 0 °C; for R1 = 3,4-Cl2, R2 = H: AlCl3 (CH3)3CNH2.BH3, THF, 0 °C; (b) n-BuLi, THF, -20 °C; for R1 = 
3,4-Cl2, R2 = H: LDA, HMPA, THF, -78 °C; for R1 = 4-OCH3, R2 = H: n-BuLi, (CH3)3COK, -100 °C, THF; 
(c) 1-Bromo-3-chloropropane; (d) 30, NaI, Na2CO3, CH3CN, reflux. 
 
Results and discussion 
To identify a potential inverse agonist acting on US28, several GPCR-directed 
ligands were screened for their ability to modulate the basal signaling of this 
receptor. This resulted in the identification of compound 1 as the first 
nonpeptidergic inverse agonist acting on US28, as reported in an earlier paper 
describing US28 pharmacology.18 It is noted that compound 1 has previously 
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been reported as a potent antagonist for the human chemokine receptor CCR1, 
but it has no effects on the human chemokine receptors CCR5, CCR2, and 
CXCR4. Additionally, the selectivity of 1 was tested by screening against a 
number of human GPCRs and an at least 250-fold selectivity for the CCR1 
chemokine receptor was observed. As expected, the only cross-reactivity of 
compound 1 was demonstrated for several biogenic amine neurotransmitter 
receptors.24 Recently, it was also shown that this molecule binds to the human 
chemokine receptor CCR3 with micromolar affinity.33  In all, we consider 1 to be 
an unique and interesting lead structure for the development of ligands directed 
toward the new class of viral GPCRs and a good tool to study viral GPCRs in a 
variety of assays with HCMV-infected cells.  
 
Thus, compound 1 was used as a starting point for lead optimization, and 
several analogues were synthesized in order to investigate the first structure-
activity relationship for inverse agonism on US28. All the synthesized 
compounds were evaluated for their potential to dose-dependently displace 
[125I]CCL5 binding in COS-7 cells expressing US28. The effect on the US28-
mediated constitutive inositol phosphate production in transiently expressed 
COS-7 cells was investigated for a selection of compounds. It is evident from the 
results in Tables 1-4 that the IC50 and EC50 values obtained from the binding 
assay and the functional assay, respectively, correlate well with each other. To 
determine the specificity of action the selected compounds were also tested on 
the constitutively active KSHV-encoded GPCR ORF74. The observed inositol 
phosphate production in ORF74 expressing cells was not affected up to a 
concentration of 10 µM (data not shown), indicating that the influence of these 
compounds on the inositol phosphate production was selective for US28. 
 
To study the importance of the 4-chlorophenyl-4-hydroxypiperidine moiety, 
various substituted piperidine moieties were synthesized (Table 1). The influence 
of the substitution pattern of the phenyl ring was investigated by the 
substitution of the p-chlorosubstituent of 1 for substituents with different 
electronic and lipophilic properties in compounds 2-7. Interestingly, all the 
compounds with variations in the para position, including the unsubstituted 
analogue 2, were found to be less potent. The introduction of an additional 
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substituent at the meta position (m-trifluoro or m-chloro substituents in 3 and 
6, respectively) did not result in compounds with a higher affinity.  
 
Table 1. Chemical structures and pharmacological properties of compounds 1-14 and 19-20 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 and 
EC50 values of at least three independent experiments, unless otherwise indicated. 
 
CN
N
R2
R1
 
 
no. VUF R1          R2 IC50 (µM)a EC50 (µM)b 
1 2274 OH 4-Cl-phenyl 9.3 (8.7 -10.0) 3.2 (2.5 – 4.0) 
2 5660 OH phenyl 35.5 (26.9 – 46.8) 28.2 (26.3 – 30.2) 
3 5930 OH 3-CF3-4-Cl-phenyl 45.7 (38.9 – 53.7)c n.d. 
4 5931 OH 4-Br-phenyl 19.5 (15.8 – 24.0)c n.d. 
5 5753 OH 4-OCH3-phenyl 72.4 (55.0 – 95.5) 28.8 (25.7 – 32.4)c 
6 5754 OH 3,4-Cl2-phenyl 38.0 (28.2 – 51.3) n.d. 
7 5764 OH 4-CH3-phenyl 60.3 (39.8 – 91.2) n.d. 
8 5786 OH benzyl 63.1 (50.1 – 79.4) n.d. 
9 5787 OH methyl > 100 > 100 
10 5765 OH n-butyl > 100 > 100 
11 5744 OH H > 100 > 100 
12 5929 CN phenyl > 100 > 100 
13 5662 H 4-Cl-phenyl 10.5 (8.1 – 13.5) 13.8 (13.5 – 14.1) 
14 5720 H C(O)NH2 >100c > 100c 
19 5719 H COOEt 34.7 (26.3 – 45.7) > 100 
20 5718 H COOH > 100c  > 100 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Result of two 
independent experiments. n.d. = not determined.  
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For the human chemokine receptor CCR1 there is a 2-fold improvement in Ki 
value when p-chloro is replaced by a p-bromo substituent,25 but on the viral-
encoded receptor US28 the bromo substitution in 4 causes a 2-fold decrease in 
binding affinity. The binding affinities of the unsubstituted analogue 2 and 
compound 8, with a benzyl group at the 4-position of the piperidine ring, were 
comparable, but both affinities were lower than that of lead compound 1. 
Apparently, the introduction of an additional methylene group has no positive 
effect on the affinity of the compound. Removal of the 4-chlorophenyl group in 
compound 11 or substitution of this group by a CH3 group in 9 or an n-butyl 
chain in 10 resulted in complete loss of affinity. This suggests that a phenyl ring 
at the 4-position is of importance. 
 
Next, the role of the 4-hydroxy group was studied in compounds 12 and 13. It 
is noted that the 4-chlorophenyl-4-hydroxypiperidine moiety is a structural motif 
that is also present in, for example, haloperidol. For this antipsychotic drug it is 
known that the 4-hydroxy group is responsible for the conversion to potentially 
neurotoxic metabolites.34,35 In this respect, it is interesting to see that the 
affinity and activity on US28 did not change significantly after removal of the 4-
hydroxy group in 13. Substitution of the hydroxy group of 2 into a nitrile group 
in compound 12 resulted in a complete loss of both affinity and activity. Next to 
this, substitution of the 4-position of the piperidine ring with an amide (14) or 
carboxylic acid (20) function caused a complete loss of affinity and efficacy, 
while an ethyl ester at this position (19) resulted in a more than 3-fold loss of 
affinity compared to lead compound 1. 
 
The influence of the piperidine ring was investigated by the synthesis of 
compounds 15-18 (Table 2). Previously, we described that the basic nitrogen 
atom of the piperidine ring of 1 probably has an important interaction with a 
glutamic acid residue in transmembrane 7 (Glu277).18 For this reason, the 
nitrogen atom at this position was maintained. But substitution of the piperidine 
ring into a piperazine ring in 17 or tetrahydropyridine moiety in 18 abolished 
activity. The loss of activity of both compounds might be due to a change in 
conformation of the 4-chlorophenyl ring through which the interaction of the 
aromatic moiety with the receptor is lost.  
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Table 2. Chemical structures and pharmacological properties of compounds 1 and 15-18 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 and 
EC50 values of at least three independent experiments, unless otherwise indicated. 
 
CN
R
 
 
no. VUF        R IC50 (µM)a EC50 (µM)b 
1 2274 N
OH
Cl
 
9.3 (8.7 -10.0) 3.2 (2.5 – 4.0) 
15 5875 N
 
> 100 > 100 
16 4999 N+
OH
Cl
 
> 100 > 100 
17 5658 N N Cl
 
> 100 > 100 
18 5664 N Cl  
 
> 100 > 100 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. 
 
Introduction of the bulky 4-(diphenylmethylene)piperidine moiety of analogue 
15 was detrimental for both affinity and potency. Methylation of the piperidine 
nitrogen atom of compound 1 gave quaternary ammonium salt 16. 
Interestingly, this variation resulted in complete loss of binding affinity and 
activity on US28. For the human chemokine receptor CCR1 this modification 
resulted in a more than 6-fold increase in binding affinity,25 clearly illustrating 
selectivity of compound 16 in favor of the CCR1 chemokine receptor. This 
indicates that there is a difference in structure-activity relationships of these 
compounds for both receptors, like that shown earlier in this section for 
compound 4. Taken together, several analogues were synthesized to optimize 
the piperidine motif in the molecule, but all the variations in this part of the 
molecule resulted in a loss of affinity and potency.  
 
Next, the influence of the diphenylacetonitrile moiety was investigated (Tables 3 
and 4). The influence of the two phenyl rings was investigated by removal of 
one of the phenyl rings in compound 27 or replacement by more hydrophilic 
groups, namely a carbonyl group in compound 31 and a hydroxy group in 
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compound 32. Previously, it was suggested that a bulky lipophilic moiety is 
important at this position,18 but we observed that removal of a phenyl ring as in 
27 resulted in a binding affinity comparable to that of lead compound 1. In 
contrast, the more hydrophilic groups in 31-32 resulted in loss of effect. Also 
the introduction of an isosteric oxygen atom in the butyl chain in compound 26 
did not improve affinity.  
 
Table 3. Chemical structures and pharmacological properties of compounds 1, 26-27, 31-32 and 39 
for the HCMV-encoded receptor US28. The values are represented as the mean and the interval of the 
IC50 and EC50 values of at least three independent experiments, unless otherwise indicated. 
 
N
OH
Cl
R
 
 
no. VUF R IC50 (µM)a EC50 (µM)b 
1 2274 
Ph
Ph
NC
 
9.3 (8.7 -10.0) 3.2 (2.5 – 4.0) 
39 5667 
Ph
Ph  
6.5 (6.0 – 6.9) 4.2 (3.1 – 5.6) 
26 5714 
Ph
O
 
61.7 (57.5 – 66.1)c n.d 
27 5746 
Ph  
14.8 (13.8 – 15.8) n.d. 
31 5666 
Ph
O
 
> 100c n.d. 
32 (±)-5715 
Ph
HO
 
 
> 100 > 100 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Result of two experiments. 
n.d. = not determined. 
 
Interestingly, the nitrile group of compound 1 is not essential in the molecule 
because its removal, resulting in compound 39, did not affect the activity of the 
compound (Table 4). Compounds 40-42 and 44-47 possess a chiral center as a 
result of the substitution in one or both of the phenyl rings. The two 
enantiomers were not separated, and the activity was thus determined for the 
racemic mixtures. Compounds 40-42 and 46 were synthesized to determine the 
effects of the introduction of para substituents with different electronic and 
lipohilic properties in the two aromatic rings. The variations in the substitution 
pattern in the para position did not significantly influence the activity of the 
compounds. Also, the introduction of an additional p-chloro atom (compound 
43) did not increase the affinity of the compound for US28.  
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Table 4. Chemical structures and pharmacological properties of compounds 39-47 for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments, unless otherwise indicated. 
 
N
OH
Cl
R1
R2  
no. VUF R1 R2 IC50 (µM)a EC50 (µM)b 
39 5667 H H 6.5 (6.0 – 6.9) 4.2 (3.1 – 5.6) 
40 (±)-5857 4-OCH3 H 15.5 (13.2 – 18.2) n.d 
41 (±)-5858 3,4-Cl2 H 15.8 (14.5 – 17.4) n.d. 
42 (±)-5859 4-Cl H 17.0 (16.6 – 17.4) n.d. 
43 5860 4-Cl 4-Cl 17.4 (16.2 – 18.6) n.d. 
44 (±)-5861 2-CH3 H 5.5 (5.0 – 6.0) 9.8 (9.5 – 10.0)c 
45 (±)-5862 3-CH3 H 11.5 (8.7 – 15.1) n.d. 
46 (±)-5863 4-CH3 H 30.9 (27.5 – 34.7) 11.5 (11.0 – 12.0)c 
47 (±)-5864 4-Cl 4-phenyl > 100 > 100 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Result of two independent 
experiments. n.d. = not determined. 
 
The differences in binding affinities between the methyl-substituted analogues 
44-46 and the unsubstituted analogue 39 reveal a slight preference for o-
methyl substitution. This could be caused by the restricted conformational 
freedom of the substructure in compound 44. Methyl substitution at the ortho 
position of a similar aromatic benzhydryl sytem was previously described for a 
series of histamine H1 receptor antagonists. It is suggested that the o-methyl 
analogue of diphenhydramine has a markedly reduced antihistamine activity 
because the methyl group in that position prevents the molecule from adopting 
the conformation necessary for antihistamine activity.36 The influence of a bulky 
aromatic substituent in the para position was investigated by the synthesis of 
analogue 47. The additional p-phenyl group resulted in a loss of affinity and 
potency, and it seems that bulky substituents are not allowed at this position.  
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Conclusions 
This is the very first study of small molecules acting as inverse agonists on 
US28. We described the synthesis of compound 1 and different analogues, which 
were evaluated for their binding affinity by displacement of [125I]CCL5. 
Moreover, a selection of compounds was evaluated for their functionality by 
measuring the effect on the US28-mediated constitutive inositol phosphate 
production. This resulted in unique structure-activity relationships for the first 
small molecule US28 receptor ligands.  
With this study we have acquired important new insights about the first inverse 
agonists acting on US28. These structural insights will be used to develop new 
compounds with an improved affinity and potency as well as a better selectivity 
for this receptor. These small molecules may serve as important tools to 
investigate the significance of the constitutive activity and the role of US28 
during viral infection. 
 
Experimental section 
General procedures. 1H NMR spectra were recorded on a Bruker AC-200 (200 MHz) spectrometer with 
tetramethylsilane as internal standard. J.T. Baker silica gel was used for flash chromatography. Mass 
spectra were recorded on a Finnigan MAT-90 mass spectrometer. Melting points were measured on an 
Electrothermal IA9200 apparatus and were uncorrected. Elemental analyses were performed by 
Microanalytisches Labor Pascher, Remagen-Bandorf, Germany and the results were within ± 0.4% of 
the theoretical values unless otherwise stated. The solvents were dried according to standard 
procedures. All reactions were performed under an atmosphere of dry nitrogen. 
 General method A. 5-(4-(4-Chlorophenyl)-piperazin-1-yl)-2,2-diphenypentanenitrile 
(17). A solution of 22a (0.51 g, 1.88 mmol), which was synthesized according to literature 
procedure,24 4-chlorophenylpiperazine (0.45 g, 1.67 mmol), and K2CO3 (3.53 g, 25.6 mmol) in DMF (25 
mL) was stirred overnight at 90 °C. The solvent was removed in vacuo, and the residue was dissolved 
in water (25 mL) followed by an extraction with EtOAc (3 x 10 mL). The combined organic layers were 
washed with water (2 x 10 mL), dried over anhydrous MgSO4, and filtered. After evaporation in vacuo, 
the residue was purified by flash chromatography (0-100% EtOAc in DCM) to give 107 mg (15%) of 17 
as a light-yellow solid. Mp: 126.2-126.7 °C. 1H NMR (CDCl3): δ 1.52-1.71 (m, 2H), 2.37-2.51 (m, 8H), 
3.11 (m, 4H), 6.80 (d, J = 9.0 Hz, 2H), 7.15-7.40 (m, 12H). MS ESI m/z: 431.0 (M+H)+. Anal. 
(C27H28ClN3) C, H, N.  
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 General method B. 5-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenyl- 
pentanenitrile (1). A solution of 22b (0.94 g, 3.00 mmol), which was synthesized according to 
literature procedure,25 4-(4-chlorophenyl)-4-piperidinol 30 (0.67 g, 3.15 mmol), NaI (0.50 g, 3.31 
mmol), and Na2CO3 (0.64 g, 6.04 mmol) in CH3CN (25 mL) was refluxed overnight. The solvent was 
removed in vacuo and the residue was diluted with water (50 mL) followed by an extraction with DCM 
(3 x 30 mL). The combined organic layers were dried over anhydrous MgSO4, filtered, and evaporated 
in vacuo. Purification by flash chromatography (0-100% EtOAc in DCM) and crystallization from EtOAc 
gave 1.04 g (78%) of 1 as a white solid. Mp: 133.6-135.2 °C. 1H NMR (CDCl3): δ 1.55-1.70 (m, 4H), 
1.93-2.12 (m, 3H), 2.28-2.50 (m, 6H), 2.61-2.78 (m, 2H), 7.18-7.48 (m, 14H). MS ESI m/z: 446.9 
(M+H)+. Anal. (C28H29N2ClO·0.21EtOAc) C, H, N. 
 General method C. 5-(4-(4-Methoxyphenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenyl- 
pentanenitrile (5). A solution of (4-methoxyphenyl)magnesium bromide37 (7.7 mL, 0.5 M in dry Et2O, 
3.6 mmol) was cooled to 0 °C, and a solution of 25 (1.00 g, 3.00 mmol), which was synthesized 
according to literature procedure,25 dissolved in THF (15 mL) was added in one portion via a dropping 
funnel. The reaction mixture was stirred at room temperature for 4 h, and the reaction was quenched 
with water (30 mL). This solution was acidified with 1 N HCl, stirred for 15 min and basified with K2CO3. 
The product was extracted with EtOAc (3 x 100mL) and the combined organic layers were washed with 
water (2 x 100 mL) and brine (100 mL), dried over anhydrous MgSO4, filtered, and evaporated under 
reduced pressure. Purification by flash chromatography (EtOAc) afforded 780 mg (59%) of 5. 
Recrystallization of one batch from Et2O gave 190 mg (14%) of 5 as white crystals. Mp: 84.7-86.6 °C. 
1H NMR (CDCl3): δ 1.69-1.74 (m, 5H), 2.02-2.18 (m, 2H), 2.35-2.50 (m, 6H), 2.68-2.79 (m, 2H), 3.78 
(s, 3H), 6.86 (d, J = 8.9 Hz, 2H), 7.24-7.42 (m, 12H). MS ESI m/z: 441.4 (M+H)+. Anal. 
(C29H32N2O2) C, H, N.  
 General method D. 4-(4-Chlorophenyl)-1-(4-phenyl-4-o-tolylbutyl)piperidin-4-ol (44).  
(i) A solution of 2-methylbenzophenone (5.34 g, 27.2 mmol) in THF (125 mL) was cooled to 0 °C, and 
subsequently AlCl3 (10.06 g, 75.4 mmol) and NaBH4 (5.26 g, 139 mmol) were added. The reaction 
mixture was heated and refluxed for 3 h. Next, the mixture was cooled to 0 °C and diluted carefully by 
the dropwise addition of water (100 mL). After separation of the organic layer, the water layer was 
extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (3 x 150 mL) 
and brine (150 mL), dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
Purification by flash chromatography (hexane) gave 3.81 g (77%) of 2-methyldiphenylmethane as a 
colourless oil. 1H NMR (CDCl3): δ 2.37 (s, 3H), 4.11 (s, 2H), 7.20-7.46 (m, 9H).  
(ii) A solution of 2-methyldiphenylmethane (1.87 g, 10.3 mmol) in THF (20 mL) was cooled to -20 °C, 
and n-BuLi (6.40 mL, 1.6 M in hexane, 10.2 mmol) was added. The solution was stirred for 1 h and 
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added slowly to a solution of 1,3-dibromopropane (2.30 mL, 22.7 mmol) in THF (35 mL) at -76 °C. The 
mixture was allowed to warm to room temperature and stirred for 30 min. The solvent was evaporated 
under reduced pressure. Water (25 mL) was added to the residue, and the water layer was extracted 
with EtOAc (3 × 25 mL). The combined organic layers were washed with water (3 × 50 mL) and brine 
(50 mL), dried over anhydrous MgSO4, filtered, and evaporated under reduced pressure. The residue 
was purified by flash chromatography (hexane) to give 0.81 g (26%) of bromide 50 (R1 = 2-Me; R2 = 
H) as a colourless oil. 1H NMR (CDCl3): δ 1.87-2.00 (m, 2H), 2.18-2.30 (m, 2H), 2.34 (s, 3H), 3.44 (t, J 
= 6.6 Hz, 2H), 4.18 (t, J = 8.1 Hz, 1H), 7.18-7.42 (m, 9H).  
(iii) 50 was reacted with 4-(4-chlorophenyl)-4-piperidinol 30 (0.70 g, 3.3 mmol) according to method B 
to give 834 mg (72%) of 44 as white crystals after recrystallization from EtOAc. Mp: 143.1-144.4 °C. 
1H NMR (CDCl3): δ 1.55-1.69 (m, 5H), 2.00-2.12 (m, 4H), 2.25 (s, 3H), 2.33-2.44 (m, 4H), 2.71-2.78 
(m, 2H), 4.09 (t, J = 7.6 Hz, 1H), 7.07-7.33 (m, 11H), 7.41 (d, J = 8.8 Hz, 2H). MS ESI m/z: 434.4 
(M+H)+. Anal. (C28H32ClNO) C, H, N, Cl.  
 5-(4-Hydroxy-4-phenylpiperidin-1-yl)-2,2-diphenylpentanenitrile (2). Following method A 
using 22a (0.51 g, 1.90 mmol) and 4-hydroxy-4-phenylpiperidine (0.34 g, 1.93 mmol) gave 319 mg 
(42%) of 2 as a white solid.24 Mp: 73.6-74.7 °C. 1H NMR (CDCl3): δ 1.51-1.80 (m, 4H), 2.06-2.19 (m, 
3H), 2.30-2.50 (m, 6H), 2.64-2.78 (m, 2H), 7.12-7.51 (m, 15H). MS ESI m/z: 411.3 (M+H)+. Anal. 
(C28H30N2O·0.36H2O) C, H, N. 
 5-(4-(3-Chloro-4-trifluoromethylphenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenylpentane-
nitrile hydrochloride (3). Using 22a (0.65 g, 2.40 mmol) and 4-(4-chloro-3-(trifluoromethyl)phenyl)-
4-piperidinol (0.56 g, 2.01 mmol) gave 0.93 g (90%) of the free base as a thick oil. This was dissolved 
in MeOH (5 mL), and subsequently 6 N HCl (0.15 mL) and Et2O (20 mL) were added dropwise while 
stirring. The hydrochloride salt was isolated by filtration and recrystallized from Et2O/MeOH to give 666 
mg (67%) of 3 as a white solid. Mp: 231.2-234.0 °C (dec). 1H NMR (CDCl3): δ 1.61-1.82 (m, 5H), 2.07-
2.26 (m, 2H), 2.31-2.53 (m, 6H), 2.70-2.89 (m, 2H), 7.24-7.46 (m, 13H). MS ESI m/z: 513.4 (M+H)+. 
Anal. (C29H29Cl2N2F3O) C, H, N. 
 5-(4-(4-Bromophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile (4).  
Following method B using 22a (0.65 g, 2.39 mmol) and 4-(4-bromophenyl)-4-piperidinol (0.51 g, 2.01 
mmol) gave 819 mg (83%) of 4 as a white solid. Mp: 131.6-132.5 °C. 1H NMR (CDCl3): δ 1.61-1.82 (m, 
5H), 2.07-2.26 (m, 2H), 2.31-2.53 (m, 6H), 2.70-2.89 (m, 2H), 7.24-7.46 (m, 14H). MS ESI m/z: 
490.8 (M+H)+. Anal. (C28H29N2BrO·0.34DCM) C, H, N. 
 5-(4-(3,4-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile (6).  
Following method C using 25 (1.00 g, 3.00 mmol) and (3,4-dichlorophenyl)magnesium bromide37 (3.3 
mL, 1.1 M in dry Et2O, 3.6 mmol) followed by purification by flash chromatography (0-100% EtOAc in 
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DCM) afforded 944 mg of 6. Recrystallization from Et2O gave 212 mg (15%) of 6 as white crystals. Mp: 
102.0-103.4 °C. 1H NMR (CDCl3): δ 1.59-1.68 (m, 5H), 2.01-2.12 (m, 2H), 2.28-2.49 (m, 6H), 2.68-
2.79 (m, 2H), 7.24-7.41 (m, 12H), 7.59 (d, J = 2.1 Hz, 1H). MS ESI m/z: 479.5 (M+H)+. Anal. 
(C28H28Cl2N2O) C, H, N, Cl. 
 5-(4-Hydroxy-4-p-tolylpiperidin-1-yl)-2,2-diphenylpentanenitrile hydrochloride (7). 
Following method C using 25 (1.00 g, 3.00 mmol) and p-tolylmagnesium bromide37 (3.6 mL, 1.0 M in 
dry Et2O, 3.6 mmol) gave 280 mg of the free base as a thick oil. This was converted to the 
hydrochloride salt as described for 3. Recrystallization of one batch from Et2O/MeOH gave 141 mg 
(10%) of 7 as a white solid. Mp: 225.0-226.3 °C. 1H NMR (CDCl3): δ 1.81-2.03 (m, 5H), 2.30 (s, 3H), 
2.62-2.71 (m, 2H), 2.75-2.92 (m, 2H), 3.01-3.22 (m, 6H), 7.13 (d, J = 8.1 Hz, 2H), 7.24-7.45 (m, 
12H), 12.15 (br s, 1H). MS ESI m/z: 425.4 (M+H)+. Anal. (C29H33ClN2O) C, H, N, Cl. 
 5-(4-Benzyl-4-hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile hydrochloride (8). 
Following method C using 25 (1.00 g, 3.00 mmol) and benzylmagnesium bromide37 (3.4 mL, 1.1 M in 
dry Et2O, 3.7 mmol) gave 147 mg of the free base as a thick oil. This was converted to the 
hydrochloride salt as described for 3. One batch was recrystallized from Et2O/MeOH to give 86 mg (5%) 
of 8 as a white solid. Mp: 121.8-123.8 °C. 1H NMR (CDCl3): δ 1.51-1.65 (m, 3H), 1.90-1.99 (m, 2H), 
2.38-2.51 (m, 2H), 2.59-2.65 (m, 2H), 2.80 (s, 2H), 2.89-3.00 (m, 4H), 3.14-3.22 (m, 2H), 7.16-7.38 
(m, 15H), 12.02 (br s, 1H). MS ESI m/z: 425.5 (M+H)+. Anal. (C29H33ClN2O·1.0H2O) C, H, N, Cl. 
 5-(4-Hydroxy-4-methylpiperidin-1-yl)-2,2-diphenylpentanenitrile hydrochloride (9). 
Following method C using 25 (1.00 g, 4.00 mmol) and methylmagnesium iodide37 (2.8 mL, 1.3 M in dry 
Et2O, 3.6 mmol) followed by purification by flash chromatography (0-7% EtOH in DCM) gave 500 mg of 
the free base as a thick oil. This was converted to the hydrochloride salt as described for 3. 
Recrystallization from Et2O/MeOH gave 441 mg (42%) of 9 as a white solid. Mp: 192.7-193.5 °C. 1H 
NMR (CDCl3): δ 1.32 (s, 3H), 1.63-1.69 (m, 3H), 1.88-2.05 (m, 2H), 2.28-2.44 (m, 2H), 2.62 (t, J = 
7.9 Hz, 2H), 2.90-3.21 (m, 6H), 7.24-7.43 (m, 10H), 11.88 (br s, 1H). MS ESI m/z: 349.4 (M+H)+. 
Anal. (C23H29ClN2O) C, H, N, Cl. 
 5-(4-Butyl-4-hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile hydrochloride (10). This 
compound was synthesized as described in the literature25 and converted to the hydrochloride salt as 
described for 3. One batch was recrystallized from Et2O/MeOH to afford 304 mg (18%) of 10 as a white 
solid. Mp: 174.2-176.0 °C (dec). 1H NMR (CDCl3): δ 0.80-0.93 (t, J = 4.6 Hz, 3H), 1.18-1.40 (m, 4H), 
1.48-1.71 (m, 5H) 1.88-2.08 (m, 2H), 2.28-2.43 (m, 2H), 2.60-70 (m, 2H), 2.89-3.22 (m, 6H), 7.24-
7.44 (m, 10H), 12.02 (br s, 1H). MS ESI m/z: 391.4 (M+H)+. Anal. (C26H35ClN2O) C, H, N, Cl. 
 5-(4-Hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile (11). Following method B using 
22b (0.95 g, 3.01 mmol) and piperidin-4-ol (0.38 g, 3.75 mmol) followed by purification by flash 
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chromatography (10-50% MeOH in EtOAc) afforded 374 mg (37%) of 11 as a white solid. 25 Mp: 114.8-
115.8 °C. 1H NMR (CDCl3): δ 1.39-1.68 (m 5H), 1.80-1.91 (m, 2H), 1.95-2.11 (m, 2H), 2.31-2.44 (m, 
4H), 2.59-2.71 (m, 2H), 3.59-3.72 (m, 1H), 7.22-7.42 (m, 10H). MS ESI m/z: 335.3 (M+H)+. Anal. 
(C22H26N2O) C, H, N. 
 1-(4-Cyano-4,4-diphenylbutyl)-4-phenylpiperidine-4-carbonitrile (12). Following method B 
using 22a (0.65 g, 2.40 mmol) and 4-phenyl-piperidine-4-carbonitrile (0.45 g, 2.00 mmol) followed by 
crystallization from DCM/Et2O gave 599 mg (66%) of 12 as a white solid. Mp: 137.5-138.7 °C. 1H NMR 
(CDCl3): δ 1.59-1.71 (m, 2H), 2.02-2.08 (m, 4H), 2.33-2.49 (m, 6H), 2.83-2.97 (m, 2H), 7.24-7.50 
(m, 15H). MS ESI m/z: 420.7 (M+H)+. Anal. (C29H29N3) C, H, N. 
 5-(4-(4-Chlorophenyl)-piperidin-1-yl)-2,2-diphenylpentanenitrile (13). A solution of 4-(4-
chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride (1.00 g, 4.35 mmol) and 5% Pd/C (100 mg) in 
EtOH (25 mL) was stirred for 4 h under hydrogen. The solution was filtered and evaporated under 
reduced pressure. The residue was used without further purification, dissolved in DMF and reacted 
following method A using 22a (0.63 g, 2.34 mmol). This afforded 954 mg (51%) of 13 as a white solid. 
Mp: 112.6-113.4 °C. 1H NMR (CDCl3): δ 1.55-1.83 (m, 6H), 1.89-2.08 (m, 2H), 2.35-2.56 (m, 5H), 
2.89-3.01 (m, 2H), 7.09-7.43 (m, 14H). MS ESI m/z: 430.0 (M+H)+. Anal. (C28H29ClN2) C, H, N. 
 1-(4-Cyano-4,4-diphenylbutyl)piperidine-4-carboxylic acid amide (14). Following method 
B using 22b (0.94 g, 3.00 mmol) and piperidine-4-carboxylic acid amide (0.39 g, 3.00 mmol) gave 796 
mg (73%) of 14 as an orange oil. 1H NMR (CDCl3): δ 1.61-2.52 (m, 13 H), 2.76-2.99 (m, 2H), 5.57 (br 
s, 2H), 7.24-7.45 (m, 10H). MS ESI m/z: 362.3 (M+H)+. Anal. (C25H27N2O2·0.44DCM) C, H, N. 
 5-(4-(Diphenylmethylene)piperidin-1-yl)-2,2-diphenylpentanenitrile hydrochloride (15). 
Following method B using 22b (0.92 g, 2.91 mmol) and 4-(diphenylmethylene)piperidine27 (0.72 g, 
2.86 mmol) followed by purification by flash chromatography (0-25% EtOAc in DCM) gave the free base 
as a thick oil. This was dissolved in a solution of MeOH (5 mL) and subsequently 6 N HCl (0.15 mL) and 
Et2O (20 mL) were added dropwise while stirring. The hydrochloride salt was isolated by filtration and 
recrystallized from Et2O/MeOH giving 863 mg (58%) of 15 as a white solid. Mp: 106.8-108.5. 1H NMR 
(CH3OH-d4): δ 1.80-1.99 (m, 2H), 2.54-2.75 (m, 6H), 3.20-3.36 (m, 6H), 7.10-7.47 (m, 20H). MS ESI 
m/z: 483.9 (M+H)+. Anal. (C35H36Cl2N2·1.0H2O) C, H, N. 
 4-(4-Chlorophenyl)-1-(4-cyano-4,4-diphenylbutyl)-4-hydroxy-1-methylpiperidinium 
iodide (16). Following the same procedure as described in the literature25 afforded 206 mg (70%) of 
16 as a white solid. Mp: 215.8 – 216.9 1H NMR (CDCl3/DMSO-d6): δ 1.70-2.00 (m, 4H), 2.06-2.31 (m, 
2H), 2.35-2.60 (m, 2H), 3.18 (s, 3H), 3.30-3.50 (m, 2H), 3.52-3.90 (m, 4H), 4.94 (br s, OH), 7.12-
7.43 (m, 14H). MS ESI m/z: 460.0 (M+H)+. Anal. (C27H32ClN2O) C, H, N. 
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 5-(4-(4-Chlorophenyl)-3,6-dihydro-2H-pyridin-1-yl)-2,2-diphenylpentanenitrile (18). 
Following method A using 22a (0.81 g, 3.00 mmol) and 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine 
27 (0.69 g, 3.00 mmol) afforded 400 mg (31%) of 18 as a yellow solid. Mp: 142.1-142.8 °C. 1H NMR 
(CDCl3): δ 1.56-1.78 (m, 2H), 2.41-2.62 (m, 8H), 3.06 (d, J = 3.1 Hz, 2H), 6.01 (m, 1H), 7.22-7.42 
(m, 14H). MS ESI m/z: 427.9 (M+H)+. Anal. (C28H27ClN2) C, H, N. 
 1-(4-Cyano-4,4-diphenylbutyl)-piperidine-4-carboxylic acid ethyl ester (19). Following 
method B using 22b (1.26 g, 4.01 mmol) and piperidine-4-carboxylic acid ethyl ester 24 (0.79 g, 5.03 
mmol) gave 1.65 g (84%) of 19 as an orange oil. 1H NMR (CDCl3): δ 1.25 (t, J = 8.0 Hz, 3H), 1.45–
2.00 (m, 8H), 2.15-2.50 (m, 5H), 2.65-2.80 (m, 2H), 4.10 (m, 2H), 7.20-7.45 (m, 10H). MS ESI m/z: 
391.4 (M+H)+. Anal. (C25H30N2O2) C, H, N. 
 1-(4-Cyano-4,4-diphenylbutyl)piperidine-4-carboxylic acid hydrochloride (20). A solution 
of 19 (1.41 g, 3.61 mmol) and 2M NaOH (5 mL) in MeOH (30 mL) was refluxed for 3 h. The reaction 
mixture was allowed to cool to room temperature, evaporated in vacuo, diluted with water (30 mL), 
and extracted with Et2O (1 x 30 mL). The water layer was acidified with 2 N HCl, and 1.23 g (86%) of 
20 was isolated by filtration as a white solid. Mp: 231.0-233.1 °C. 1H NMR (DMSO-d6/D2O): δ 1.40–1.80 
(m, 4H), 1.75-2.15 (m, 2H), 2.40-2.65 (m, 3H), 2.70-2.94 (m, 2H), 2.96-3.18 (m, 2H), 3.27-3.39 (m, 
2H), 7.29-7.54 (m, 10H). MS ESI m/z: 363.8 (M+H)+. Anal. (C23H27ClN2O2·0.41H2O) C, H, N. 
 4-(4-Chlorophenyl)-1-(3-phenoxypropyl)piperidin-4-ol (26). Following method B using 28 
(0.65 g, 3.00 mmol) and 4-(4-chlorophenyl)-4-piperidinol 30 (0.42 g, 2.00 mmol) gave a mixture of 26 
and the quaternary product. The quaternary product was separated from 26 by fractional crystallization 
in CHCl3. The filtrate was concentrated under reduced pressure and recrystallized from EtOAc to give 
203 mg (29%) of 26 as white needles. Mp: 125.8-127.3 °C. 1H NMR (CDCl3/DMSO-d6): δ 1.61-1.82 (m, 
3H), 1.88-2.19 (m, 4H), 2.32-2.65 (m, 4H), 2.75-2.90 (m, 2H), 4.03 (t, J = 6.0 Hz, 2H), 6.80-6.95 (m, 
3H), 7.15-7.34 (m, 4H), 7.36-7.45 (m, 2H). MS ESI m/z: 347.6 (M+H)+. Anal. (C20H24ClNO2) C, H, N. 
 4-(4-Chlorophenyl)-1-(4-phenylbutyl)piperidin-4-ol (27). Following method B using 1-
chloro-4-phenylbutane 29 (0.49 mL, 2.98 mmol) and 4-(4-chlorophenyl)-4-piperidinol 30 (0.70 g, 3.30 
mmol) gave 310 mg (35%) of 27 as a white solid.33 Mp: 112.5-114.0 °C. 1H NMR (CDCl3): δ 1.50-1.72 
(m, 7H), 2.00-2.17 (m, 2H), 2.25-2.43 (m, 4H), 2.62 (t, J = 7.1 Hz, 2H), 2.72-2.85 (m, 2H), 7.15-7.31 
(m, 7H), 7.42 (d, J = 8.6 Hz, 2H). MS ESI m/z: 344.3 (M+H)+. Anal. (C21H26ClNO) C, H, N, Cl. 
 4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-phenylbutan-1-one (31). (i) A solution 
of 33 (6 mL, 37.4 mmol), ethylene glycol (6 mL, 108 mmol) and p-toluenesulphonic acid monohydrate 
(0.50 g, 2.63 mmol) in toluene (400 mL) was refluxed overnight with azeotropic removal of water. The 
organic layer was washed with 5% NaHCO3 (250 mL) and water (250 mL), dried over anhydrous 
Na2SO4, and evaporated in vacuo to give 9.69 g (98%) of 34 as an orange solid.  
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(ii) Following method B using 34 (0.72 g, 3.19 mmol) and 4-(4-chlorophenyl)-4-piperidinol 30 (0.57 g, 
2.69 mmol) gave 1.28 g of a brown oil. This was dissolved in MeOH (15 mL), and concentrated HCl (1.4 
mL) was added. The resulting reaction mixture was refluxed for 2 h, allowed to cool to room 
temperature, and evaporated in vacuo. The resulting brown oil was dissolved in EtOAc (25 mL) and 
washed with NH4OH (5% solution in water, 2 x 15 mL) and water (2 x 5 mL). The organic layer was 
dried over anhydrous MgSO4, rinsed with hexane, and evaporated in vacuo to give 522 mg (53%) of 31 
as a white solid. Mp: 130.4-131.8 °C. 1H NMR (CDCl3): δ 1.67-1.79 (m, 2H), 1.92-2.13 (m, 2H), 2.16-
2.32 (m, 2H), 2.98-3.54 (m, 8H), 4.18 (br s, OH), 7.03-7.58 (m, 7H), 7.77 (d, J = 7.0 Hz, 2H). MS ESI 
m/z: 358.2 (M+H)+. Anal. (C21H24ClNO2·0.24hexane) C, H, N.  
 4-(4-Chlorophenyl)-1-(4-hydroxy-4-phenylbutyl)piperidin-4-ol (32). (i) 33 (3.94 g, 21.64 
mmol) was dissolved in EtOH (25 mL), and NaBH4 (0.42 g, 11.10 mmol) was added in small portions at 
0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 1 h. After the 
addition of water (25 mL), the reaction mixture was extracted with Et2O (3 x 25 mL). The combined 
organic layers were dried over anhydrous MgSO4, filtered, and evaporated in vacuo to give 3.69 g 
(93%) of 36 as colourless oil, which was used without further purification.  
(ii) Et3N (8.5 mL, 61.2 mmol) and acetyl chloride (2.6 mL, 30.6 mmol) were added to a solution of 36 
in Et2O (50 mL). The reaction mixture was stirred at room temperature for 1 h, diluted with water (25 
mL) and extracted with Et2O (3 x 25 mL). The combined organic layers were washed with aqueous 
K2CO3 (25 mL), dried over anhydrous MgSO4, and evaporated in vacuo to give 2.51 g (51%) of 37 as 
brown oil, which was used without further purification. 
(iii) Following method B using 37 (0.68 g, 3.00 mmol) and 4-(4-chlorophenyl)-4-piperidinol 30 (0.70 g, 
3.32 mmol) gave 1.24 g of 38. This was dissolved in MeOH (25 mL), and 10% NaOH (5 mL) was 
added. The resulting reaction mixture was refluxed for 30 min, evaporated in vacuo and extracted with 
DCM (3 × 25 mL). The combined organic layers were dried over anhydrous MgSO4, filtered, and 
evaporated in vacuo. The residue was purified by flash chromatography (0-10% MeOH in EtOAc) to give 
449 mg (41%) of 32 as a white solid. Mp: 144.4-145.8 °C. 1H NMR (CDCl3): δ 1.51-2.07 (m, 8H), 2.09-
2.31 (m, 2H), 2.40-2.69 (m, 4H), 2.74-2.90 (m, 1H), 2.92-3.10 (m, 1H), 4.59-4.71 (m, 1H), 7.10-7.49 
(m 9H). MS ESI m/z: 360.9 (M + H)+. Anal. (C21H26ClN2O2) C, H, N. 
 4-(4-Chlorophenyl)-1-(4,4-diphenylbutyl)piperidin-4-ol (39). Following method B using 4-
chloro-1,1-diphenylbutane (0.82 g, 3.16 mmol), which was synthesized according to literature 
procedure,31 and 30 (0.52 g, 2.34 mmol) gave 329 mg (32%) of 39 as a yellow solid. Mp: 110.1-110.8 
°C. 1H NMR (CDCl3): δ 1.39-1.79 (m, 5H), 2.00-2.19 (m, 4H), 2.22-2.49 (m, 4H), 2.67-2.83 (m, 2H), 
3.89 (t, J = 7.8 Hz, 1H), 7.14-7.43 (m, 14H). MS ESI m/z: 421.2 (M+H)+. Anal. (C27H30ClNO) C, H, N. 
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 4-(4-Chlorophenyl)-1-(4-(4-methoxyphenyl)-4-phenylbutyl)piperidin-4-ol (40).  
(i) Following method D (step i) starting with 4-methoxybenzophenone (5.75 g, 27.1 mmol) gave 3.18 g 
(59%) of 4-methoxydiphenylmethane as a colourless oil. 1H NMR (CDCl3): δ 3.87 (s, 3H), 4.06 (s, 2H), 
6.97 (d, J = 8.5 Hz, 2H), 7.22-7.41 (m, 7H).  
(ii) A solution of potassium-tert-butoxide (0.90 g, 8.0 mmol) in THF (20 mL) was added to a solution of 
n-BuLi (5.00 mL, 1.6 M in hexane, 8.0 mmol) in a dry atmosphere at -100 °C. The reaction mixture was 
stirred for 5 min, and a solution of 4-methoxydiphenylmethane (1.58 g, 7.97 mmol) in THF (15 mL) 
was added slowly in a period of 15 min. The solution was stirred for 1 h at -95 °C and 1,3-
dibromopropane was added in one portion (4.0 mL, 39.4 mmol). The reaction mixture was allowed to 
warm to room temperature and was stirred for 1.5 h. The solvent was evaporated under reduced 
pressure, and the residue was diluted with water (25 mL) and extracted with EtOAc (3 × 25 mL). The 
combined organic layers were washed with water (3 × 25 mL) and brine (25 mL), dried over anhydrous 
MgSO4, filtered, and evaporated under reduced pressure to afford bromide 50 (R1 = 4-OCH3; R2 = H). 
The crude product was used without further purification.  
(iii) Bromide 50 (R1 = 4-OCH3; R2 = H) was dissolved in CH3CN, and reacted following method B. 
Purification by flash chromatography (50% DCM in EtOAc) and recrystallization from EtOAc gave 548 
mg (15%) of 40 as white crystals. Mp: 119.7-121.0 °C. 1H NMR (CDCl3): δ 1.47-1.69 (m, 5H), 2.00-
2.11 (m, 4H), 2.26-2.43 (m, 4H), 2.69-2.75 (m, 2H), 3.74 (s, 3H), 3.84 (t, J = 7.8 Hz, 1H), 6.79 (d, J 
= 8.7 Hz, 2H), 7.11-7.37 (m, 9H), 7.41 (d, J = 8.7 Hz, 2H). MS ESI m/z: 450.4 (M+H)+. Anal. 
(C28H32ClNO2) C, H, N, Cl. 
 4-(4-Chlorophenyl)-1-(4-(3,4-dichlorophenyl)-4-phenylbutyl)piperidin-4-ol 
hydrochloride (41). (i) A solution of AlCl3 (7.36 g, 55.2 mmol) and tert-butylamineborane (9.95 g, 
111 mmol) in DCM (150 mL) was stirred for 10 min at 0 °C, and a solution of 3,4-dichlorobenzophenone 
(4.64 g, 18.4 mmol) in DCM (15 mL) was added. The mixture was stirred for 2 h at 0 °C and overnight 
at room temperature. A cooled solution of 0.1 N HCl (75 mL) at 0 °C was added carefully followed by 
extraction with EtOAc (100 mL). The combined organic layers were washed with 0.1 N HCl (2 × 75 mL) 
and brine (100 mL), dried over anhydrous MgSO4, filtered, and evaporated under reduced pressure. 
The residue was purified by flash chromatography (hexane) to afford 3.43 g (78%) of 3,4-
dichloromethane as a colourless oil. 1H NMR (CDCl3): δ 3.93 (s, 2H), 6.99-7.68 (m, 8H). 
(ii) A solution of diisopropylamine (1.22 mL, 8.68 mmol) in THF (5 mL) was added to a solution of n-
BuLi (5.43 mL, 1.6 M in hexane, 8.69 mmol) and stirred for 5 min at -10 °C. The reaction mixture was 
cooled to -78 °C and a solution of 3,4-dichlorodiphenylmethane (2.07 g, 8.68 mmol) in THF (10 mL) 
was added slowly in a period of 15 min. The mixture was stirred for 1 h at -10 °C followed by the 
addition of HMPA (1.5 mL) and 1,3-dibromopropane (4.40 mL, 26.1 mmol) in one portion at -78 °C. The 
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reaction mixture was allowed to warm to room temperature and stirred for 1 h. Water (25 mL) was 
added and the solvent was evaporated. The residue was diluted with water (25 mL) and extracted with 
EtOAc (3 × 25mL). The combined organic layers were washed with water (3 × 25 mL) and brine (25 
mL), dried over anhydrous MgSO4, filtered, and evaporated under reduced pressure. The residue was 
purified by flash chromatography (hexane) to afford 4-bromo-1-(3,4-dichloro-phenyl)-1-phenylbutane 
18 (R1 = 3,4-Cl2; R2 = H) as a colourless oil (0.15 g, 5%). 1H NMR (CDCl3): δ 1.65-1.79 (m, 2H), 2.03-
2.14 (m, 2H), 3.32 (t, J = 6.5 Hz, 2H), 3.78 (t, J = 7.5 Hz, 1H), 6.96-7.26 (m, 8H).  
(iii) Following method B gave 132 mg (66%) of the free base as a thick oil. This was converted to the 
hydrochloride salt as described for 3. Recrystallization from Et2O/MeOH gave 124 mg (87%) of 41 as a 
white solid. 1H NMR (CDCl3): δ 1.80-1.86 (m, 4H), 2.01-2.16 (m, 3H), 2.80-3.01 (m, 4H), 3.08-3.46 
(m, 4H), 3.87 (t, J = 7.8 Hz, 1H), 7.08-7.46 (m, 12H), 12.23 (br s, 1H). MS ESI m/z: 488.4 (M+H)+. 
Anal. (C27H29Cl4NO·1.0H2O) C, H, N, Cl. 
 4-(4-Chlorophenyl)-1-(4-(4-chlorophenyl)-4-phenylbutyl)piperidin-4-ol (42). Following 
method D using 4-chlorobenzophenone gave 256 mg (5% overall yield) of 42 as white crystals. Mp: 
126.2-127.0 °C. 1H NMR (CDCl3): δ 1.46-1.53 (m, 2H), 1.64-1.69 (m, 3H), 1.97-2.12 (m, 4H), 2.27-
2.43 (m, 4H), 2.68-2.74 (m, 2H), 3.86 (t, J = 7.8 Hz, 1H), 7.12-7.43 (m, 13H). MS ESI m/z: 454.4 
(M+H)+. Anal. (C27H29Cl2NO) C, H, N, Cl. 
 1-(4,4-bis-(4-Chlorophenyl)butyl)-4-(4-chlorophenyl)piperidin-4-ol hydrochloride (43). 
Following method D using 4,4’-dichlorobenzophenone gave 291 mg (5% overall yield) of the free base 
as a thick oil. This was converted to the hydrochloride salt as described for 3. Recrystallization from 
Et2O/MeOH gave 302 mg (97%) of 43 as a white solid. Mp: 185.0-185.5 °C. 1H NMR (CDCl3): δ 1.80-
1.86 (m, 5H), 2.00-2.11 (m, 2H), 2.70-2.87 (m, 4H), 3.09-3.22 (m, 4H), 3.85 (t, 1H, J= 7.5 Hz), 7.09 
(d, J = 8.5 Hz, 4H), 7.20-7.26 (m, 6H), 7.39 (d, J = 8.6 Hz, 2H), 11.83 (br s, 1H). MS ESI m/z: 488.4 
(M+H)+. Anal. (C27H29Cl4NO) C, H, N, Cl. 
 4-(4-Chlorophenyl)-1-(4-phenyl-4-m-tolylbutyl)piperidin-4-ol hydrochloride (45). 
Following method D using 3-methylbenzophenone gave 294 mg (15% overall yield) of the free base as 
a thick oil. This was converted to the hydrochloride salt as described for 3. Recrystallization from 
Et2O/MeOH gave 299 mg (93%) of 45 as a white solid. Mp: 143-1-144.4 °C. 1H NMR (CDCl3): δ 1.78-
1.84 (m, 4H), 2.01-2.13 (m, 3H), 2.29 (s, 3H), 2.80-2.91 (m, 4H), 3.09-3.29 (m, 4H), 3.88 (t, J = 7.9 
Hz, 1H), 7.00-7.33 (m 11H), 7.41 (d, J = 8.5 Hz, 2H), 12.15 (br s, 1H). MS ESI m/z: 434.4 (M+H)+. 
Anal. (C28H33Cl2NO·0.17H2O) C, H, N, Cl.  
 4-(4-Chlorophenyl)-1-(4-phenyl-4-p-tolylbutyl)piperidin-4-ol hydrochloride (46).  
Following method D using 4-methylbenzophenone gave 468 mg (19% overall yield) of the free base as 
a thick oil. This was converted to the hydrochloride salt as described for 3. One batch was recrystallized 
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from Et2O/MeOH to give 304 mg (60%) of 46 as a white solid.  Mp: 174.3-176.0 °C. 1H NMR (CDCl3): δ 
1.78-1.84 (m, 4H), 1.99-2.12 (m, 2H), 2.26 (s, 3H), 2.69-2.84 (m, 5H), 3.09-3.18 (m, 4H), 3.84 (t, J 
= 7.9 Hz, 1H), 7.07-7.34 (m, 11H), 7.39 (d, J = 8.6 Hz, 2H), 11.81 (br s, 1H). MS ESI m/z: 434.4 
(M+H)+. Anal. (C28H32Cl2NO·0.19H2O) C, H, N, Cl.  
 1-(4-Biphenyl-4-y)-4-(4-chlorophenyl)-butyl]-4-(4-chlorophenyl)piperidin-4-ol (47). 
Following method D using 4-chloro-4’-phenylbenzophenone gave the final compound as a white solid. 
Recrystallization from EtOAc gave 264 mg (9% overall yield) of 47 as white crystals. Mp: 127.8-128.6 
°C. 1H NMR (CDCl3): δ 1.50-1.70 (m, 5H), 2.00-2.13 (m, 4H), 2.30-2.46 (m, 4H), 2.72-2.77 (m, 2H), 
3.91 (t, J = 7.7 Hz, 1H), 7.16-7.55 (m, 17H). MS ESI m/z: 530.5 (M+H)+. Anal. (C33H33Cl2NO) C, H, N, 
Cl. 
 
Pharmacology 
Materials. ATP disodium salt, bovine serum albumin, chloroquine diphosphate, and DEAE-dextran 
(chloride form) were obtained from Sigma. Cell culture media, penicillin, and streptomycin were 
obtained from Life Technologies, Inc., and fetal calf serum was purchased from Integro B.V. (Dieren, 
The Netherlands). Myo-[2-3H]Inositol (17 Ci/mmol) was obtained from Perkin-Elmer Life Sciences, and 
Sephadex G-25 gel filtration columns were purchased from ICN Pharmaceuticals Inc. (Costa Mesa, CA). 
The human chemokine CCL5 (regulated on activation, normal T cell expressed and secreted) was 
obtained from Peprotech (Rocky Hill, NJ). 
Cell Culture and Transfection. COS-7 cells were grown at 5% CO2 at 37 °C in Dulbecco's modified 
Eagle's medium supplemented with 5% fetal calf serum, 2 mM l-glutamine, 50 IU/mL penicillin, and 50 
µg/mL streptomycin. Transfection of the COS-7 cells was performed by DEAE-dextran using 2 µg of 
DNA of each US28 construct pcDEF3-US28 or empty factor per million cells.17 The total amount of DNA 
in transfected cells was maintained constant by addition of the empty vector. 
[125I]Chemokine Binding Study. Labeling of CCL5 with [125I] and binding in COS-7 cells were 
performed as previously described.20 Briefly, transfected cells were seeded in 24-well plates; 48 h after 
transfection binding was performed on whole cells for 3 h at 4 °C using 0.3 nM [125I]CCL5 in binding 
buffer (50 mM Hepes, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin) in the 
presence or absence of varying concentrations of compounds. After incubation, cells were washed four 
times at 4 °C with binding buffer supplemented with 0.5 M NaCl. Nonspecific binding was determined in 
the presence of 0.1 µM cold competitor (CCL5). 
[3H]Inositol Phoshate Production. Cells were seeded in 24-well plates, and 24 h after transfection 
they were labeled overnight in inositol-free medium (modified Eagle's medium with Earle's salts) 
supplemented with 2 mM l-glutamine, l-cysteine, l-leucine, l-methionine, lL-arginine, glucose, 0.2% 
bovine serum albumin, and 2 µCi/mL myo-[2-3H]inositol. Subsequently, the labeling medium was 
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aspirated, cells were washed for 10 min with Dulbecco's modified Eagle's medium containing 25 mM 
HEPES (pH 7.4) and 20 mM LiCl and incubated for 2 h in the same medium in the absence or presence 
of varying concentrations of compounds. The incubation was stopped by aspiration of the medium and 
addition of cold 10 mM formic acid. After 90 min of incubation on ice, inositol phosphates were isolated 
by anion exchange chromatography (Dowex AG1-X8 columns, Bio-Rad) and counted by liquid 
scintillation. 
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Abstract  
G protein-coupled receptors encoded by viruses represent an unexplored class of 
potential drug targets. In this study we describe the synthesis and 
pharmacological characterization of the first class of inverse agonists acting on 
the HCMV-encoded receptor US28. It is shown that replacement of the 4-
hydroxy group of lead compound 1 with a methylamine group results in a 
significant 6-fold increase in affinity. Interestingly, increasing the rigidity of the 
spacer by the introduction of a double bond leads to a significant increase in 
binding affinity compared to 1 as well. These novel inverse agonists serve as 
valuable tools to elucidate the role of constitutive signaling in the pathogenesis 
of viral infection and may have therapeutic potential as leads for new anti-viral 
drugs. 
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Introduction 
Chemokines are a group of small (8-14 kDa) soluble proteins that belong to a 
large family of chemotactic cytokines.1 They play an important role in the 
migration and activation of leukocytes in a wide variety of immune-mediated 
disorders. These proteins are subdivided by structure into four major groups, 
namely CC, CXC, CX3C and XC chemokines, based on the number and position 
of conserved cysteine residues in their amino terminus.2 Chemokines mediate 
their effects by binding to chemokine receptors, which belong to the family of G 
protein-coupled receptors. These cell surface proteins are major targets for 
therapeutic intervention and are targeted by more than 40% of all marketed 
drugs.3 Binding of chemokines to their cognate receptors appears promiscuous 
and redundant, as most chemokine receptors can bind more than one 
chemokine and most chemokines can activate several chemokine receptor 
subtypes.4 However, binding to chemokine receptors is often restricted to a 
single subclass of chemokines; CC chemokine receptors can only be activated by 
CC chemokines, while CXC chemokines only bind to CXC chemokine receptors.2 
Two exceptions are the promiscuous chemokine binding protein DARC (Duffy 
antigen receptor for chemokines), and the human cytomegalovirus (HCMV) 
encoded receptor US28. DARC binds chemokines of both the CC and CXC 
subclasses with high affinity,5 while the viral-encoded receptor US28 binds 
several CC-chemokines, including CCL2, CCL3, CCL4 and CCL5, as well as the 
only member of the CX3C chemokine subclass, namely CX3CL1.6-9 
 
HCMV is a species specific β-herpesvirus that persists lifelong in the host without 
any clinical symptomes in immunocompetent individuals. However, the virus can 
cause severe illness in immunocompromised individuals, like premature 
neonates, transplant recipients, and human immunodeficiency virus (HIV) 
infected people.10,11 After primary infection, the viral genome establishes a 
lifelong latent infection within the host. The virus has developed several 
strategies to evade the immune system, such as the expression of genes that 
mimic host genes that are involved in the immune system.12-14 One of these viral 
genes encodes a G protein-coupled receptor, namely US28, with significant 
homology to mammalian chemokine receptors.6,8 US28 shows a 30% amino acid 
sequence homology with the human CCR1 chemokine receptor,6 suggesting that 
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HCMV exploits chemokine signaling pathways to interfere with the host immune 
system through chemokine mimicry.15 The homology of US28 compared to the 
CC chemokine receptors is even higher within the N-terminus, crucial for 
chemokine binding, with an amino acid sequence homology of 70% and 52% 
with the human CCR1 and CCR2 chemokine receptors, respectively.6 
 
Currently, the role of US28 is still unknown, but due to its promiscuous 
chemokine binding profile it is suggested that the receptor acts as a chemokine 
scavenger by sequestering CC chemokines from the extracellular 
environment.16,17 By this means the virus would elude immune surveillance, as 
chemokines play an important role in the regulation of the immune response. 
Furthermore, US28 induces the migration of vascular smooth muscle cells upon 
binding with the chemokines CCL2 and CCL5, which could be exploited by HCMV 
to disseminate the virus through the human body.18 This could also provide a 
possible link between HCMV and the development of vascular diseases, such as 
arterial restenosis,19 atherosclerosis,20 and chronic allograft rejection.21 
Moreover, CCL2 and CCL5 play an important role in the pathogenesis of vascular 
disease.22 Like many mammalian chemokine receptors, of which CCR5 and 
CXCR4 are the primary HIV-1 co-receptors in vivo, US28 can also act as a co-
receptor for HIV-1 entry into cells in vitro.23 
 
Chemokine receptors have been shown to be involved in the pathophysiology of 
different diseases.1,2 The identification of small nonpeptidergic chemokine 
receptor antagonists that are able to block these receptors proceeds rapidly, 
with some compounds in clinical trials at the moment. In contrast to mammalian 
chemokine receptors, we previously showed that US28 signals in a constitutively 
active manner. The receptor affects different signaling pathways, such as 
phospholipase C, NF-κB,24 and the transcription factors nuclear factor of 
activated T cells (NFAT) and cAMP response element binding protein (CREB).25-27 
The putative role of constitutive activity in viral pathogenesis is not elucidated 
yet, but it could be a way of the virus to alter the normal homeostasis of a host 
cell for its own benefit.24,27 Potent inverse agonists that are able to influence the 
constitutive signaling of viral-encoded GPCRs could be valuable tools to elucidate 
the role of constitutive signaling in the pathogenesis of viral infection and may 
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have therapeutic potential as new anti-viral drugs acting against pathologies 
caused by HCMV infection. Screening of a variety of GPCR-directed ligands for 
their ability to modulate the basal signaling of US28 resulted in the identification 
of the small nonpeptidergic molecule VUF2274 (1) as an inverse agonist.28 This 
molecule is not only able to block the basal signaling of US28, but also inhibits 
60 % of the US28-mediated HIV entry in cells. 
 
Recently, a limited series of analogues of 1 was synthesized to study the very 
first structure-activity relationships for inverse agonism on US28.29 To our 
knowledge, these molecules are currently the only nonpeptidergic inverse 
agonists acting on a viral-encoded chemokine receptor. In this study, we 
describe a new series of molecules, in which the rigidity is increased by the 
introduction of conformationally restrained tricyclic ring systems or rigid fused 
and nonfused piperidine ring systems. Moreover, we changed the spacer length 
between the diphenylacetonitrile group and the piperidine moiety and introduced 
rigidity in this part of the molecule. These novel inverse agonists acting on US28 
give us more knowledge about the SAR of this class of compounds.  
 
Chemistry 
Target compounds 1-12 were synthesized via an N-alkylation of the appropriate 
bromide or chloride intermediates with commercially available 4-(4-
chlorophenyl)piperidin-4-ol 13 as outlined in Scheme 1.29-31 Compounds 14-21 
were synthesized following an analogue synthetic route. Microwave chemistry 
was used for the N-alkylations to shorten the reaction times.  
 
a,b
c Z
R2
1-12
X Z R2 X
Z
R2
X
R1 = H, Cl or C(=O)CH3; R2 = H or CN
Y = Cl or Br; Z = C or N
For X see table 1
R1 R1
R1
HN
OH
Cl
13
Y
N
OH
Cl
 
 
Scheme 1. Synthetic pathway for the synthesis of 1-12. Reagents and conditions: (a) NaH in DMF or 
di-n-butylether; (b) 1-Bromo-3-chloropropane; (c) NaI, Na2CO3, CH3CN, reflux or NaI, Na2CO3, CH3CN, 
microwave (15 min, 160 °C).  
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The tricyclic precursors for compounds 2-6 were synthesized following methods 
previously described in the literature.31-33 9H-carbazole, 10H-phenothiazine, 2-
chloro-10H-phenothiazine and 1-(10H-phenothiazin-2-yl)ethanone were easily 
deprotonated with NaH at room temperature followed by an alkylation with 1-
bromo-3-chloropropane and a reaction with 13 to give target compounds 7 and 
10-12.34,35 However, the deprotonation of 10,11-dihydro-5H-dibenzo-
[b,f]azepine and diphenylamine, which were used for the synthesis of 8 and 9, 
could not be accomplished under these reaction conditions and was therefore 
achieved with NaH as a base in di-n-butylether at reflux temperature.36 
Cyclohexyl analogue 14 was synthesized starting from cyclohexylphenyl-
acetonitrile.31 1-Benzyl-4-tert-butylbenzene, which was used for the synthesis of 
15, was synthesized from the corresponding benzophenone,29 and 4-(2-
benzothiazolyl)propylamine, an intermediate for the synthesis of 16, was 
synthesized using o-aminothiophenol and 4-chlorobutyryl chloride.37  
 
The unsaturated compounds 22 and 23 were synthesized according to the 
procedure shown in Scheme 2. Cyclopropyldiphenylmethanol 24 was reacted 
with MgI2, formed in situ from Mg and I2, to give 4-iodo-1,1-diphenylbut-1-ene 
25, which was reacted with piperidine 13 to give compound 22.38,39 
 
O
Cl
OH
Cl Cl
c d
e
OH a I b N
OH
Cl
R
22 : R = Ph
23 : R = H
26 27 28
24 25
 
 
Scheme 2. Synthetic pathway for the synthesis of 22-23. Reagents and conditions: (a) MgI2, Et2O, 
reflux; (b) 13, Na2CO3, CH3CN, reflux; (c) NaHCO3, NaBH4, EtOH; (d) HCl, reflux; (e) 13, NaI, Na2CO3, 
CH3CN, microwave (15 min, 160 °C). 
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A reduction of the carbonyl group of 26 with NaBH4 gave alcohol 27 in a 
quantitative yield.40 This alcohol was dehydrated under acidic conditions to give 
intermediate 28, which was used for the alkylation of 13 to afford target 
compound 23. Compounds 29-31 were synthesized following the same method 
as described in Scheme 1. Reduction of the carbonyl group of 31 with NaBH4 
resulted in target compound 32. The different fused and non-fused piperidine 
moieties of compounds 33-36 were reacted with the appropriate chloride 
intermediates in a manner similar to that described for target compounds 1-12. 
The fused and non-fused ring systems of 33-34 and 36 were commercially 
available, and the 6-membered spiropiperidine moiety of 35 was synthesized 
following a literature procedure.41 1-Benzyl-2-methylbenzene, which was used 
for the synthesis of 34, was synthesized by the reduction of 2-
methylbenzophenone.29  
 
The synthesis of compounds 37 and 38 is outlined in Scheme 3. Compound 37 
was synthesized by reacting o-bromobenzoic acid with two equivalents of n-
BuLi,42 followed by a reaction with ketone 39.  
 
Br
a
N O
+
N
37
COOH
O O
R1
CN
39 R1 = CN
40 R2 = H
NO2
Fd
N NH CO2-t-Bu
N N
38
O
NH2
CO2-t -Bu
CO2-t-Bu
t -Bu-O2C
e
42
b, c
41
 
 
Scheme 3. Synthetic pathway for the synthesis of 37-38. Reagents and conditions: (a) n-BuLi, THF, -
78 °C; (b) Di-t-butylmalonate, NaH, DMF, 90 °C; (c) Pd/C, H2, EtOAc; (d) AcOH, NaBH(OAc)3, 1,2-
dichloroethane; (e) PTSA, toluene, reflux. 
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Reductive amination of 40 with di-t-butyl 2-(2-aminophenyl)malonate 41, which 
was synthesized from the reaction of 2-fluoronitrobenzene with di-t-butyl 
malonate and subsequent reduction of the nitro group, yielded intermediate 42. 
The indoline-2-one compound 38 was obtained by an intramolecular cyclisation 
reaction of 42 by treatment with p-toluenesulfonic acid (PTSA).43 Compounds 
43 and 44 were synthesized following a method previously described in the 
literature.31 The acetate group of compound 45 was formed by reacting 
compound 1 with acetylchloride in the presence of triethylamine. Reduction of 
the methyl ester group of compound 43 with LiAlH4 resulted in alcohol 46.
31  
 
The synthetic route for the preparation of 47-52 is outlined in Scheme 4 and 5. 
Target compounds 47 and 50 were synthesized by a reaction of 4-chloro-1,1-
diphenylbutane44 with 53 or 54 to give intermediates 55 or 56, followed by a 
reduction of the nitrile group in the presence of AlCl3 and LiAlH4. 
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c
NN
NH2 HN
R2
N
CN
R1
R1
R1
N
ClCl N
CN
Clb
O
O
d
e
f
53 R1 = H
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Scheme 4. Synthetic pathway for the synthesis of 47-50. Reagents and conditions: (a) Di-tert-butyl 
dicarbonate, Et3N, DCM; (b) NaNH2, 2-(4-chlorophenyl)acetonitrile, toluene, 70 °C; (c) EtOH/HCl; (d) 4-
Chloro-1,1-diphenylbutane, NaI, Na2CO3, CH3CN, reflux; (e) AlCl3, LiAlH4, THF; (f) Formic acid, 
microwave (5 min, 200 °C); (g) LiAlH4, THF, reflux. 
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Compound 53, which was used for the synthesis of 47, was commercially 
available as the hydrochloride salt, but piperidine moiety 54 needed to be 
synthesized. Thus, 2-(4-chlorophenyl)acetonitrile was deprotonated by NaNH2 
and treated with BOC-protected bis-(2-chloro-ethyl)amine 57 resulting in 
intermediate 58, which was deprotected under acidic conditions to give the 
desired piperidine moiety 54.45 Substituents were easily introduced on the 
amine group of 47, so 48 was synthesized in a high yield by reacting 47 with 
formic acid in the microwave. The monomethyl substituted amine 49 was 
synthesized by refluxing 48 in THF in the presence of LiAlH4.  
 
The hydroxy group of 59 was converted to an acetamide group in 51 via a Ritter 
reaction (Scheme 5).46 In strongly acidic media, a highly electrophilic tertiary 
carbocation is formed from the tertiary hydroxy group of 59, and this is followed 
by an acid-induced nucleophilic addition of the nitrile group of acetonitrile and a 
hydrolysis resulting in the desired compound 51. The acetamide group of 51 
was hydrolysed under acidic conditions to the corresponding amine group in 
52.47 
 
59 51 R = NHC(=O)CH3
52 R = NH2
a N R
Cl
N
OH
Cl
b
 
 
Scheme 5. Synthetic pathway for the synthesis of 51-52. Reagents and conditions: (a) H2SO4, CH3CN; 
(b) HCl, reflux. 
 
Results and discussion 
Starting from lead compound 1 we synthesized a novel series of compounds, 
which were evaluated for their potential to dose-dependently displace [125I]CCL5 
binding to US28. The inverse agonistic properties of a selection of compounds 
was investigated by testing their potential to inhibit the US28-mediated 
constitutive inositol phosphate production in SVEC4-10 cells.  
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In our previous study29 it was shown that a piperidine ring was important for 
activity and therefore this structural motif was maintained. It was also revealed 
that the nitrile group in the structure was not essential for affinity and efficacy, 
so this group could be omitted.29 In this study, we focussed our chemistry 
program on other parts of the structure, namely on the diphenyl group (Table 1) 
and the propyl linker (Table 2). Furthermore, we introduced different 
substitutents at the 4-position of the piperidine ring (Table 3 and 4). 
 
First, more rigidity was introduced by incorporation of the two phenyl rings in 
different tricyclic moieties (Table 1). The rotation of the two aromatic phenyl 
rings is restricted by incorporation of an ethylene group between the two phenyl 
rings in 3, a bioisosteric thiomethylene or oxomethylene bridge in 4 and 5 or an 
unsaturated bridge as in 6. All these changes were tolerated and did not 
influence the affinity and potency of the compounds. Interestingly, introduction 
of a nearly planar tricyclic ring system in 2 resulted in a compound with a 
comparable affinity as well.  
 
The introduction of a nitrogen atom in the tricyclic system as in 7-12 could 
provide an additional position for hydrogen bonding, but this structural 
modification did not influence the affinity of the compounds. For tricyclic 
antipsychotics and antidepressants it is known that there is a relationship 
between the folding of the tricyclic moiety and biological activity. If the sulphur 
atom of neuroleptic phenothiazine drugs is replaced by an ethylene bridge this 
results in dibenzazepine derivatives, which have an antidepressant activity.48 In 
contrast, replacement of the sulphur atom of phenothiazine analogue 10 into an 
ethylene bridge, resulting in the tricyclic moiety of dibenzazepine analogue 8, 
did not result in any change in affinity or potency on US28. Additionally, 
introduction of the more rigid and planar carbazole ring system in analogue 7 
did not change the affinity for the receptor, as was shown for compound 2 as 
well. The introduction of a chloro or acetyl group in one of the aromatic rings in 
phenothiazine analogues 11 and 12 resulted in a decrease in binding affinity, so 
these substitutions are not preferred in the phenothiazine ring.  
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Table 1. Chemical structures and pharmacological properties of compounds 1-12 and 14-16 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 
and EC50 values of at least three independent experiments. 
 
N
OH
ClR  
 
no. VUF R IC50 (µM)a EC50 (µM)b 
1 2274 CN
 
4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
2 10004 
CN  
6.0 (5.5 - 6.5) 5.7 (4.3 - 7.1) 
3 5713 
CN  
6.6 (4.8 - 8.3) 5.7 (3.0 - 8.5) 
4 5727 
S
CN  
6.1 (4.6 - 7.6) 5.4 (4.0 - 6.9) 
5 10007 
O
CN  
7.7 (5.9 - 9.3) 6.2 (3.4 - 8.9) 
6 10003 
CN  
6.0 (4.7 - 7.4) 5.1 (2.5 - 7.8) 
7 5932 
N
 
8.4 (6.2 - 10.7) 4.5 (2.8 - 6.2) 
8 5982 
N
 
6.4 (4.6 - 8.3) 7.1 (3.0 - 11.2) 
9 5983 
N
 
6.9 (3.5 - 10.2) 4.4 (2.4 - 6.3) 
10 10005 
S
N
 
6.4 (5.2 - 7.6) 6.8 (5.2 - 8.3) 
11 10006 
S
N Cl
 
10.5 (6.5 - 14.5) n.d. 
12 6902 
S
N O
 
11.0 (5.5 - 16.6) 10.7 (6.9 - 14.5) 
14 5892 
CN  
7.7 (5.5 - 10.0) 5.2 (3.2 - 7.1) 
15 (±)-5937 
 
5.9 (4.6 - 7.2) 7.6 (3.2 - 12.0) 
16 5933 
    
N S
 
 
18.0 (13.2 - 22.9) n.d. 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.d. = not determined. 
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Previously, we found that introduction of a bulky phenyl substituent at the 4-
position of one of the phenyl rings was not allowed to maintain binding affinity.29 
In contrast, the bulky t-butyl group in compound 15 is permitted at this 
position. Interestingly, replacement of the diphenylacetonitrile group by a 
benzothiazole ring in compound 16 caused a more than 3-fold drop in binding 
affinity to the receptor.  
 
Furthermore, the importance of the propyl linker between the 
diphenylacetonitrile group and the piperidine moiety was investigated by the 
introduction of different structural modifications in this part of the molecule 
(Table 2).  
 
Table 2. Chemical structures and pharmacological properties of compounds 1 and 17-23 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 
and EC50 values of at least three independent experiments. 
 
N
OH
Cl  
 
no. VUF R IC50 (µM)a EC50 (µM)b 
17 5742 
Ph
Ph
CN
 
9.2 (7.9 - 10.5) 4.1 (1.5 - 6.6) 
1 2274 
Ph
Ph
CN
 
4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
18 5743 
Ph
Ph
CN
 
4.6 (3.6 - 5.5) 5.5 (1.9 - 9.1) 
19 5745 
Ph
 
21.1 (15.8 - 26.3) n.d. 
20 5746 
Ph
 
7.8 (6.8 - 8.9) n.d. 
21 5752 
Ph
 
6.6 (4.6 - 8.7) n.d. 
22 6869 
Ph
Ph
 
1.7 (1.1 - 2.3) 4.8 (1.3 – 8.3) 
23 (E/Z) 6870 
Ph
 
20.0 (19.5 - 20.4) n.d. 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.d. = not determined. 
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First, we studied the effect of varying the chain length of the linker. Compound 
1 has been previously reported as a potent antagonist acting on the human 
CCR1 chemokine receptor.34 Interestingly, we recently demonstrated that the 
SAR of compound 1 and its analogues is completely different on the viral-
encoded receptor US28 compared to the human chemokine receptor CCR1.29 
Now, the shortening of the propyl spacer with one methylene group in 17 
caused a small decrease in affinity on US28, while the addition of one 
methylene group in the structure of 1, resulting in compound 18, did not 
change the affinity or efficacy. In contrast, for the human CCR1 chemokine 
receptor it was shown that shortening of the propyl chain with one methylene 
group caused a large decrease in Ki value, while addition of one or two 
methylene groups in the structure of 1, resulting in, respectively, a butyl and a 
pentyl chain, did not change the affinity on the CCR1 chemokine receptor.31 In 
compounds 19-21 one of the phenyl rings was removed and this series of 
compounds showed a similar trend as demonstrated for compounds 1, 17 and 
18, namely that removal of one methylene group in 19 resulted in a decrease 
of binding affinity, while compounds 20 and 21 have binding affinities 
comparable to compounds 1 and 18.  
 
Interestingly, the introduction of a more rigid chain in unsaturated analogue 22 
resulted in a 3-fold increase in binding affinity compared to lead compound 1. 
However, in the functional assay both compounds were equipotent. In our 
previous study it was shown that removal of a phenyl ring as in 20 resulted in a 
binding affinity comparable to compound 1, but this is not true for the more 
rigid rigid and unsaturated analogues 22 and 23. Compound 23 has a binding 
affinity that is more than 10-fold reduced compared to compound 22.  
 
Next, the influence of the substitution pattern at the 4-position of the piperidine 
ring was investigated to further define the structure-activity relationships on 
US28 (Tables 3 and 4). We previously showed that a phenyl ring at this position 
is important,29 so this was maintained in the structure. In compounds 33-38 the 
aromatic ring is incorporated in a heterocyclic system, while in compounds 30-
32 an additional carbon atom is present between the piperidine ring and the 
phenyl ring.  
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Table 3. Chemical structures and pharmacological properties of compounds 1 and 29-38 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 
and EC50 values of at least three independent experiments. 
 
R3
R2
R1
 
 
no. VUF R1 R2 R3 IC50 (µM)a EC50 (µM)b 
1 2274 H CN N
OH
Cl
 
4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
29 6984 H CN N
OH
CF3  
5.2 (4.2 - 6.3) 4.3 (2.5 - 6.2) 
30 5729 H CN N OH
 
4.8 (4.3 - 5.4) 6.1 (2.3 - 10.0) 
31 6868 H H 
O
F
N
 
4.8 (3.9 - 5.6) n.d. 
32 (±)-10010 H H 
N
F
OH  
6.4 (4.6 - 8.3) 3.0 (2.8 - 3.2) 
33 5893 H CN 
N
N
NH
O
 
3.7 (3.5 - 4.0) 2.0 (1.3 - 2.8) 
34 (±)-5997 Me H 
N
N
NH
O
 
2.6 (1.2 - 3.9) 4.2 (1.1 - 7.4) 
35 6967 H CN N NH
O
O
 
7.6 (6.0 - 9.1) n.d. 
36 6985 H CN N N
NH
O
Cl  
7.1 (6.3 - 7.9) n.d. 
37 6047 H CN 
O
N
O
 
11.9 (10.0 - 13.8) n.d. 
38 6048 H H N N
O
 
 
5.5 (4.9 - 6.2) 7.3 (2.2 - 12.3) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.d. = not determined. 
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Both the replacement of the 4-chloro atom in the phenyl ring by a 3-
trifluoromethyl group in 29 as well as the introduction of a bulky 
diphenylmethanol group in compound 30 did not influence the potency of the 
compounds. In compound 31 a 4-fluorophenylmethanone group was introduced 
at the 4-postion of the piperidine ring and reduction of the carbonyl group 
resulted in analogue 32. The introduction of both the 4-fluorophenylmethanone 
group in compound 31 as well as the 4-fluorophenylmethanol group in analogue 
32 did not influence the affinity for US28. 
 
Different fused and non-fused ring systems (heterocyclic substituted piperidine 
analogues or bicyclic heterocyclic groups) were introduced at the 4-position of 
the piperidine ring, because these structural motifs appear frequently in CC 
chemokine receptor antagonists. Additionally, the heterocyclic groups contain 
different functional groups, which can act as hydrogen bond acceptor or donor 
groups. Both compounds 33 and 34 contain a spiropiperidine amide group, but 
compound 34 was not synthesized with a diphenylacetonitrile group as in 
compound 33, but with a ortho methyl substituted diphenyl group, because 
recently it was demonstrated that there was a slight preference for this 
structural motif.29 However, in this series of compounds the binding affinities of 
33 and 34 were comparable and in the same order as lead compound 1. 
Additionally, the introduction of the spiropiperidine moieties in both compounds 
35 and 37 were allowed to maintain affinity for US28. The benzimidazolone 
piperidine moiety of 36 is often seen in ligands acting on various G protein-
coupled receptors, such as serotonergic and dopaminergic receptors.43 
Interestingly, the introduction of an indolin-2-one group in compound 38 
resulted in a compound with an activity compared to 1, while the introduction of 
the benzimidazolone piperidine moiety of 36 made the affinity drop slightly.  
 
Moreover, the 4-hydroxy group was replaced by other substituents (Table 4), 
because a hydroxy group at this position of a piperidine ring is suggested to be a 
site of potential metabolic toxicity.49 The introduction of an ester group in 43, an 
acetyl group in 44, an acetate group in 45 or a hydroxy methyl group in 46 did 
not result in compounds with a higher affinity. Furthermore, amine analogue 47 
was synthesized to investigate the influence of a primary amine group at the 4-
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position of the piperidine ring. It was demonstrated earlier that a nitrile group at 
the 4-position of the piperidine ring was detrimental for both affinity and 
activity.29 However, the reduction of this group into a methylamine group of 
derivative 47 resulted in a 3-fold increase in binding affinity compared to lead 
compound 1, while the efficiacy of both compounds was comparable.  
 
Table 4. Chemical structures and pharmacological properties of compounds 1 and 43-52 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 
and EC50 values of at least three independent experiments. 
 
N
R2
R1
X  
 
no. VUF R1 R2 X IC50 (µM)a EC50 (µM)b 
1 2274 CN OH Cl 4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
43 5934 CN (C=O)OCH3 H 8.0 (6.0 - 10.0) n.d. 
44 5984 CN (C=O)CH3 H 7.9 (6.3 - 9.5) n.d. 
45 5936 CN O(C=O)CH3 Cl 8.6 (7.4 - 9.8) n.d. 
46 6881 H CH2OH H 7.5 (5.6 - 9.3) n.d. 
47 6046 H CH2NH2 H 1.6 (1.1 - 2.0) 3.1 (1.7 - 4.6) 
48 6987 H CH2NHC(=O)H H 2.5 (2.0 - 3.0) n.d. 
49 6989 H CH2NHCH3 H 1.3 (1.1 - 1.5) 3.1 (1.2 - 4.9) 
50 6966 H CH2NH2 Cl 0.8 (0.7 - 1.0) 3.6 (2.6 - 4.6) 
51 6981 H NHC(=O)CH3 Cl 2.2 (2.0 - 2.5) 4.1 (1.0 - 7.1) 
52 6993 H NH2 Cl 1.4 (1.3 - 1.4) 5.7 (2.5 - 8.9) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.d. = not determined. 
 
From previous studies28,29 it was known that removal of the p-chloro substituent 
resulted in a decrease in binding affinity. Thus, a chloro atom was introduced at 
the 4-position of the phenyl ring in compound 50, which resulted in a further 2-
fold increase of binding affinity compared to unsubstituted analogue 47. The 
amine group of compound 47 was substituted, resulting in compounds 48 and 
49. Unfortunately, these substitutions did not cause an increase in the binding 
affinity on US28. Compound 51 was synthesized to investigate the importance 
of the position of the amine group and this amine was synthesized starting from 
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compound 52, in which the amine group is substituted with an acetyl group. 
Both compounds have an affinity higher than lead compound 1, but slightly 
lower than that of our novel lead compound 50. 
 
Conclusions 
In summary, we described the synthesis and structure-activity relationships of 
inverse agonists acting on the viral-encoded GPCR US28. These molecules are 
considered as valuable tools to investigate the (patho)physiological role of US28 
during viral infection. Replacement of the 4-hydroxy group of lead compound 1 
into a methylamine group as in compound 50 resulted in the, to our knowledge, 
highest affinity inverse agonist acting on US28 currently known. Interestingly, 
the introduction of a double bond in the propyl linker between the diphenyl 
group and the piperidine moiety in compound 22 caused a significant increase in 
binding affinity to US28. Currently, these molecules are being used as tools to 
further investigate the role of constitutive signaling of US28 in the pathogenesis 
of viral infection. In the future, potent and selective inverse agonists acting on 
constitutively active viral GPCRs may have therapeutical potential in the 
treatment of pathologies caused by viral infections. 
 
Experimental section 
General procedures. The solvents were dried according to standard procedures. All reactions were 
performed under an atmosphere of dry nitrogen. Microwave reactions were performed in a CEM 
Explorer single mode MW reactor equipped with auto sampler. 1H NMR and 13C NMR spectra were 
recorded on a Bruker AC-200 (200 MHz) spectrometer. J.T. Baker silica gel was used for flash 
chromatography. HRMS mass spectra were recorded on a Finnigan MAT 900 mass spectrometer. 
Melting points were measured on a MPA100 OptiMelt automated melting point system apparatus and 
were uncorrected. Analytical HPLC-MS analyses were conducted using a Shimadzu LC-8A preparative 
liquid chromatograph pump system with a Shimadzu SPD-10AV UV-VIS detector set at 254 nm, with 
the MS detection performed with a Shimadzu LCMS-2010 liquid chromatograph mass spectrometer. The 
analyses were performed using the following conditions; condition I: an Alltima(C18)5u column (150 
mm x 4.6 mm) with 70% MeOH - 30% H2O-0.1% formic acid (Method Ia); 60% MeOH - 40% H2O-
0.1% formic acid (Method Ib) or 50% MeOH - 50% H2O-0.1% formic acid (Method Ic). Flow rate = 1.0 
mL/min. Total run time 15 min unless otherwise stated. Condition II: an Alltima(C18)5u column (150 
mm x 4.6 mm) with 50% CH3CN - 50% H2O-0.1% formic acid (Method IIa); 40% CH3CN - 60% H2O-
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0.1% formic acid (Method IIb) or 30% CH3CN - 70% H2O-0.1% formic acid (Method IIc). Flow rate = 
1.0 mL/min. Total run time 20 min. Compounds that were isolated as fumaric acid salts all showed a 
fumaric acid peak around 2 minutes. Fumaric acid blancs were used to determine the tR of fumaric 
acid. Purities calculated are based on RP HPLC-UV peak surface area of the compounds (disregarding 
the fumaric acid peak). Reference compounds 1 and 20 have been described previously and were taken 
from stock.29 Compounds 3-6, 14, 17-18, 43 and 46 were synthesized as previously described in the 
literature31 and the characterization data confirmed that the desired compounds had been formed. 
Compounds 15, 32 and 34 were tested as racemic mixtures. 
 General method A. 5-(4-Hydroxy-4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)-2,2- 
diphenylpentanenitrile fumarate (29). 4-(3-(Trifluoromethyl)phenyl)piperidine-4-ol (0.51 g, 2.07 
mmol), 5-chloro-2,2-diphenylpentanenitrile34 (0.54 g, 2.00 mmol), NaI (0.30 g, 2.00 mmol), Na2CO3 
(0.42 g, 3.96 mmol) and 3 mL CH3CN were added in a 10 mL microwave vessel and this mixture was 
reacted during 15 minutes in the microwave at a temperature of 160 °C (settings: ramp time 5 min, 
hold time 15 min, power 200 watt, pressure 17.2 bar). The solvent was removed in vacuo and the 
residue was diluted with water (20 mL), followed by an extraction with DCM (3 x 15 mL). The combined 
organic layers were washed with water (3 x 40 mL) and brine (40 mL), dried over anhydrous MgSO4, 
filtered, and evaporated in vacuo. Purification by flash chromatography (0-50% EtOAc in DCM) gave 
772 mg (81%) of the free base as an oil. This was dissolved in EtOH and converted to the 
corresponding fumaric salt by the addition of fumaric acid (0.19 g, 1.6 mmol). The fumaric salt was 
isolated by evaporation in vacuo and recrystallized from EtOH/Et2O to give 803 mg (68%) of 29 as a 
white solid. Mp: 123.7-125.3 °C (dec). 1H NMR (DMSO-d6): δ 1.47-1.78 (m, 5H), 1.98-2.20 (m, 2H), 
2.35-2.91 (m, 8H), 6.57 (s, 2H), 7.33-7.81 (m, 14H). 13C NMR (CDCl3): δ 30.74, 35.31, 36.14, 47.91, 
51.18, 55.68, 68.78, 121.49, 121.85, 123.64, 126.44, 127.89, 128.20, 128.69, 128.84, 134.72, 
134.91, 139.22, 148.43, 169.59. Anal. RP-HPLC Ib: tR = 6.64 min (purity 100%), IIb: tR = 11.69 min 
(purity 100%). HRMS (EI) m/z calcd for C29H29F3N2O: 478.2232; found: 478.2225. 
 General method B. 5-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)-2,2-diphenylpentane- 
nitrile (30). A solution of 4-bromo-2,2-diphenylbutanitrile34 (0.31 g, 1.00 mmol), diphenyl(piperidin-4-
yl)methanol (0.36 g, 1.20 mmol), NaI (0.15 g, 1.00 mmol), and Na2CO3 (0.22 g, 2.08 mmol) in CH3CN 
(30 mL) was refluxed overnight. The solvent was removed in vacuo, the residue was diluted with water 
(50 mL) and extracted with DCM (3 x 30 mL). The combined organic layers were washed with water (3 
x 50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered, and evaporated in vacuo. 
Purification by flash chromatography (EtOAc) and recrystallization from EtOAc gave 293 mg (59%) of 
30 as a white solid. Mp: 77.9-78.5 °C. 1H NMR (CDCl3): δ 1.34-1.69 (m, 5H), 1.85-2.20 (m, 4H) 2.30-
2.50 (m, 5H), 2.79-2.99 (m, 2H), 7.11-7.47 (m, 20H). 13C NMR (CDCl3): 22.80, 26.03, 37.25, 43.85, 
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51.47, 53.71, 57.60, 79.32, 122.22, 125.57, 126.39, 126.69, 127.69, 128.04, 128.71, 129.23, 139.94, 
145.70. Anal. RP-HPLC Ib: tR = 9.48 min (purity 98%), IIa: tR = 6.11 min (purity 98%). HRMS (EI) m/z 
calcd for C35H36N2O: 500.2828; found: 500.2817. 
 General method C. 1-(3-(9H-Carbazol-9-yl)propyl)-4-(4-chlorophenyl)piperidin-4-ol (7).  
(i) A solution of 9H-carbazole (0.84 g, 5.01 mmol) in DMF (20 mL) was cooled to 0 °C and NaH (0.22 g, 
5.58 mmol) was added in small portions. After stirring for 1 h at room temperature, the reaction 
mixture was cooled to 0 °C and 1-bromo-3-chloropropane (0.5 mL, 5.06 mmol) was added. The 
reaction mixture was allowed to warm to room temperature and stirred overnight. Water (50 mL) was 
added and the water layer was extracted with EtOAc (3 x 25 mL). The combined organic extracts were 
washed with water (3 x 25 mL) and brine (25 mL), dried over anhydrous Na2SO4 and filtered. After 
evaporation under reduced pressure, the residue was purified by flash chromatography (0-15% DCM in 
hexane) to give 853 mg (70%) of 9-(3-chloropropyl)-9H-carbazole. 1H NMR (CDCl3): δ 2.28-2.49 (m, 
2H), 3.51 (t, J = 6.0 Hz, 2H), 4.50 (t, J = 6.4 Hz, 2H), 7.21-7.31 (m, 2H), 7.40-7.48 (m, 4H), 8.11 (d, 
J = 7.7 Hz, 2H) 
(ii) Following method B using 9-(3-chloropropyl)-9H-carbazole (0.57 g, 2.34 mmol) gave 727 mg 
(75%) of 7 as a light yellow solid after recrystallization in EtOAc. Mp: 130.1-131.4 °C. 1H NMR (CDCl3): 
δ 1.54-1.72 (m, 3H), 2.01-2.14 (m, 4H), 2.28-2.41 (m, 4H), 2.68-2.73 (m, 2H), 4.41 (t, J = 6.6 Hz, 
2H), 7.17-7.49 (m, 10H), 8.09 (d, J = 7.7 Hz, 2H). 13C NMR (CDCl3): δ 25.91, 38.24, 40.54, 49.17, 
55.20, 70.92, 108.62, 118.64, 120.17, 122.67, 125.40, 125.97, 128.27, 132.66, 140.33, 146.60. Anal. 
RP-HPLC Ib: tR = 9.37 min (purity 100%), IIb: tR = 10.33 min (purity 100%). HRMS (EI) m/z calcd for 
C
26
H
27
ClN
2
O: 418.1812; found: 418.1815. 
 9-(3-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-propyl)-9H-fluorene-9-carbonitrile 
hydrochloride (2). (i) 9H-Fluorene-9-carbonitrile33 (1.03 g, 5.39 mmol) was dissolved in DMF (25 mL) 
and NaH (0.22 g, 5.58 mmol) was added in small portions. The reaction was heated to 70 °C and 1-
bromo-3-chloropropane (2.75 mL, 27.8 mmol) was added in one portion after 2 h. The reaction mixture 
was allowed to cool to room temperature and stirred overnight. Water (50 mL) was added and the 
water layer was extracted with Et2O (3 x 50 mL). The combined organic extracts were washed with 
water (3 x 50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered and evaporated in vacuo to 
give 1.06 g of 9-(3-chloropropyl)-9H-fluorene-9-carbonitrile as a yellow solid. The crude product was 
used without further purification. 
(ii) Following method A using crude 9-(3-chloropropyl)-9H-fluorene-9-carbonitrile (0.49 g, 2.16 mmol) 
gave 445 mg of the free base as an oil. This was dissolved in Et2O and dry hydrochloride gas was 
bubbled through the solution. Isolation of the hydrochloride salt by filtration and recrystallization from 
MeOH/Et2O gave 201 mg (17%) of 2 as a white solid. Mp: 156.2-158.1 °C. 1H NMR (CDCl3): δ 1.55-
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1.94 (m, 5H), 2.33-2.54 (m, 2H), 2.77-3.18 (m, 6H), 3.26-3.40 (m, 2H), 7.35- 7.60 (m, 8H), 7.66-
7.88 (m, 4H). 13C NMR (CDCl3/DMSO-d6): δ 18.52, 34.88, 36.00, 47.29, 48.64, 56.16, 68.26, 120.45, 
120.68, 124.08, 126.17, 128.22, 128.57, 129.67, 132.92, 139.93, 141.57, 145.12. Anal. RP-HPLC Ib: 
tR = 5.10 min (purity 99%), IIb: tR = 8.39 min (purity 99%). HRMS (EI) m/z calcd for C28H27ClN2O: 
442.1812; found: 442.1807. 
 4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)piperidin-4-
ol (8). (i) NaH (0.40 g, 10.03 mmol) was added portion wise to a solution of 10,11-dihydro-5H-
dibenzo[b,f]azepine (1.95 g, 9.99 mmol) in di-n-butylether (30 mL). The reaction mixture was heated, 
refluxed for 3.5 h, and 1-bromo-3-chloropropane (4.00 mL, 40.5 mmol) was added at 100 °C. The 
reaction mixture was refluxed overnight, water was added (50 mL) and the water layer was extracted 
with toluene (3 x 75 mL). The combined organic extracts were washed with water (3 x 100 mL) and 
brine (100 mL), dried over anhydrous Na2SO4 and filtered. After evaporation in vacuo, the residue was 
purified by flash chromatography (5% DCM in hexane) to give 737 mg (27%) of 5-(3-chloropropyl)-
10,11-dihydro-5H-dibenzo[b,f]azepine as a colourless oil. 1H NMR (CDCl3): δ 1.99-2.16 (m, 2H), 3.18 
(s, 4H), 3.57 (t, J = 6.4 Hz, 2H), 3.91 (t, J = 6.5 Hz, 2H), 6.91-6.99 (m, 2H), 7.08-7.24 (m, 6H).  
(ii) Following method A using 5-(3-chloropropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine (0.42 g, 1.55 
mmol) gave 494 mg (71%) of 8 as white crystals after recrystallization from EtOAc. Mp: 116.0-117.6 
°C. 1H NMR (CDCl3): δ 1.61-1.84 (m, 5H), 1.96-2.11 (m, 2H), 2.26-2.47 (m, 4H), 2.62-2.78 (m, 2H), 
3.15 (s, 4H), 3.76 (t, J = 6.8 Hz, 2H), 6.85-6.93 (m, 2H), 7.06-7.15 (m, 6H), 7.24-7.41 (m, 4H). 13C 
NMR (CDCl3): δ 25.74, 32.63, 38.67, 49.33, 49.83, 56.95, 71.40, 120.35, 122.86, 126.48, 126.77, 
128.79, 130.22, 133.18, 134.64, 147.17, 148.65. Anal. RP-HPLC Ib (total run time 20 min): tR = 12.71 
min (purity 99%), IIa: tR = 4.76 min (purity 100%), IIb: tR = 15.55 min (purity 99%). HRMS (EI) m/z 
calcd for C28H31ClN2O: 446.2125; found: 446.2131. 
 4-(4-Chlorophenyl)-1-(3-(diphenylamino)propyl)piperidin-4-ol (9). This was synthesized 
as described for 8 starting with diphenylamine (1.69 g, 10.00 mmol) to give 683 mg (16% over two 
steps) of 9 as a white solid after recrystallization from EtOAc. Mp: 109.9-111.9 °C. 1H NMR (CDCl3): δ 
1.50-1.95 (m, 5H), 2.03-2.22 (m, 2H), 2.32-2.47 (m, 4H), 2.69-2.87 (m, 2H), 3.77 (t, J = 7.3 Hz, 2H), 
6.88-7.03 (m, 4H), 7.21-7.45 (m, 10H). 13C NMR (CDCl3): δ 25.33, 38.84, 49.86, 50.54, 56.20, 71.47, 
121.38, 121.60, 126.49, 128.83, 129.64, 133.23, 136.18, 148.43. Anal. RP-HPLC Ib: tR = 8.62 min 
(purity 100%), IIb: tR = 11.11 min (purity 99%). HRMS (EI) m/z calcd for C26H29ClN2O: 420.1968; 
found: 420.1970. 
 1-(3-(10H-phenothiazin-10-yl)propyl)-4-(4-chlorophenyl)piperidin-4-ol (10). Following 
method C starting with 10H-phenothiazine gave 462 mg (34% over two steps) of 10 as a light yellow 
solid. Mp: 59.0-60.6 oC. 1H NMR (CDCl3): δ 1.51-2.11 (m, 7H), 2.21-2.56 (m, 4H), 2.63-2.89 (m, 2H), 
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3.93 (t, J = 6.7 Hz, 2H), 6.87-7.41 (m, 12H). 13C NMR (CDCl3): δ 25.34, 38.86, 45.61, 49.84, 55.99, 
71.28, 115.97, 117.14, 122.90, 125.64, 126.47, 127.63, 127.89, 128.82, 133.26, 145.58. Anal. RP-
HPLC Ia: tR = 3.45 min (purity 97%), Ib (total run time 20 min): tR = 13.93 min (purity 98%), IIb: tR = 
13.46 min (purity 99%). HRMS (EI) m/z calcd for C26H27ClN2OS: 450.1533; found: 450.1539. 
 1-(3-(2-Chloro-10H-phenothiazin-10-yl)propyl)-4-(4-chlorophenyl)piperidin-4-ol (11). 
Following method C starting with 2-chloro-10H-phenothiazine gave 376 mg (24% over two steps) of 11 
as a light yellow solid. Mp: 66.1-66.7 oC.  1H NMR (CDCl3): δ 1.49-1.80 (m, 3H), 1.87-2.18 (m, 4H), 
2.30-2.58 (m, 4H), 2.68-2.85 (m, 2H), 3.91 (t, J = 6.8 Hz, 2H), 6.84-7.42 (m, 11H). 13C NMR (CDCl3): 
δ 24.12, 38.33, 45.62, 49.84, 55.71, 71.01, 116.31, 116.33, 122.76, 123.42, 124.08, 125.35, 126.48, 
127.87, 127.97, 128.34, 128.83, 133.30, 133.68, 144.77, 146.89. Anal. RP-HPLC Ib: tR = 4.27 min 
(purity 97%), IIa: tR = 6.45 min (purity 98%). HRMS (EI) m/z calcd for C26H26Cl2N2OS: 484.1143; 
found: 484.1133. 
 1-(10-(3-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)propyl)-10H-phenothiazin-2-
yl)ethanone (12). Following method C starting with 1-(10H-phenothiazin-2-yl)ethanone gave 410 mg 
(22% over two steps) of 12 as a light yellow solid. Mp: 108.9-110.6 oC. 1H NMR (CDCl3): δ 1.39-1.68 
(m, 5H), 1.81-2.12 (m, 4H), 2.22-2.81 (m, 4H), 2.50 (s, 3H), 3.96 (t, J = 6.7 Hz, 2H), 6.79-6.92 (m, 
2H), 7.01-7.42 (m, 9H). 13C NMR (CDCl3): δ 23.71, 26.47, 37.90, 45.11, 49.22, 55.29, 70.70, 113.81, 
115.76, 122.75, 123.00, 123.71, 125.92, 126.89, 127.33, 127.54, 128.24, 132.13, 132.65, 136.10, 
144.19, 145.33, 197.31. Anal. RP-HPLC Ib: tR = 10.46 min (purity 100%), IIb: tR = 10.90 min (purity 
100%). HRMS (EI) m/z calcd for C28H29ClN2O2S: 492.1638; found: 492.1631. 
 1-(4-(4-tert-Butylphenyl)-4-phenylbutyl)-4-(4-chlorophenyl)piperidin-4-ol (15). This 
was synthesized following a method previously described29 starting with 4-tert-butylbenzophenone 
(1.43 g, 6.01 mmol) to give 801 mg (28% over three steps) of 15 as white crystals after 
recrystallization from hexane/EtOAc. Mp: 104.0–105.3 °C. 1H NMR (CDCl3): δ 1.26 (s, 9H), 1.48-1.72 
(m, 5H), 2.02-2.14 (m, 4H), 2.28-2.44 (m, 4H), 2.64-2.79 (m, 2H), 3.85 (t, J = 7.8 Hz, 1H), 7.12-7.43 
(m, 13H). 13C NMR (CDCl3): δ 27.14, 31.21, 33.15, 34.17, 37.31, 49.08, 50.62, 58.24, 70.45, 125.19, 
125.89, 125.99, 127.13, 127.66, 128.30, 128.33, 132.91, 135.46, 141.59, 144.64, 148.71. Anal. RP-
HPLC Ib: tR = 5.24 min (purity 100%), IIa: tR = 9.46 min (purity 99%). HRMS (EI) m/z calcd for 
C31H38ClN2O: 475.2642; found: 475.2630. 
 1-(3-Benzo[d]thiazol-2-yl)propyl)-4-(4-chlorophenyl)piperidin-4-ol (16). Following 
method B using 2-(3-chloropropyl)benzo[d]thiazole (0.636 g, 3.00 mmol), which was synthesized 
according to literature procedure,37 gave 306 mg (26 %) of 16 as a light yellow solid after 
recrystallization from EtOAc. Mp: 109.3-110.8 °C. 1H NMR (CDCl3): δ 1.61-1.76 (m, 3H), 2.21-2.39 (m, 
4H), 2.50-2.79 (m, 4H), 2.93-3.08 (m, 2H), 3.18 (t, J = 7.3 Hz, 2H), 7.24-7.48 (m, 6H), 7.82-7.96 (m, 
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2H). 13C NMR (CDCl3): δ 25.76, 31.85, 37.48, 49.11, 57.13, 70.51, 121.41, 122.36, 124.68, 125.86, 
125.90, 128.34, 132.83, 134.98, 146.01, 152.97, 170.99. Anal. RP-HPLC Ic: tR = 8.42 min (purity 
99%), IIc: tR = 10.70 min (purity 99%). HRMS (EI) m/z calcd for C21H23ClN2OS: 386.1220; found: 
386.1230. 
 4-(4-Chlorophenyl)-1-(3-phenylpropyl)piperidin-4-ol (19). Following method B using 1-
bromo-3-phenylpropane (0.60 g, 3.03 mmol) afforded 729 mg (73%) of 19 as a light yellow solid. Mp: 
95.7-96.8 °C. 1H NMR (CDCl3): δ 1.60-1.95 (m, 5H), 2.03-2.21 (m, 2H), 2.36-2.49 (m, 4H), 2.64 (t, J 
= 7.7 Hz, 2H), 2.80-2.86 (m, 2H), 7.16-7.31 (m, 7H), 7.42 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3): δ 
28.80, 34.12, 38.61, 49.76, 58.44, 71.39, 126.25, 126.49, 128.75, 128.77, 128.83, 133.26, 142.27, 
147.06. Anal. RP-HPLC Ic: tR = 6.17 min (purity 100%), IIc: tR = 10.14 min (purity 100%). HRMS (EI) 
m/z calcd for C
20
H
24
ClNO: 329.1546; found: 329.1549. 
 4-(4-Chlorophenyl)-1-(5-phenylpentyl)piperidin-4-ol (21). (i) PBr3 (0.22 mL, 2.34 mmol) 
was added to a solution of 5-phenyl-1-pentanol (0.82 g, 5.02 mmol) in Et2O (25 mL) and this was 
stirred for 24 h at room temperature. Water (50 mL) was added and the solution was basified with 
K2CO3 followed by an extraction with Et2O (3 x 30 mL). The combined organic extracts were washed 
with water (100 mL) and brine (100 mL), dried over anhydrous MgSO4 and filtered. Evaporation in 
vacuo and purification by flash chromatography (hexane) gave 555 mg (49%) of 1-bromo-5-
phenylpentane as a colourless oil. 1H NMR (CDCl3): δ 1.36-1.54 (m, 2H), 1.58-1.75 (m, 2H), 1.82-1.98 
(m, 2H), 2.61 (t, J = 7.5 Hz, 2H), 3.38 (t, J = 6.8 Hz, 2H), 7.13-7.38 (m, 5H).  
(ii) This was synthesized according to method B using 1-bromo-5-phenylpentane (0.55 g, 2.44 mmol) 
to give 666 mg (77%) of 21 as white crystals after recrystallization from EtOAc. Mp: 103.4-105.2 °C. 
1H NMR (CDCl3): δ 1.30-1.42 (m, 2H), 1.50-1.73 (m, 7H), 2.02-2.19 (m, 2H), 2.34-2.42 (m, 4H), 2.60 
(t, J = 7.7 Hz, 2H), 2.78-2.84 (m, 2H), 7.15-7.45 (m, 9H). 13C NMR (CDCl3): δ 27.07, 27.66, 31.72, 
36.25, 38.66, 49.82, 59.10, 71.41, 126.05, 126.50, 128.65, 128.78, 128.82, 133.22, 142.98, 147.15. 
Anal. RP-HPLC Ib: tR = 4.57 min (purity 100%), IIb: tR = 6.49 min (purity 100%). HRMS (EI) m/z calcd 
for C
22
H
28
ClNO: 357.1859; found: 357.1862. 
 4-(4-Chlorophenyl)-1-(4,4-diphenylbut-3-enyl)piperidin-4-ol (22). Following method B 
using 25 (1.00 g, 3.00 mmol), which was synthesized according to literature procedure,38,39 followed by 
recrystallization from EtOAc/hexane gave 611 mg (49%) of 22 as a white solid. Mp 117.6-118.6 °C. 1H 
NMR (CDCl3): δ 1.48-1.79 (m, 3H), 1.98-2.20 (m, 2H), 2.29-2.62 (m, 6H), 2.67-2.89 (m, 2H), 6.07 (t, 
J = 7.2 Hz, 1H), 7.15-7.44 (m, 14H). 13C NMR (CDCl3): δ 27.44, 38.27, 49.13, 58.43, 70.88, 125.97, 
126.06, 126.83, 126.89, 127.03, 127.08, 127.96, 128.09, 128.25, 129.66, 132.58, 139.86, 142.40, 
142.55, 146.80. Anal. RP-HPLC Ib: tR = 10.43 min (purity 100%), IIb: tR = 13.29 min (purity 100%). 
HRMS (EI) m/z calcd for C27H28ClNO: 417.1859; found: 417.1845. 
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 4-(4-Chlorophenyl)-1-(4-phenylbut-3-enyl)piperidin-4-ol (23). (i) A solution of HCl (6 mL) 
and 27 (0.55 g, 2.98 mmol), which was synthesized as previously described,40 was heated and refluxed 
for 4.5 h. The reaction mixture was allowed to cool to room temperature, slowly basified with a 
saturated solution of Na2CO3 and the water layer was extracted with EtOAc (3 x 25 mL). The combined 
organic extracts were washed with water (3 x 50 mL) and brine (50 mL) and dried over anhydrous 
MgSO4. Evaporation in vacuo and purification by flash chromatography (hexane) gave 99 mg (20%) of 
28 as a colourless oil. 1H NMR (CDCl3): δ 2.61-2.72 (m, 2H), 3.61 (t, J = 6.9 Hz, 2H), 6.12-6.26 (dt, J 
= 6.9 Hz, 1H), 6.48 (d, J = 15.9 Hz, 1H), 7.19-7.38 (m, 5H). 
(ii) Following method A using 28 (0.10 g, 0.59 mmol) gave 101 mg (50%) of 23 as white needles after 
recrystallization from EtOAc. Mp: 136.3-137.2 °C. 1H NMR (CDCl3): δ 1.51-1.82 (m, 3H), 2.02-2.30 (m, 
2H), 2.38-2.70 (m, 6H), 2.79-3.00 (m, 2H), 6.12-6.29 (dt, J = 6.6 Hz, 1H), 6.44 (d, J = 16.0 Hz, 1H), 
7.18-7.46 (m, 9H). 13C NMR (CDCl3): δ 30.66, 38.30, 49.21, 58.21, 70.96, 125.83, 125.95, 126.89, 
128.27, 128.36, 130.89, 133.01, 137.79. Anal. RP-HPLC Ic: tR = 8.94 min (purity 100%), IIb: tR = 
4.79 min (purity 99%). HRMS (EI) m/z calcd for C21H24ClNO: 341.1546; found: 341.1560. 
 (1-(4,4-Diphenylbutyl)-piperidin-4-yl)(4-fluorophenyl)methanone (31). This was 
synthesized according to method B using 4-chloro-1,1-diphenylbutane44 (1.59 g, 6.50 mmol) and 4-(4-
fluorobenzoyl)piperidine toluenesulfonate (2.28 g, 6.00 mmol) to give 1.25 g (50%) of 31 as white 
crystals after recrystallization from EtOAc. Mp: 88.9-90.6 °C. 1H NMR (CDCl3): δ 1.38-1.53 (m, 2H), 
1.69-2.12 (m, 8H), 2.36 (t, J = 7.5 Hz, 2H), 2.80-2.99 (m, 2H), 3.06-3.23 (m, 1H), 3.88 (t, J = 7.8 Hz, 
1H), 6.98-7.34 (m, 12H), 7.80-8.00 (m, 2H). 13C NMR (CDCl3): δ 25.34, 28.59, 33.48, 43.64, 51.17, 
53.12, 58.61, 115.36, 115.80, 125.94, 127.68, 128.27, 130.61, 130.79, 144.89, 162.90, 167.96, 
200.92. Anal. RP-HPLC Ib: tR = 8.30 min (purity 100%), IIa: tR = 5.13 min (purity 100%), IIb: tR = 
16.06 min (purity 100%). HRMS (EI) m/z calcd for C28H30FNO: 415.2311; found: 415.2305. 
 (1-(4,4-Diphenylbutyl)piperidin-4-yl)(4-fluorophenyl)methanol fumarate (32). A solution 
of 31 (0.16 g, 0.38 mmol) and NaBH4 (0.050 g, 1.32 mmol) in MeOH (20 mL) was stirred overnight at 
room temperature. The reaction mixture was evaporated in vacuo, water was added (15 mL) and the 
water layer was extracted with DCM (3 x 10 mL). The combined organic extracts were washed with 
water (3 x 25 mL) and brine (25 mL), dried over anhydrous MgSO4, filtered and evaporated in vacuo to 
give 149 mg of the free base as a thick oil. This was dissolved in EtOAc and acidified by the addition of 
a saturated solution of fumaric acid in Et2O. The fumaric salt was isolated by filtration and recrystallized 
from IPA/Et2O to give 161 mg (79%) of 32 as a white solid. Mp: 77.4-79.3 °C. 1H NMR (CDCl3/DMSO-
d6): δ 1.29-1.79 (m, 7H), 1.91-2.40 (m, 5H), 2.61-2.83 (m, 2H), 3.08-3.40 (m, 2H), 3.77 (t, J = 7.9 
Hz, 1H), 4.12-4.30 (m, 1H), 6.64 (s, 2H), 6.89 (t, J = 8.7 Hz, 2H), 7.05-7.24 (m, 12H). 13C NMR 
(CDCl3): δ 22.03, 25.75, 32.32, 41.46, 50.48, 56.29, 77.08, 114.81, 115.23, 126.25, 127.51, 127.85, 
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128.00, 128.45, 135.12, 138.56, 143.89, 159.51, 170.43. Anal. RP-HPLC Ib: tR = 6.38 min (purity 
100%), IIb: tR = 10.26 min (purity 96%). HRMS (EI) m/z calcd for C28H32FNO: 417.2468; found: 
417.2449. 
 5-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2,2-diphenylpentanenitrile (33). 
Following method B using 1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one (0.83 g, 3.61 mmol) afforded 
842 mg (60%) of 33 after recrystallization from CHCl3. Mp: 204.1-206.0 °C. 1H NMR (CDCl3): δ 1.60-
1.76 (m, 4H), 2.38-2.68 (m, 10H), 4.70 (s, 2H), 6.45 (s, 1H), 6.80-6.92 (m, 3H), 7.24-7.42 (m, 12H). 
13C NMR (CDCl3): δ 23.22, 28.84, 37.34, 49.58, 51.49, 57.38, 59.14, 115.11, 118.75, 122.23, 126.70, 
127.71, 128.74, 129.11, 140.07, 142.92, 177.93. Anal. RP-HPLC Ib: tR = 5.41 min (purity 100%), IIb: 
tR = 8.17 min (purity 100%). HRMS (EI) m/z calcd for C30H32N4O: 464.2576; found: 464.2586. 
 1-Phenyl-8-(4-phenyl-4-o-tolylbutyl)-1,3,8-triazaspiro[4.5]decan-4-one (34). Following 
method A using 1-(4-chloro-1-phenylbutyl)-2-methylbenzene29 (0.16 g, 0.52 mmol) and 1-phenyl-
1,3,8-triaza-spiro[4.5]decan-4-one (0.14 g, 0.62 mmol) gave 188 mg (80%) of 34 as white crystals 
after recrystallization from hexane/CHCl3. Mp: 184.3-186.0 °C. 1H NMR (CDCl3): δ 1.39-1.83 (m, 4H), 
1.93-2.11 (m, 2H), 2.19 (s, 3H), 2.33-2.81 (m, 8H), 4.11 (t, J = 7.7 Hz, 1H), 4.80 (s, 2H), 6.61 (br s, 
1H), 6.86-6.92 (m, 2H), 7.00-7.38 (m, 12H). 13C NMR (CDCl3): δ 19.78, 29.00, 33.97, 41.28, 46.59, 
49.57, 58.24, 58.89, 115.36, 118.89, 125.76, 125.85, 126.41, 128.04, 128.15, 129.12, 130.34, 
136.14, 177.56. Anal. RP-HPLC Ib: tR = 8.12 min (purity 100%), IIb: tR = 11.45 min (purity 100%). 
HRMS (EI) m/z calcd for C30H35N3O: 453.2780; found: 453.2795. 
 5-(2-oxo-1,2-dihydrospiro[benzo[d][1,3]oxazine-4,4’-piperidine]-1’-yl)-2,2-diphenyl-
pentanenitrile (35). Following method A using spiro[benzo[d][1,3]oxazine-4,4’-piperidin]-2(1H)one 
(0.41 g, 1.62 mmol), which was synthesized according to literature procedure,41 afforded 416 mg 
(57%) of 35 as a white solid. Mp: 172.7-174.3 °C. 1H NMR (CDCl3): δ 1.56-1.78 (m, 2H), 1.96-2.21 (m, 
4H), 2.34-2.83 (m, 8H), 6.83 (d, J = 9.0 Hz, 2H), 6.98-7.56 (m, 12H), 8.89 (br s, 1H). 13C NMR 
(CDCl3): δ 23.65, 35.76, 37.83, 48.59, 52.04, 58.08, 81.91, 114.97, 122.71, 123.66, 124.08, 127.27, 
128.28, 129.28, 129.44, 124.71, 140.57, 152.52. Anal. RP-HPLC Ic: tR = 9.84 min (purity 100%), IIb: 
tR = 4.58 min (purity 99%). HRMS (EI) m/z calcd for C29H29N3O2: 451.2260; found: 451.2263. 
 5-(4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-2,2-
diphenylpentanenitrile (36). Following method A using 5-chloro-1-(piperidin-4-yl)-1H-
benzo[d]imidazol-2(3H)-one (0.50 g, 2.00 mmol) gave 734 mg (76%) of 36 as a white solid. Mp: 
203.1-204.6 °C. 1H NMR (DMSO-d6): δ 1.35-1.68 (m, 4H), 1.82-2.09 (m, 2H), 2.20-2.59 (m, 6H), 2.77-
2.98 (m, 2H), 4.02-4.23 (m, 1H), 6.98-7.04 (m, 2H), 7.20-7.45 (m, 11H), 11.05 (br s, 1H). 13C NMR 
(CDCl3): δ 23.23, 29.02, 37.27, 50.85, 51.49, 52.98, 57.51, 110.21, 120.87, 122.21, 126.66, 126.72, 
127.52, 127.77, 128.61, 128.75, 128.82, 139.99, 155.03. Anal. RP-HPLC Ib: tR = 5.81 min (purity 
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100%), IIb: tR = 8.83 min (purity 100%). HRMS (EI) m/z calcd for C29H29ClN4O: 484.2030; found: 
484.2055. 
 5-(3-oxo-3H-spiro[isobenzofuran-1,4’-piperidine]-1’-yl-2,2-diphenylpentanenitrile 
hydrochloride (37). A solution of o-bromobenzoic acid (0.76 g, 3.76 mmol) in THF (20 mL) was 
cooled to -78 °C and n-BuLi (4.7 mL, 1.6 M in hexane, 7.52 mmol) was added slowly in a period of 20 
min. The solution was stirred for 2 h at -78 °C and 39 (1.5 g, 4.51 mmol), which was synthesized 
according to literature procedure,31 was added slowly in a period of 30 min. The reaction mixture was 
allowed to warm to room temperature and water (30 mL) was added. The water layer was extracted 
with Et2O (5 x 10 mL) and acidified with HCl until a pH of 2. The solution was heated to reflux 
temperature for 1h, cooled to room temperature and stirred overnight. A 10% NaOH solution was 
added to a pH of 10, and the water layer was rapidly extracted with CHCl3 (5 x 20 mL). The combined 
organic extracts were washed with water (3 x 10 mL) and brine (20 mL), dried over anhydrous MgSO4, 
filtered and evaporated in vacuo to afford 1.01 g of the free base. This was converted to the 
hydrochloride salt as described for 2 to give 516 mg (31%) of 37 after recrystallization from 
MeOH/Et2O. Mp: 129.8-131.5 °C. 1H NMR (CDCl3): δ 1.68-1.92 (m, 4H), 2.48-2.91 (m, 8H), 2.98-3.21 
(m, 2H), 7.18-7.60 (m, 12H), 7.66 (d, J = 9.0 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H). 13C NMR (CDCl3): δ 
21.60, 34.28, 36.80, 49.27, 51.40, 57.08, 82.78, 121.26, 121.94, 125.00, 125.88, 126.56, 127.86, 
128.91, 129.63, 134.49, 139.51, 152.25, 169.01. Anal. RP-HPLC Ic: tR = 9.86 min (purity 98%), IIb: tR 
= 5.64 min (purity 95%). HRMS (EI) m/z calcd for C29H28N2O2: 436.2151; found: 436.2153. 
 1-(1-(4,4-Diphenylbutyl)piperidin-4-yl)indolin-2-one (38). (i) NaH (1.96 g, 49.00 mmol) 
was added in 5 min to a solution of di-t-butyl malonate (10 mL, 44.61 mmol) in DMF (250 mL) and this 
was stirred for 15 min. Subsequently, 2-fluoro-nitrobenzene (4.95 mL, 46.83 mmol) was added in one 
portion and the reaction mixture was stirred for 8 h at 90 °C and two days at room temperature. Water 
(300 mL) was added and the water layer was extracted with Et2O (3 x 200 mL). The combined organic 
extracts were washed with water (4 x 150 mL) and brine (150 mL), dried over Na2SO4 and filtered. 
After evaporation in vacuo, the residue was purified by flash chromatography (20% EtOAc in hexane) to 
give 3.0 g (20%) of di-t-butyl 2-(2-nitrophenyl)malonate as a light brown solid. 1H NMR (CDCl3): δ 1.48 
(s, 18H), 5.09 (s, 1H), 7.39-7.78 (m, 3H), 8.01 (d, J = 9.1 Hz, 1H).  
(ii) This was dissolved in EtOAc (100 mL) and 10% Pd/C (0.35 g) was added. The reaction mixture was 
hydrogenated with H2 (5 bar) overnight, filtrated over Hyflo and washed with EtOAc. After evaporated 
in vacuo, the residue was purified by recrystallization (Et2O/hexane) to give 915 mg (34%) of 41 as 
purple crystals. 1H NMR (CDCl3): δ 1.43 (s, 18H), 4.48 (s, 1H), 6.62-6.78 (m, 2H), 7.03-7.19 (m, 2H). 
(iii) Both 41 (0.31 g, 1.00 mmol) and 40 (0.31 g, 1.00 mmol), which was synthesized following 
literature procedures,29,31 were dissolved in 1,2-dichloroethane (10 mL). Next, molsieves (4Å) and 
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acetic acid (0.06 mL, 1.00 mmol) were added. The reaction mixture was stirred for 30 min, NaBH(OAc)3 
(0.30 g, 1.42 mmol) was added and this was stirred for another 24 h. A saturated solution of NaHCO3 
(15 mL) was added and the water layer was extracted with Et2O (3 x 20 mL). The combined organic 
extracts were washed with water (3 x 25 mL) and brine (25 mL), dried over MgSO4, filtered and 
evaporated in vacuo to give 520 mg of 42 as a white solid. The crude product was used without further 
purification. 
(iv) This was dissolved in toluene (20 mL) and p-toluene sulphonic acid (0.19 g, 9.99 mmol) was 
added. The reaction mixture was refluxed for 3 h, quenched with a saturated solution of NaHCO3 (25 
mL) and the water layer was extracted with Et2O (3 x 15 mL). The combined organic extracts were 
washed with water (3 x 20 mL) and brine (20 mL), dried over anhydrous MgSO4 and filtered. After 
evaporation in vacuo, the residue was purified by flash chromatography (0-50% EtOAc in DCM) and 
recrystallized from Et2O to give 112 mg (26%) of 38 as white crystals. Mp: 139.2-140.8 °C. 1H NMR 
(CDCl3): δ 1.31-1.78 (m, 4H), 1.91-2.19 (m, 4H), 2.22-2.50 (m, 4H), 2.95 (m, 2H), 3.48 (s, 2H), 3.89 
(t, J = 7.7 Hz, 1H), 4.19-4.35 (m, 1H), 7.02-7.31 (m, 14H). 13C NMR (CDCl3): δ 26.04, 28.45, 31.30, 
34.01, 36.25, 50.27, 51.73, 53.69, 58.81, 110.91, 122.19, 124.89, 125.19, 126.52, 127.92, 128.24, 
128.83, 144.07, 145.42, 175.25. Anal. RP-HPLC Ib: tR = 5.58 min (purity 99%), IIb: tR = 9.11 min 
(purity 99%). HRMS (EI) m/z calcd for C29H32N2O: 424.2515; found: 424.2501. 
 5-(4-Acetyl-4-phenylpiperidin-1-yl)-2,2-diphenylpentanenitrile hydrochloride (44). 
Following method A using 1-(4-phenylpiperidin-4-yl)ethanone (0.48 g, 2.00 mmol) gave 728 mg of the 
free base as an oil. This was converted to the hydrochloride salt as described for 2 and recrystallized 
from MeOH/Et2O to give 552 mg (54 %) of 44 as a white solid. Mp: 247.1-249.0 °C. 1H NMR (CDCl3): δ 
1.75-2.02 (m, 2H), 1.91 (s, 3H), 2.42-3.08 (m, 10H), 3.29-3.51 (m, 2H), 7.11-7.56 (m, 15H), 12.44 
(br s, 1H). 13C NMR (CDCl3): δ 20.11, 25.13, 27.23, 28.92, 29.61, 34.87, 48.43, 49.59, 51.17, 121.72, 
125.25, 125.53, 126.19, 127.39, 127.85, 139.05, 139.42, 207.72. Anal. RP-HPLC Ib: tR = 4.84 min 
(purity 100%), IIb: tR = 10.56 min (purity 100%). HRMS (EI) m/z calcd for C30H32N2O: 436.2515; 
found: 436.2525. 
 4-(4-Chlorophenyl)-1-(4-cyano-4,4-diphenylbutyl)piperidin-4-yl acetate fumarate (45). 
Et3N (0.12 mL, 0.9 mmol) and acetyl chloride (0.02 mL, 0.28 mmol) were added to a solution of 1 
(0.13 g, 0.30 mmol) in DCM (5 mL) at 0 °C. The reaction was stirred at 0 °C for 30 min and 1 h at room 
temperature. Water (10 mL) was added and the water layer was extracted with DCM (3 x 10 mL). The 
combined organic extracts were washed with water (3 x 15 mL) and brine (15 mL), dried over 
anhydrous MgSO4, and filtered. After evaporation in vacuo, the residue was purified by flash 
chromatography (0-25% EtOAc in DCM) to afford 89 mg of the free base as a thick oil. This was 
converted to the fumaric salt as described for 32 and recrystallized from MeOH/Et2O to give 75 mg 
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(41%) of 45 as white crystals. Mp: 176.4-177.3 °C. 1H NMR (CDCl3/DMSO-d6): δ 1.42-1.69 (m, 2H), 
1.81-2.07 (m, 5H), 2.16-2.56 (m, 8H), 2.65-2.83 (m, 2H), 6.59 (s, 2H), 7.11-7.24 (m, 14H). 13C NMR 
(DMSO-d6): δ 21.46, 34.51, 35.57, 48.27, 51.19, 56.18, 64.70, 78.96, 122.21, 126.21, 126.38, 
127.68, 127.94, 128.82, 131.37, 133.92, 139.79, 143.16, 166.01, 168.76. Anal. RP-HPLC Ib: tR = 6.42 
min (purity 100%), IIa: tR = 5.39 min (purity 100%), IIb: tR = 17.41 min (purity 100%). HRMS (EI) 
m/z calcd for C30H31ClNO2: 486.2074; found: 486.2062. 
 (1-(4,4-Diphenylbutyl)-4-phenylpiperidin-4-yl)methanamine (47). (i) Following method B 
using 4-chloro-1,1-diphenylbutane44 (1.22 g, 4.98 mmol) and 53 (0.92 g, 4.15 mmol) gave 1.59 g 
(81%) of 55 as a white solid. 1H NMR (CDCl3): δ 1.36-1.71 (m, 2H), 1.99-2.21 (m, 6H), 2.30-2.56 (m, 
4H), 2.88-3.05 (m, 2H), 3.88 (t, J = 7.8 Hz, 1H), 7.09-7.51 (m, 15H).  
(ii) A suspension of AlCl3 (0.93 g, 6.98 mmol) in THF (10 mL) was added to a suspension of LiAlH4 (0.26 
g, 6.85 mmol) in THF (10 mL) at 0 °C and this was stirred for 5 min, followed by the drop wise addition 
of a solution of 55 (1.36 g, 3.45 mmol) in THF (15 mL). The reaction mixture was allowed to warm to 
room temperature, stirred overnight, cooled with an ice bath and quenched with a saturated solution of 
Na2CO3 in water until the foaming stopped. Subsequently, the suspension was filtered, and the filtrate 
was dried over anhydrous MgSO4. Filtration, evaporation in vacuo and purification by flash 
chromatography (5% Et3N in EtOAc) afforded 863 mg (63%) of 47 as a white solid. Mp: 228.2-230.2 
°C. 1H NMR (MeOH-d4): δ 1.53-1.72 (m, 2H), 1.98-2.21 (m, 4H), 2.42-2.99 (m, 6H), 3.15 (s, 2H), 
3.21-3.40 (m, 2H), 3.94 (t, J = 7.9 Hz, 1H), 7.02-7.54 (m, 15H). 13C NMR (DMSO-d6): δ 22.45, 29.81, 
31.80, 47.69, 49.87, 55.33, 64.70, 125.87, 126.70, 126.98, 127.31, 127.48, 128.21, 128.79, 144.60. 
Anal. RP-HPLC Ic: tR = 3.91 min (purity 100%), IIc: tR = 4.44 min (purity 100%). HRMS (EI) m/z calcd 
for C28H34N2: 398.2722; found: 398.2741. 
 N-((1-(4,4-Diphenylbutyl)-4-phenylpiperidin-4-yl)methyl)formamide hydrochloride 
(48). 47 (0.11 g, 0.23 mmol) and formic acid (2 mL) were added in a 10 mL microwave vessel and 
this was reacted during 5 min in the microwave at a temperature of 200 °C (settings: ramp time 5 min, 
hold time 5 min, power 200 watt, pressure 17.2 bar). The reaction mixture was quenched with a 
saturated solution of Na2CO3 (2 mL) and the water layer was extracted with DCM (3 x 5 mL). The 
combined organic extracts were dried over MgSO4 and filtered. After evaporation in vacuo, the residue 
was purified by flash chromatography (5% Et3N in EtOAc) and the free base was converted to the 
hydrochloride salt as described for 2 to give 100 mg (94%) of 48 as a white solid. Mp: 52.2-52.8 °C. 1H 
NMR (CDCl3): δ 1.42-1.74 (m, 2H), 1.86-2.42 (m, 8H), 2.50-2.89 (m, 2H), 3.10-3.29 (m, 2H), 3.39 (d, 
J = 7.6 Hz, 2H), 3.87 (t, J = 7.8 Hz, 1H), 5.05 (br s, 1H), 7.01-7.61 (m, 15H), 8.03 (s 1H). 13C NMR 
(CDCl3): δ 24.62, 31.69, 32.24, 33.72, 49.83, 51.45, 58.51, 126.65, 127.42, 128.14, 128.87, 129.00, 
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129.60, 144.51, 144.96, 161.78. Anal. RP-HPLC Ib: tR = 5.20 min (purity 100%), IIb: tR = 6.08 min 
(purity 93%). HRMS (EI) m/z calcd for C29H34N2O: 426.2671; found: 426.2678. 
 1-(1-(4,4-Diphenylbutyl)-4-phenylpiperidin-4-ylmethyl)-N-methylmethanamine 
dihydrochloride (49). LiAlH4 (0.75 g, 19.76 mmol) was added to a solution of 48 (0.20 g, 0.47 
mmol) in THF (10 mL) at 0 °C. The reaction mixture was refluxed for 6h, quenched with a saturated 
solution of Na2CO3 and the water layer was extracted with DCM (3 x 10 mL). The combined organic 
extracts were dried over anhydrous MgSO4 and evaporated in vacuo. The residue was purified by flash 
chromatography (5% Et3N in EtOAc) to give 150 mg of the free base. This was converted to the 
corresponding hydrochloride salt as described for 2 to give 104 mg (46%) of 49 as a white solid. Mp: 
50.9-52.5 °C. 1H NMR (MeOH-d4): δ 1.57-1.79 (m, 2H), 1.98-2.27 (m, 4H), 2.59 (s, 3H), 2.60-2.82 (m, 
4H), 2.92-3.06 (m, 2H), 3.18-3.30 (m, 2H), 3.40-3.57 (m, 2H), 3.88-4.09 (m, 1H), 7.10-7.33 (m, 
10H), 7.36-7.61 (m, 5H). 13C NMR (CDCl3): δ 22.66, 30.45, 35.42, 40.00, 49.34, 51.01, 55.53, 57.59, 
61.17, 127.33, 128.08, 128.27, 128.98, 129.03, 130.66, 137.48, 144.28. Anal. RP-HPLC Ic: tR = 3.52 
min (purity 100%), IIc: tR = 4.63 min (purity 100%). HRMS (EI) m/z calcd for C29H36N2: 412.2878; 
found: 412.2861. 
 (4-(4-Chlorophenyl)-1-(4,4-diphenylbutyl)piperidin-4-yl)methanamine dihydrochloride 
(50). (i) Et3N (20 mL) was added to a solution of bis-(2-chloroethyl)amine hydrochloride (8.17 g, 
45.77 mmol) in DCM (75 mL) and this was stirred for 15 min. After the addition of di-tert-butyl 
dicarbonate (10.0 g, 45.8 mmol) in DCM (50 mL), the reaction mixture was stirred for 20 h and 
quenched with water (200 mL). The water layer was extracted with DCM (4 x 100 mL) and the 
combined organic extracts were dried over anhydrous Na2SO4 and filtered. After evaporation in vacuo, 
the residue was purified by flash chromatography (30% hexane in DCM) to give 3.90 g (35%) of 57 as 
a light yellow oil. 1H NMR (CDCl3): δ 1.48 (s, 9H), 3.49-3.70 (m, 8H). 
(ii) A suspension of NaNH2 (0.80 g, 20.51 mmol) in toluene (10 mL) was added to a solution of 2-(4-
chlorophenyl)acetonitrile in toluene (10 mL) at 0 °C. The reaction mixture was stirred for 30 min at 0 °C 
and added drop wise to a solution of 57 (2.78 g, 10.01 mmol) in toluene (50 mL) at 0 °C. This was 
heated to 70 °C, stirred overnight and quenched with water (100 mL). The organic layer was separated 
and the water layer was extracted with DCM (3 x 50 mL). The combined organic extracts were dried 
over anhydrous Na2SO4 and filtered. Evaporation in vacuo and purification by flash chromatography 
(DCM) gave 600 mg (19%) of 58 as a light yellow oil. 1H NMR (CDCl3): δ 1.44 (s, 9H), 1.72-2.11 (m, 
4H), 3.04-3.29 (m, 2H), 4.13-4.35 (m, 2H), 7.31-7.49 (m, 4H). 
(iii) This was dissolved in EtOH (30 mL), which was saturated with hydrochloride gas, and the resulting 
reaction mixture was stirred for 5 min. Evaporation in vacuo gave a quantitative yield of 54 as a white 
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solid. 1H NMR (DMSO-d6): δ 2.31-2.44 (m, 4H), 2.99-3.20 (m, 2H), 3.39-3.48 (m, 2H), 7.49-7.62 (m, 
4H). 
(iv) Following method B using 4-chloro-1,1-diphenylbutane44 (0.56 g, 2.28 mmol) and 54 (0.49 g, 1.90 
mmol) afforded 500 mg (62%) of 56 as a white solid. 1H NMR (CDCl3): δ 1.32-1.72 (m, 2H), 1.90-2.08 
(m, 6H), 2.23-2.59 (m, 4H), 2.72-3.02 (m, 2H), 3.91 (t, J = 7.8 Hz, 1H), 6.99-7.52 (m, 14H). 
(v) This was synthesized as described for 47 starting from 56 (0.30 g, 0.47 mmol) to give 130 mg of 
the free base as an oil. This was converted to the hydrochloride salt as described for 2 to give 100 mg 
(42%) of 50 as a white solid. Mp: 257.3-258.9 °C (dec). 1H NMR (MeOH-d4): δ 1.57-1.80 (m, 2H), 
2.01-2.29 (m, 6H), 2.56-2.81 (m, 2H), 2.92-3.20 (m, 4H), 3.32-3.54 (m, 2H), 3.82-4.00 (m, 1H), 
7.09-7.59 (m, 14H). 13C NMR (DMSO-d6): δ 21.80, 29.23, 30.48, 31.64, 47.21, 49.80, 54.98, 60.16, 
125.92, 127.30, 128.23, 128.80, 131.97, 135.28, 144.46. Anal. RP-HPLC Ic: tR = 6.07 min (purity 
100%), IIc: tR = 7.57 min (purity 100%). HRMS (EI) m/z calcd for C28H33ClN2: 432.2332; found: 
432.2319. 
 N-(4-(4-Chlorophenyl)-1-(4,4-diphenylbutyl)-piperidin-4-yl)acetamide (51). A solution of 
95% H2SO4 (3.3 mL, 12.4 mmol) was added dropwise to a solution of 59 (1.37 g, 3.26 mmol) in CH3CN 
(16 mL), while the temperature was maintained between 25 °C and 30 °C. The reaction mixture was 
stirred overnight at room temperature, poured into ice and neutralized with a 30% solution of NaOH. 
Water was added (20 mL) and the water layer was extracted with DCM (3 x 30 mL). The combined 
organic layers were washed with water (3 x 30 mL) and brine (20 mL), dried over anhydrous Na2SO4 
and filtered. After evaporation in vacuo, the residue was purified by flash chromatography (0-50% 
MeOH in EtOAc) and recrystallized from EtOH/Et2O to give 655 mg (75%) of 51 as a white solid. Mp: 
189.1-190.4 °C. 1H NMR (CDCl3): δ 1.39-1.83 (m, 6H), 1.89-2.50 (m, 6H), 1.98 (s, 3H), 2.67-2.88 (m, 
2H), 3.88 (t, J = 7.8 Hz, 1H), 5.52 (br s, 1H), 7.13-7.27 (m, 14H). 13C NMR (CDCl3): δ 24.02, 24.52, 
33.14, 34.32, 49.21, 50.97, 55.54, 57.82, 126.14, 126.47, 127.30, 127.59, 128.38, 132.51, 143.40, 
144.45, 169.58. Anal. RP-HPLC Ib: tR = 5.66 min (purity 100%), IIb: tR = 8.20 min (purity 100%). 
HRMS (EI) m/z calcd for C29H33ClN2O: 460.2281; found: 460.2299. 
 4-(4-Chlorophenyl)-1-(4,4-diphenylbutyl)piperidin-4-amine fumarate (52). A solution of 
51 (0.66 g, 1.42 mmol) in 8% HCl (240 mL) was refluxed for three days. Water was added (40 mL), 
the water layer was basified with a 20% solution of NaOH and extracted with DCM (3 x 30 mL). The 
combined organic layers were dried over anhydrous Na2SO4 and filtered. After evaporation in vacuo, the 
residue was purified by flash chromatography (5% MeOH and 1% Et3N in EtOAc) to give 290 mg of a 
white solid. This was converted to the fumaric salt as described for 29 to give 110 mg (19%) of 52 as 
white crystals after recrystallization from MeOH/Et2O. Mp: 189.9-190.7 °C. 1H NMR (MeOH-d4): δ 1.57-
1.68 (m, 2H), 1.98-2.08 (m, 2H), 2.08-2.18 (m, 2H), 2.13-2.18 (s, 2H), 2.31-2.42 (m, 2H), 1.82-2.95 
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(m, 4H), 3.15-3.24 (m, 2H), 3.96 (t, J = 7.8 Hz, 1H), 7.11-7.19 (m, 2H) 7.23-7.32 (m, 8H) 7.44 (d, J 
= 8.7 Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H). 13C NMR (DMSO-d6): δ 23.88, 35.02, 48.17, 50.04, 52.48, 
56.42, 125.78, 127.32, 127.79, 127.90, 128.16, 131.43, 134.70, 144.85, 167.23. Anal. RP-HPLC Ic: tR 
= 5.85 min (purity 100%), IIc: tR = 6.63 min (purity 100%). HRMS (EI) m/z calcd for C27H31ClN2: 
418.2176; found: 418.2176. 
 
Pharmacology 
Transient and stable expression of US28. COS-7 cells were grown as previously described.50 
Transient transfection of COS-7 cells was performed by DEAE-dextran, using 2 µg of US28-pcDEF3 DNA 
per million cells.50 SVEC4-10 (ATCC CRL2181) is a cell line derived by SV40 transformation of 
endothelial cells from the murine axillary lymph node vessels. SVEC4-10 cells were grown as described 
previously.50 SVEC4-10 cells were transfected with US28-pTJE8 using 25kDa linear polethylenimine 
(PEI; Polysciences, Inc.). “Empty” vector was used for mock transfections. Briefly, 10 µg DNA and 50 µg 
PEI were separately diluted into 250 µl 150 mM NaCl solution. The PEI solution was added to the DNA 
solution, vortexed and incubated for 15 min at room temperature. One million SVEC4-10 cells were 
seeded in a 10-cm dish the day before transfection. Culture medium was replaced by 6 mL DMEM and 
the DNA/PEI solution was added drop wise to the cells. The solution was mixed by gently shaking and 
the dish was incubated at 37 °C for 5 h. The transfection solution was replaced by culture medium and 
incubated O/N. SVEC4-10 cells stably expressing US28 were selected in culture medium containing 500 
µg/mL neomycin G418. Clones were selected based on US28-mediated constitutive IPx accumulation 
and chemokine binding analysis. 
[125I]CCL5 binding experiments. Radioiodination [125I] of CCL5 (Peprotech, Rocky Hill, NJ) was 
performed using iodogen (Pierce Chemical Co., Rockford, IL) as described previously.51 Displacement 
binding experiments were performed on US28-expressing COS-7 cell membranes. Two days after 
transfection COS-7 cells were homogenized in ice-cold buffer A (i.e. 15 mM Tris-HCl, pH 7.5, 2 mM 
MgCl2, 0.3 mM EDTA, and 1 mM EGTA) and centrifuged at 200 x g for 10 min. Supernatant was 
collected and centrifuged at 48,000 x g for 30 min. The pellet was resuspended in buffer B (i.e. 7.5 mM 
Tris-HCl, pH 7.5, 12,5 mM MgCl2, 0.3 mM EDTA, 1 mM EGTA, and 250 mM sucrose), aliquoted and 
stored at -80 °C until use. Cell membranes (approximately 0.2 µg/sample) were incubated with 0.3 nM 
[125I]CCL5 in binding buffer (i.e. 50 mM Hepes, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, and 
0.2% bovine serum albumin) in the absence or presence of various concentrations of nonpeptidergic 
ligands at 37 °C for 1 h. Incubations were terminated by filtration through a UniFilter-96 GF/C filter 
plate (PerkinElmer Life Sciences, Wellesley, MA) presoaked in 0.3% PEI, followed by three rapid washes 
with ice-cold binding washing buffer (i.e. 50 mM Hepes, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 500 mM 
Chapter 3 
90 
NaCl) using a MicroBeta FilterMate-96 Harvester (PerkinElmer). Non-specific binding was determined on 
membranes from mock-transfected cells. Radioactivity was quantified with a liquid scintillation using a 
Wallac MicroBeta TriLux (PerkinElmer). 
[3H]inositol phosphate accumulation. SVEC4-10 cells (approximately 4 x 105 cells/well) were 
seeded into poly-L-lysine coated 96-well plates in 200 µl culture medium. After approximately 24h, 
medium was replaced with 100 µl/well inositol-free Dulbecco’s modified Eagle’s medium supplemented 
with 10 µCi/mL myo-[2-3H]inositol (PerkinElmer) and the cells were further incubated. The next day, 
cells were washed and preincubated for 10 min with assay buffer (i.e. Dulbecco’s modified Eagle’s 
medium containing 10 mM LiCl). Next, cells were incubated in assay buffer in the absence or presence 
of various concentrations of nonpeptidergic ligands at 37 °C for 2 h. Inositol phosphates were extracted 
using 10 mM formic acid and quantified using 0.5 mg/well Ysi-RNA-binding SPA beads (Amersham 
Biosciences), in a white clear bottom 96-well isoplates (PerkinElmer) using a Wallac MicroBeta TriLux, 
essentially as previously described.52 
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Design of a diverse library of ligands for the viral-encoded GPCR US28 
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Abstract 
Lead compound 1 {5-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-
diphenylpentanenitrile} has recently been identified as the very first inverse 
agonist acting on the human cytomegalovirus encoded GPCR US28. To identify 
novel inverse agonists for this receptor that have a significant structural 
diversity, a focused virtual library around the 4-(4-chlorophenyl)piperidin-4-ol 
scaffold 2 has been designed. Virtual compounds were generated by the 
enumeration of commercially available reagents that can react with 2 via 
standard synthetic procedures, namely carboxylic acids, acid chlorides, 
sulphonyl chlorides, alkyl halides, aldehydes and ketones. The potential products 
were processed through different filtering processes to remove compounds with 
undesirable properties or functional groups. Of the remaining compounds 
different 1-D and 2-D descriptors, i.e. the logP (o/w), TPSA (2D), the number of 
single rotatable bonds and the number of H-bond acceptors and donors, were 
calculated. Based on these descriptors, a diverse subset of 50 compounds was 
calculated to cover the maximal chemical space of the virtual library. 
Subsequently, this library was synthesized in a parallel chemistry approach. In 
the end, 18 compounds could be readily isolated and characterized. 
Pharmacological evaluation of the synthesized compounds revealed compound 
10 as novel inverse agonist acting on US28. All other compounds showed no 
affinity or efficacy on the receptor. 
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Introduction 
Over the last decades, the G protein-coupled receptor (GPCR) family has 
emerged as a major target for therapeutic intervention and currently many 
known marketed drugs are targeted on GPCRs.1 Chemokine receptors belong to 
Class A GPCRs, which are characterized by a high homology with rhodopsin. 
These receptors have been successfully targeted by small molecules and thus 
constitute a solid database of knowledge that should aid the design of novel 
ligands for other GPCRs.2 With the discovery that viruses also encode GPCRs, a 
new unexplored class of potential drug targets has emerged. Several of these 
receptors, such as the human cytomegalovirus-encoded (HCMV) US28 or the 
human herpesvirus 8 (HHV-8) or Kaposi’s sarcoma-associated herpesvirus 
(KSHV) receptor ORF74, are suggested to play an important role in the 
pathogenesis of virus infection.3 Selective small nonpeptidergic inhibitors for 
these receptors could serve as new promising therapeutics for innovative anti-
viral intervention. However, the constitutively active receptor US28 is currently 
the only viral-encoded GPCR for which small nonpeptide ligands have been 
identified.  
 
VUF 2274 (1) was the first small nonpeptidergic ligand acting as an inverse 
agonist on US28 by completely blocking the basal signaling of this receptor.4 
Recently, various analogues of 1 have been synthesized, leading to the very first 
structure-activity relationships for inverse agonism on a viral-encoded 
receptor.5,6 Although many changes were introduced in the structure of 1, only 
small improvements in affinity and efficacy were observed. This prompted the 
question whether more rigorous structural changes where needed to optimize 
US28 affinity. Therefore, molecular modelling techniques were applied to design 
a virtual library around the piperidine scaffold (2) of lead compound 1.  
 
NR Cl
OH
N Cl
OH
CN
1 2  
Figure 1. Chemical structures of lead compound 1 and piperidine scaffold 2. 
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Currently, focussed libraries are considered as a better alternative to the 
screening of random libraries containing more than 106 compounds.7-9 For many 
years, screening libraries and corporate compound collections were optimized in 
terms of size and diversity. Combinatorial chemistry was applied to generate as 
many compounds as possible and it was believed that the relatively low hit rate 
from high throughput screening could be overcome by screening more 
compounds.10  
 
It was expected that the combination of HTS and combinatorial chemistry would 
deliver multiple new promising lead compounds for drug discovery projects, but 
it has so far not fulfillled all expectations. HTS drug discovery requires large and 
expensive compound libraries and resulted in high attrition rates in later stages 
of drug development due to poor physicochemical properties, such as a poor 
chemical stability in the gut, poor permeability and a poor metabolic and/or 
elimination profile.11,12 Thus, it is important that drug-like properties are 
considered as early as possible and all potential compounds with 
disadvantageous properties or functional groups should be removed at the 
earliest possible stage in the drug discovery process.13-15 Examples of such 
undesirable molecules are compounds that can interfere with the biological 
assays, including fluorescent compounds, dyes and promiscuous compounds 
(compounds of which the activity is not specific for the target).16 Moreover, 
chemically toxic or reactive species, such as compounds with electrophilic 
functional groups, are a potential risk of giving false positives.16,17  
 
Over the past few years, additional filters have been introduced focusing on 
more subtle properties, e.g. trying to asses whether or not the ligands are drug-
like (suitable to be drugs).18-21 The first widely used drug-like filter was 
developed by Lipinski and co-workers,14 who suggested that poor absorption or 
permeation are more likely when there are more than 5 hydrogen bond donors 
(OH and NH), when the molecular weight is over 500, when the calculated 
octanol/water partition coefficient (CLOGP) is over 5, and when there are more 
than 10 hydrogen bond acceptors (O and N). This Lipinski rule of five and other 
drug-like filters can be used as a guide for a proper selection of compounds.22 
This early assessment of a virtual library reduces the size of the library and 
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improves the chance that any potential hit represents a promising starting point 
for lead optimization.23 
 
In order to find novel structurally diverse inverse agonists for the HCMV-
encoded receptor US28 the molecular modelling program MOE (molecular 
operating environment) was applied to design a small virtual library based on 
compound 1 by enumeration of commercially available reagents that could 
potentially react with scaffold 2 via standard synthetic procedures. The virtual 
library was taken through a filtering process to remove compounds with 
undesirable features. To ensure maximum coverage of chemical space, but to 
limit the amount of compounds to be synthesized, a diverse subset based on 
different descriptors was calculated. This small focussed library was synthesized 
using parallel chemistry. The synthesized library consists of compounds based 
on the piperidine scaffold of lead compound 1. These molecules will provide new 
important insights about the SAR of this class of compounds. 
 
Methods 
An overview of the approach discussed in this chapter is outlined in Scheme 1. 
The successive steps will be discussed in detail in the following subsections. 
 
Import of all commercially available
reagents into MOE
Removal of reagents with more than
one of the same reactive groups
Enumeration of the virtual library
in MOE
Removal of undesired compounds
as defined by Hann21 and
Baurin22
Processing of all virtual compounds,
e.g. removal of all counter ions and
salts, addition of explicit hydrogen
atoms etc.
Selection of the virtual compounds
on their druglike properties
Calculation of diverse subset based
on the molecular structure of 1
Purchase of the reagents and
parallel synthesis of the compounds
Pharmacological evaluation of the
synthesized compounds
 
 
Scheme 1. Flow chart summarizing the successive steps that were followed in this chapter. 
 
Design of the virtual library. The molecular modeling program MOE 
(Molecular Operating Environment 2004.03) was used to generate a virtual 
compound library by combinatorial substitution of the commercially available 4-
(4-chlorophenyl)piperidin-4-ol (2) with reagents selected from the available 
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chemicals directory (ACD). All commercially available reagents that could 
potentially react with 2 under reductive amination, acylation or alkylation 
conditions were selected, namely aldehydes, ketones, alkyl halides, carboxylic 
acids, acid chlorides and sulfonyl chlorides were considered (Scheme 2).  
 
N Cl
OH
HN Cl
OH
R1 R2
c
N Cl
OH
R1 X or R1
O
H
NR Cl
OH
R1 S
O
Cl
O
N
OH
Cl
d or e
f
a or b
2
R1
O
OH or R1
O
Cl
O R2
R1
S
O
O
R1
R1
O
 
 
Scheme 2. Schematic representation of the synthetic procedures applied for the synthesis of the small 
focussed library. Reagents and conditions: (a) NaI, Na2CO3, CH3CN, microwave (15 min, 160 °C) for 
alkylchlorides, alkylbromides and alkyliodes (X = Cl, Br or I); (b) AcOH, NaCNBH3, MeOH; (c) 
Ti(IV)isopropoxide, NaBH3CN, EtOH for ketones; (d) EDCI, HOBT, DIPEA, DCM for carboxylic acids; (e) 
Et3N, DCM for acid chlorides; (f) Et3N, DCM for sulphonyl chlorides. 
 
Suppliers that were taken into account were Acros, Aldrich, Sigma, Lancaster, 
Fluka and Avocado. Each group of reagents was imported into a separate 
database and filtered, e.g. reagents that contained more than one of the same 
reactive group, such as two carboxylic acid groups that can both react with the 
nitrogen atom of 2, were removed. The library was generated by virtually 
reacting piperidine 2 with the reagents from each database under the intended 
reaction conditions, for example, a reductive amination reaction with the 
aldehydes or ketones, an alkylation with alkyl halides and an acylation with the 
carboxylic acids or acid halides. After enumeration of the library, all virtual 
compounds were combined in one library followed by a second filtering step. The 
undesired compounds were eliminated by applying a set of structural filters, as 
defined by Hann21 and Baurin.22 Thus, all virtual molecules containing reactive 
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functional groups, metal atoms or isotopes were removed. Moreover, duplicates, 
unsuitable lead structures, such as crown ethers or β-lactams, unsuitable natural 
products and dyes, were expelled.21,22 The remaining molecules were processed 
to remove all counter ions and salts, to add all explicit hydrogen atoms, to 
deprotonate acidic groups and protonate basic groups and to calculate the 
forcefield partial charges, resulting in a library of 7950 virtual compounds. Next, 
a drug-like filter based on different 1D and 2D molecular descriptors was 
applied. All virtual compounds, which did not fulfill the following criteria, were 
removed: molecular weight ≤ 800, logP (o/w) < 7, number of single rotatable 
bonds ≤ 10, number of H-bond donors < 5, number of H-bond acceptors < 10, 
number of halogens < 7 and number of rings < 6. After this process, 5282 
entries were left.  
 
Of all these compounds, a selection of 1-D and 2-D descriptors were calculated, 
i.e. the logP (o/w), TPSA (2D), the number of single rotatable bonds and the 
number of H-bond acceptors and donors. Lead compound 1 was taken as a 
starting point and based on the five descriptors, a diverse subset of 50 
compounds was calculated. Furthermore, all reagents were passed through a 
visual inspection and all chemicals were removed that had passed the filtering 
process, but that were deemed not to be reactive under the chosen reaction 
conditions, too expensive or not commercially available anymore. To remove as 
many undesirable compounds as possible, this iterative process was repeated for 
ten times followed by purchasing all reagents that satisfied the criteria.  
 
Parallel synthesis of the calculated diverse subset. The different synthetic 
procedures (Scheme 2) were validated and optimized with reagents from our in-
house database. The N-alkylations of the alkyl halides with piperidine 2 were 
performed in the microwave in the presence of NaI, Na2CO3 and CH3CN to afford 
amines 3-7 in moderate to high yields.6 The aldehydes were reacted following a 
reductive amination procedure utilizing sodium triacetoxyborohydride and acetic 
acid in 1,2-dichloroethane to give amines 8-11.24 A reductive amination 
procedure using titanium(IV) isopropoxide and sodium cyanoborohydride was 
applied to react the ketones with amine 2.25 Unfortunately, this procedure was 
not successful with the selected ketones and no products were obtained.  
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Amides 12-19 were synthesized using a modified method described by Palani et 
al.26 by reacting the carboxylic acids with 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDCI), 4-hydroxy benzotriazole (HOBT) and diisopropylethylamine 
(DIPEA) in DCM, followed by the addition of amine 2. No synthetic procedure for 
the synthesis of amides by the reaction of piperidine 2 with acid chlorides was 
applied, because no acid chlorides were present in the selected compounds. 
Sulphonamide 20 was synthesized in the presence of Et3N in DCM. 
 
Results and discussion 
To introduce more rigorous changes into the structure of lead compound 1, we 
designed a virtual library around generic structure 2 and a diverse subset was 
composed based on the calculation of different descriptors. The structural 
diversity was introduced at the piperidine ring of compound 1, because previous 
lead optimization procedures5,6 had shown that this part of the molecule was 
important for inverse agonism. However, it was mentioned in Chapter 3 that 
introduction of a methylamine group attached to the 4-position of the piperidine 
ring gives a 6-fold increase in binding affinity compared to lead compound 1, but 
this substituted piperidine ring was not commercially available and could not be 
synthesized in large quantities. 
 
From these 50 reagents, already 8 compounds had to be removed before 
ordering, because they were not commercially available anymore, too expensive 
or not reactive under the given reaction conditions (e.g. Michael acceptors that 
were selected to react with piperidine 2 under reductive aminations conditions). 
The remaining 42 reagents were purchased and reacted with 2 using the 
standard synthetic procedures described previously in this chapter. All reactions 
that did not work were repeated following the same synthetic procedure to 
confirm that the desired compound could not be formed. The question arises if 
42 reagents are enough to obtain satisfactory results. In literature,27 it was 
mentioned that general experience over the years has indicated that around 
2000 rationally designed compounds have to be synthesized and 
pharmacologically evaluated to determine good structure-activity relationships. 
Moreover, it was stated that an interative construction is preferred to acquire a 
useful final compound. However, this was not possible for us due to time and 
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cost restraints. Following our approach, 18 compounds were succesfully isolated 
and pharmacologically evaluated for their potential to dose-dependently displace 
[125I]CCL5 binding to US28 at a concentration of 10 µM. The inverse agonistic 
properties of these compounds were investigated by testing their potential to 
inhibit the US28-mediated constitutive inositol phosphate production in SVEC4-
10 cells at the same concentration. For all compounds that showed more than 
50% displacement of [125I]CCL5 the IC50 and EC50 values were obtained. 
 
Table 1 shows the compounds that were synthesized by alkylation of piperidine 
2 with the corresponding alkyl halides (compounds 3-7). Unfortunately, none of 
these compounds showed any affinity or efficacy on US28. Thus, the addition of 
the two ester moieties in compound 3, the methyl group in 4 or the ether 
functionalities in 5 did not result in compounds with any activity on US28. 
 
Table 1. Chemical structures and pharmacological properties of compounds 1 and 3-7 for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments, unless otherwise indicated. 
 
N
OH
ClR  
 
no. VUF R IC50 (µM)a EC50 (µM)b 
1 2274 CN
 
4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
3 10082 O O
OO
 
n.a. n.a. 
4 10109 H3C  
n.a. n.a. 
5 10116 O
O
 
n.a. n.a. 
6 
10084 
N
NH
 
n.a. n.a. 
7 10221 
O
N
 
 
n.a. n.a. 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.a.= not active.  
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In a previous study, it was shown that the nitrile group of 1 is not essential in 
the structure and that removal of one of the phenyl rings from the structure 
resulted in a binding affinity comparable to that of lead compound 1 (see 
Chapter 2). Moreover, it was shown that the length of the linker between the 
phenyl ring and piperidine moiety 2 is not of importance, because removal of 
one methylene group resulted in a slight decrease in binding affinity, while the 
addition of one methylene group did not change the affinity or efficacy. 
However, incorporation of the phenyl ring in a benzimidazole ring (6) or in a 4-
benzyl-morpholine moiety (7), resulting in a decrease of conformational 
freedom, completely abolished activity. A possible explanation of the loss of 
activity might be that the phenyl rings of both compounds are in the wrong 
conformation, resulting in a loss of the interaction of the phenyl ring with the 
receptor.  
 
All selected aldehydes reacted with scaffold 2 under reductive amination 
conditions (Table 2). The introduction of the sugar moieties, as in compounds 8-
10, did not result in compounds with any binding affinity or potency on US28. 
Interestingly, the introduction of a sugar moiety as linker between two phenyl 
rings (11) did positively influence the activity on US28 and resulted in a 8-fold 
decrease in binding affinity, while the inverse agonistic properties were only 
slightly lower. 
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Table 2. Chemical structures and pharmacological properties of compounds 1 and 8-11 for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments, unless otherwise indicated. 
 
N
OH
ClR  
 
no. VUF R IC50 (µM)a EC50 (µM)b 
1 2274 CN
 
4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
8 10115 O
O O
O
 
n.a. n.a. 
9 10118 
O
O
O
O
 
n.a. n.a. 
10 10222 
OH
O
HO
OH
O  
n.a. n.a. 
11 10223 
O
O
O
O
H
H
 
 
42.3 (25.7 – 58.9) 6.2 (3.0 – 9.3) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.a.= not active. 
 
Table 3 shows the compounds that were successfully synthesized by reacting 
piperidine 2 with the corresponding carboxylic acids. Despite the high diversity 
of this selection of compounds, none of them showed any activity on US28. 
Remarkably, the large lipophilic pyrene group of compound 13 passed all drug-
like filters, although this group does not seem to be beneficial in drugs. We did 
not remove this compound manually, because we wanted to obtain the highest 
diversity as possible with as only limitation the amount of compounds that could 
be synthesized due to a lack of reactivity 
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Table 3. Chemical structures and pharmacological properties of compounds 1 and 12-19 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 and 
EC50 values of at least three independent experiments, unless otherwise indicated. 
 
N
OH
ClR  
 
no. VUF R IC50 (µM)a EC50 (µM)b 
1 2274 CN
 
4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
12 10083 
O
O
 
n.a. n.a. 
13 10114 O
O
 
n.a. n.a. 
14 10120 
O O
O
Br
Br
 
n.a. n.a. 
15 10121 S NH
O
O O
H2N
O
Cl  
n.a. n.a. 
16 10122 
O
O
NH2
 
n.a. n.a. 
17 10124 
O
H
N
O
O  
n.a. n.a. 
18 10125 
NH
O
 
n.a. n.a. 
19 10224 
O
N
N
S
O
 
 
n.a. n.a. 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.a. = not active. 
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Table 4. Chemical structures and pharmacological properties of compounds 1 and 20 for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments, unless otherwise indicated. 
 
N
OH
ClR
 
no. VUF R IC50 (µM)a EC50 (µM)b 
1 2274 CN
 
4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
20 10119 
S
S
N
OO
O O
O
 
n.a. n.a. 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. n.a.= not active. 
 
Only one of the selected reagents had a sulphonyl chloride reactive group, 
which successfully reacted with piperidine 2 to give sulphonamide 20 (Table 
4). Unfortunately, this compound had no affinity nor efficacy on US28 either.  
 
As mentioned earlier in this chapter, none of the selected ketones (11 ketones in 
totall) reacted with scaffold 2 to the desired products under the chosen reaction 
conditions, although succesfull reductive amination reactions with titanium(IV) 
isopropoxide to tertiary amines were previously described.25,28,29 Due to the lack 
of reactivity of the selected ketones to react with piperidine 2, it would have 
been better if the ketones were not taken into account as reagents. 
 
Conclusions 
An approach for the rational design of a focussed virtual library based on the 4-
(4-chlorophenyl)piperidin-4-ol scaffold 2 has been developed. The commercially 
available compounds that could react with 2 under reductive amination, 
acylation or alkylation conditions were selected. After enumeration of the library 
and filtering of the virtual compounds, a diverse subset of 50 compounds based 
on different 1D and 2D descriptors was calculated. Efforts were made to 
synthesize this selection in a parallel chemistry approach. Eventually, 18 
compounds were easily synthesized and characterized. Pharmacological 
evaluation of the synthesized compounds revealed only compound 11 as as 
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novel inverse agonists acting on US28. All other variations attached to piperidine 
ring 2 resulted in compounds with no activity on the receptor.  
 
Experimental section 
General procedures. DCM was freshly distilled from lithium aluminium hydride. All reactions were 
performed under an atmosphere of dry nitrogen. Microwave reactions were performed in a CEM 
Explorer single mode MW reactor equipped with auto sampler. 1H NMR and 13C NMR spectra were 
recorded on a Bruker AC-200 (200 MHz) spectrometer. J.T. Baker silica gel was used for flash 
chromatography. HRMS mass spectra were recorded on a Finnigan MAT 900 mass spectrometer by 
electron ionization (EI) mass spectrometry or on a Shimadzu IT TOF (ion trap – time-of flight) mass 
spectrometer by electron spray ionization (ESI) mass spectrometry. Analytical HPLC-MS analyses were 
conducted using a Shimadzu LC-8A preparative liquid chromatograph pump system with a Shimadzu 
SPD-10AV UV-VIS detector set at 254 nm, with the MS detection performed with a Shimadzu LCMS-
2010 liquid chromatograph mass spectrometer. The analyses were performed using two of the following 
conditions; condition I: a Xbridge(C18)5um column (100 mm x 4.9 mm) with 70% MeOH - 30% H2O-
0.1% formic acid (Method Ia); 60% MeOH - 40% H2O-0.1% formic acid (Method Ib) or 50% MeOH - 
50% H2O-0.1% formic acid (Method Ic). Flow rate = 1.0 mL/min. Total run time 15 min unless 
otherwise stated. Condition II: a Xbridge(C18)5um column (100 mm x 4.9 mm) with 50% CH3CN - 
50% H2O-0.1% formic acid (Method IIa); 40% CH3CN - 60% H2O-0.1% formic acid (Method IIb), 30% 
CH3CN - 70% H2O-0.1% formic acid (Method IIc) or 20% CH3CN - 80% H2O-0.1% formic acid (Method 
IId). Flow rate = 1.0 mL/min. Total run time 20 min unless otherwise stated. Condition III: a 
Xbridge(C18)5um column (100 mm x 4.9 mm) with solvent A, 5% CH3CN - 95% H2O with 0.1% formic 
acid; solvent B, 90% CH3CN - 10% H2O with 0.1% formic acid; flow rate = 2.0 mL/min; start: 100% A, 
linear gradient time 10 min, then 5 min at 100% B, then 15 min at 100% A. Total run time 30 min 
(method IIIa) or start: 100% A, lineair gradient time 5 min, then 5 min at 100% B, then 10 min at 
100% A. Total run time 20 min (method IIIb). Condition IV: a Xbridge(C18)5um column (100 mm x 4.9 
mm) with solvent A, 5% CH3CN - 95% H2O with 10% NH4HCO3/NH4OH buffer pH 8; solvent B, 90% 
CH3CN - 5% H2O with 10% NH4HCO3/NH4OH buffer pH 8; flow rate = 2.0 mL/min; start: 100% A, linear 
gradient time 10 min, then 5 min at 100% B, then 15 min at 100% A. Total run time 30 min (method 
IVa or start: 100% A, lineair gradient time 5 min, then 5 min at 100% B, then 10 min at 100% A. Total 
run time 20 min (method IVb). Compounds that were isolated as fumaric acid salts all showed an extra 
peak around two minutes. Fumaric acid blancs were used to determine the tR of fumaric acid. Purities 
calculated are based on RP HPLC-UV peak surface area of the compounds (disregarding the fumaric acid 
peak). Reference compound 1 has been described previously and was taken from stock.5 
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 General method A for the synthesis of target ccompounds 3-7. Dimethyl 2-(4-(4-
chlorophenyl)-4-hydroxypiperidin-1-yl)malonate (3). 4-(4-Chlorophenyl)-4-piperidinol 2 (0.21 g, 
1.00 mmol), dimethyl 2-bromomalonate (0.21 g, 1.00 mmol), NaI (0.15 g, 1.00 mmol), Na2CO3 (0.21 
g, 2.00 mmol) and 3 mL CH3CN were added in a microwave vessel and this was reacted during 15 
minutes in the microwave at a temperature of 160 °C (settings: ramp time 5 min, hold time 15 min, 
power 200 watt, pressure 17.2 bar). The solvent was removed in vacuo and the residue was diluted 
with water (20 mL), followed by an extraction with DCM (3 x 15 mL). The combined organic layers were 
washed with water (3 x 30 mL) and brine (30 mL), dried over anhydrous NaSO4, filtered, and 
evaporated in vacuo to give 132 mg (39%) of 3 as a white solid. 1H NMR (CDCl3): δ 1.61-1.82 (m, 2H), 
2.08-2.31 (m, 2H), 2.82-2.98 (m, 4H), 3.81 (s, 6H), 4.13 (s, 1H), 7.22-7.50 (m, 4H). 13C NMR (CDCl3): 
δ 38.48, 46.31, 52.27, 70.62, 70.82, 125.89, 128.28, 132.70, 146.51, 167.37. Anal. RP-HPLC Id: tR = 
10.45 min (purity 100%), IV: tR = 11.92 min (purity 96%). HRMS (EI) m/z calcd for C16H20ClNO5: 
341.1030; found: 341.1015. 
 4-(4-Chlorophenyl)-1-methylpiperidin-4-ol (4) Yield: 197 mg (87%) of 4 as white crystals. 
1H NMR (CDCl3): δ 1.62-1.81 (m, 3H), 2.08-2.27 (m, 2H) 2.31-2.52 (m, 5H), 2.69-2.81 (m, 2H), 7.23-
7.44 (m, 4H). 13C NMR (CDCl3): δ 38.19, 46.09, 51.27, 70.03, 125.96, 128.22, 132.53, 146.94. Anal. 
RP-HPLC Ig: tR = 11.45 min (purity 100%), IId: tR = 4.06 min (purity 100%). HRMS (EI) m/z calcd for 
C12H16ClNO: 225.0920; found: 225.0928. 
 4-(4-Chlorophenyl)-1-(2,2-diethoxyethyl)piperidin-4-ol hydrochloride (5). Yield: 257 mg 
(71%). 1H NMR (CDCl3): δ 1.05-1.39 (m, 6H), 1.73-1.98 (m, 2H), 2.63-3.13 (m, 4H), 3.26-3.89 (m, 
8H), 5.19-5.34 (m, 1H), 7.11-7.54 (m, 4H). 13C NMR (MeOH-d4): δ 15.60, 36.42, 51.83, 59.68, 65.01, 
69.00, 98.79, 127.50, 129.51, 134.24, 147.09. Anal. RP-HPLC IIIb: tR= 9.02 min (purity 94%), IVb: tR 
= 9.81 min (purity 96%). HRMS (ESI) m/z calcd for C17H27Cl2NO3: 363.1368; found: 363.1360. 
 1-((1H-benzo[d]imidazol-2-yl)methyl)-4-(4-chlorophenyl)piperidin-4-ol (6). Yield: 161 
mg (47%). 1H NMR (MeOH-d4): δ 1.95-2.21 (m, 2H), 2.46-2.75 (m, 2H), 3.63-3.92 (m, 4H), 5.05 (s, 
2H), 7.34-8.07 (m, 8H). 13C NMR (CDCl3/DMSO-d6): δ 34.50, 48.88, 59.41, 67.08, 114.35, 125.42, 
125.84, 127.55, 131.83, 132.28, 141.23, 145.32. Anal. RP-HPLC Id: tR = 6.81 min (purity 100%), IIIa: 
tR = 12.45 min (purity 99%), IVa: tR = 11.62 min (purity 96%). HRMS (ESI) m/z calcd for C19H20ClN3O: 
341.1295; found: 341.1289. 
 1-((4-Benzylmorpholin-2-yl)methyl)-4-(4-chlorophenyl)piperidin-4-ol dihydrochloride 
(7). Yield: 91 mg (19%). 1H NMR (MeOH-d4): δ 1.87-1.99 (m, 2H), 2.31-2.48 (m, 2H), 2.97-3.08 (m, 
1H), 3.19-3.70 (m, 10H), 3.98-4.06 (m, 1H), 4.15-4.24 (m, 1H), 4.33-4.54 (m, 3H), 7.36 (d, J = 8.6 
Hz, 2H), 7.42-7.65 (m, 7H). 13C NMR (MeOH-d4): δ 36.45, 52.06, 52.32, 53.22, 58.82, 62.36, 64.74, 
68.93, 69.59, 127.45, 129.53, 130.47, 131.52, 132.69, 134.38, 147.21. Anal. RP-HPLC If: tR = 5.44 
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min (purity 100%), IIIa: tR = 9.55 min (purity 96%), IVa: tR = 12.86 min (purity 100%). HRMS (ESI) 
m/z calcd for C23H29ClN2O2: 400.1918; found: 400.1918. 
 General method B for the synthesis of target compounds 8-11 . 4-(4-Chlorophenyl)-1-
(((3a’R,5’R,6’S,6a’R)-6’-hydroxytetrahydro-spiro[cyclohexane-1,2’-furo[2,3-d][1,3]dioxole]-
5’-yl)methyl)piperidin-4-ol (8). Acetic acid (0.05 mL) was added to a solution of 4-(4-
chlorophenyl)-4-piperidinol 2 (0.21 g, 1.00 mmol) and (3a'R,5'S,6'S,6a'R)-6'-
hydroxytetrahydrospiro[cyclohexane-1,2'-furo[2,3-d][1,3]dioxole]-5'-carbaldehyde (0.23 g, 0.50 mmol) 
in MeOH (3 mL). The reaction mixture was stirred overnight, NaCNBH3 (0.18 g, 2.86 mmol) was added 
and this was stirred for another 2 days. The solvent was evaporated in vacuo, water (10 mL) was 
added and the water layer was extracted with EtOAc (3 x 5 mL). The combined organic extracts were 
washed with water (3 x 10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered and 
evaporated in vacuo. Purification by recrystallization afforded 322 mg (76%) of 8 as a white solid. 1H 
NMR (CDCl3): δ 1.26-1.88 (m, 11H), 1.91-2.18 (m, 2H), 2.42-2.62 (m, 1H), 2.68-2.83 (m, 2H), 2.84-
3.00 (m, 1H), 3.05-3.25 (m, 1H), 3.31-3.49 (m, 1H), 4.08-4.21 (m, 1H), 4.28-4.39 (m, 1H), 4.40-4.51 
(m, 1H), 5.96 (d, 1H, J = 2.8 Hz), 7.21-7.42 (m, 4H). 13C NMR (CDCl3/DMSO-d6): δ 23.36, 23.68, 
24.70, 35.40, 36.16, 37.84, 38.44, 50.43, 51.00, 57.09, 69.29, 76.80, 84.95, 104.15, 111.71, 126.09, 
127.95, 132.18, 147.21. Anal. RP-HPLC Ic: tR = 5.69 min (purity 100%), IVa: tR = 12.73 min (purity 
100%). HRMS (EI) m/z calcd for C22H30ClNO5: 423.1813; found: 423.1818. 
 4-(4-chlorophenyl)-1-(((3aR,5R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[2,3-
d][1,3]dioxol-5-yl)methyl)piperidin-4-ol fumarate (9). Yield: 189 mg (41%). 1H NMR (DMSO-d6): 
δ 1.29 (s, 3H), 1.42 (s, 3H), 1.51-1.69 (m, 2H), 1.82-2.08 (m, 2H), 2.44-2.93 (m, 6H), 3.38 (s, 3H), 
3.61-3.74 (m, 1H), 4.19-4.32 (m, 1H), 4.59-4.70 (m, 1H), 5.32 (d, 1H, J = 2.4 Hz), 6.61 (s, 2H), 
7.31-7.60 (m, 4H). 13C NMR (CDCl3/DMSO-d6): δ 26.00, 26.49, 36.77, 36.90, 48.81, 49.62, 56.10, 
57.47, 69.08, 76.86, 80.59, 84.96, 104.75, 111.27, 126.12, 127.85, 131.99, 134.72, 147.14, 169.01. 
Anal. RP-HPLC Id: tR = 5.84 min (purity 100%), IVa: tR = 12.04 min (purity 96%). HRMS (EI) m/z 
calcd for C20H28ClNO5: 397.1656; found: 397.1646. 
 (3S,4R,5R)-5-((S)-2-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-hydroxyethyl)-3,4-
dihydroxydihydro-furan-2(3H)-one (10). Yield: 110 mg (30%). 1H-NMR (MeOH-d4): δ 1.61-1.80 
(m, 2H), 2.05-2.19 (m, 2H), 2.61-3.12 (m, 4H), 3.31-3.50 (m, 2H), 3.71-3.89 (m, 2H), 3.98-4.08 (m, 
2H), 7.31 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 8.6Hz, 2H). 13C NMR (MeOH-d4): δ 36.91, 49.34, 50.12, 
60.29, 71.83, 72.38, 73.11, 126.00, 127.62, 131.79, 146.98, 173.79. Anal. RP-HPLC If: tR = 7.11 min 
(purity 97%), IVb: tR = 7.94 min (purity 90%). HRMS (ESI) m/z calcd for C17H22ClNO6: 371.1136; 
found: 371.1136. 
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 4-(4-chlorophenyl)-1-(((2R,4R,4aR,6S,8aS)-2,6-diphenyltetrahydro-[1,3]dioxino[5,4-
d][1,3]dioxin-4-yl)methyl)piperidine-4-ol (11). Yield: 342 mg (66%). 1H NMR (DMSO-d6): δ 1.61-
1.90 (m, 2H), 1.91-2.28 (m, 2H), 3.18-4.11 (m, 8H), 4.13-4.37 (m, 1H), 4.40-4.62 (m, 1H), 5.50 (s, 
1H), 5.75 (s, 1H), 5.96 (s, 1H), 7.13-7.68 (m, 14H). 13C NMR (DMSO-d6): δ 34.72, 48.06, 49.36, 
55.64, 67.29, 71.88, 74.51, 99.97, 100.79, 126.01, 126.37, 127.88, 127.99, 128.84, 131.32, 136.62, 
136.95. Anal. RP-HPLC Ic (total run time 25 min): tR= 13.82 min (purity 100%), IIIa: tR = 13.95 min 
(purity 100%), IVa: tR = 15.41 min (purity 100%). HRMS (EI) m/z calcd for C30H32ClNO5: 521.1969; 
found: 521.1956. 
 General method C for the synthesis of target compounds 12-19. 1-(4-(4-Chlorophenyl)-
4-hydroxypiperidin-1-yl)-7-phenylheptane-1,7-dione (12). EDCI (0.19 g, 1.00 mmol), DIPEA 
(0.19 g, 1.50 mmol), and HOBT (0.14 g, 1.00 mmol) were added to a solution of 7-oxo-7-
phenylheptanoic acid (0.22 g, 1.00 mmol) in DCM (70 mL) and this was stirred for 15 min. 4-(4-
Chlorophenyl)-4-piperidinol 2 (0.21 g, 1.00 mmol) was added, and the resulting reaction mixture was 
stirred for another 18 h. 10% NaOH (2 x 50 mL) was added followed by 0.001 M HCl (2 x 50 mL). The 
water layer was extracted with DCM (3 x 50 mL), and the combined organic layers were washed with 
water (2 x 50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and evaporated under 
reduced pressure. Recrystallization from EtOAc/hexane gave 124 mg (30%) of 12 as a white solid. 1H 
NMR (CDCl3): δ 1.31-1.54 (m, 2H), 1.58-2.09 (m, 8H), 2.38 (t, J = 8.6 Hz, 2H), 2.93-3.18 (m, 3H), 
3.41-3.65 (m, 1H), 3.66-3.83 (m, 1H), 4.46-4.64 (m, 1H), 7.18-7.60 (m, 7H), 8.93 (d, J = 9.4 Hz, 
2H). 13C NMR (CDCl3): δ 23.77, 25.00, 28.89, 32.92, 37.58, 38.14, 41.70, 70.97, 125.90, 125.98, 
127.87, 128.34, 128.43, 132.86, 136.74, 146.24, 171.21, 200.29. Anal. RP-HPLC Ib: tR = 10.20 min 
(purity 100%), IVb: tR = 10.58 min (purity 100%). HRMS (EI) m/z calcd for C24H28ClNO3: 413.1758; 
found: 413.1753. 
 1-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-4-(pyren-1-yl)butane-1,4-dione (13). 
Yield: 180 mg (36%). 1H NMR (CDCl3): δ 1.59-2.11 (m, 5H), 2.79-3.22 (m, 3H), 3.40-3.65 (m, 3H), 
3.80-4.02 (m, 1H), 4.48-4.69 (m, 1H), 7.20-7.41 (m, 4H), 7.93-8.30 (m, 2H), 8.52 (d, J = 9.0 Hz, 
1H), 8.90 (d, J = 9.5 Hz, 1H). 13C NMR (CDCl3/DMSO-d6): δ 27.50, 37.22, 37.49, 37.94, 38.33, 41.57, 
70.25, 123.91, 123.97, 124.62, 125.64, 125.92, 126.09, 126.13, 126.90, 127.93, 128.80, 129.07, 
130.20, 130.75, 132.12, 132.56, 133.26, 147.16, 169.66, 203.60. Anal. RP-HPLC IIIa: tR= 16.32 min 
(purity 100%), IV: tR = 14.99 min (purity 100%). HRMS (ESI) m/z calcd for C31H26ClNO3: 495.1601; 
found:.495.1601. 
 5,7-Dibromo-3-(4-(4-chlorophenyl)-4-hydroxypiperidine-1-carbonyl)-2H-chromen-2-
one (14). Yield: 371 mg (68%) 1H NMR (CDCl3/DMSO-d6): δ 1.57-1.89 (m, 2H), 1.91-2.18 (m, 2H), 
3.15-3.46 (m, 2H), 3.53-3.71 (m, 1H), 4.48-4.65 (m, 1H), 7.24-7.41 (m, 4H), 7.58 (d, J = 2.2 Hz, 
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1H), 7.74 (s, 1H), 7.88 (d, J = 2.2 Hz, 1H). 13C NMR (DMSO-d6): δ 37.46, 42.55, 69.70, 110.02, 
116.09, 121.18, 126.51, 127.67, 130.28, 130.90, 136.54, 139.94, 147.89, 149.20, 156.58, 161.66. 
Anal. RP-HPLC IIa: tR= 7.27 min (purity 97%), IIIa: tR= 15.61 min (purity 100%), IVa: tR = 13.50 min 
(purity 100%). This compound could not be ionized with EI or ESI, so the HRMS value could not be 
determined.  
 2-Chloro-5-(4-(4-chlorophenyl)-4-hydroxypiperidine-1-carbonyl)-4-(furan-2-ylmethyl-
amino)benzenesulfonamide (15). Yield: 176 mg (34%). 1H NMR (CDCl3): δ 1.39-2.08 (m, 7H), 
3.29-3.51 (m, 2H), 3.93-4.40 (m, 3H), 5.07 (s, 2H), 6.11-6.35 (m, 3H), 6.84 (s, 1H), 7.24-7.41 (m, 
4H), 7.82 (s, 1H). 13C NMR (CDCl3): δ 37.83, 39.85, 69.88, 107.28, 110.09, 112.64, 116.89, 126.07, 
126.82, 127.72, 129.11, 131.89, 133.38, 141.88, 146.99, 148.83, 150.60, 166.96. Anal. RP-HPLC Ib: 
tR = 4.59 min (purity 97%), IIb: tR = 7.86 min (purity 96%). HRMS (ESI) m/z calcd for C23H23Cl2N3O5S: 
523.0735; found: 523.0718. 
 (2-(2-Aminobenzoyl)phenyl)(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)methanone 
(16). Yield: 276 mg (68%). 1H NMR (CDCl3): δ 1.42-2.25 (m, 5H), 3.02-3.29 (m, 1H), 3.35-3.70 (m, 
2H), 4.30-4.53 (m, 1H), 6.48-6.76 (m, 2H), 7.07-7.52 (m, 10H). 13C NMR (CDCl3): δ 37.89, 43.93, 
71.47, 115.69, 116.65, 118.07, 125.85, 126.92, 128.23, 128.34, 128.96, 129.81, 132.88, 134.62, 
136.36, 139.01, 146.23, 150.78, 169.16, 198.48. Anal. RP-HPLC Ia: tR = 7.63 min (purity 100%), IIb: 
tR = 10.21 min (purity 99%). HRMS (EI) m/z calcd for C25H23ClN2O3: 434.1397; found: 434.1385. 
 (E)-4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N-(4-methoxyphenyl)-4-oxobut-2-
enamide (17). Yield: 96 mg (23%). 1H NMR (CDCl3): δ 1.63-1.82 (m, 2H), 2.05-2.27 (m, 2H), 2.64-
3.30 (m, 5H), 3.80 (s, 3H), 3.95-4.08 (m, 1H), 6.95 (d, J = 9.0 Hz, 2H), 7.15-7.44 (m, 8H). 13C NMR 
(CDCl3): δ 31.29, 44.37, 55.35, 62.57, 114.36, 123.88, 125.86, 127.51, 128.35, 132.82, 146.32, 
159.44, 174.33, 175.36. Anal. RP-HPLC Ic: tR = 7.85 min (purity 100%), IIb: tR = 3.88 min (purity 
100%). HRMS (ESI) m/z calcd for C22H23ClN2O4: 414.1346; found: 414.1358. 
 (4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)(1H-pyrrol-2-yl)methanone (18). Yield: 212 
mg (70%). 1H NMR (CDCl3): δ 1.60-2.19 (m, 8H), 3.31-3.61 (m, 2H), 4.47-4.64 (m, 2H), 6.19-6.27 
(m, 1H), 6.51-6.59 (m, 1H), 6.89-6.96 (m, 1H), 7.24-7.42 (m, 4H), 9.48 (br s, 1H). 13C NMR 
(CDCl3/DMSO-d6): δ 38.14, 70.51, 108.83, 111.57, 120.67, 124.48, 126.10, 128.00, 132.24, 147.11, 
161.50. Anal. RP-HPLC Ib: tR = 4.66 min (purity 98%), IIb: tR = 4.06 min (purity 100%). HRMS (EI) 
m/z calcd for C16H17ClN2O2: 304.0979; found: 304.0992. 
 6-(4-(4-Chlorophenyl)-4-hydroxypiperidine-1-carbonyl)-2H-thiazolo[3,2-a]pyrimidin-
5(3H)-one (19). Yield: 105 mg (27%). 1H NMR (CDCl3): δ 1.58-1.82 (m, 2H), 1.85-2.11 (m, 2H), 
3.16-3.33 (m, 1H), 3.41-3.63 (m, 4H), 4.43-4.72 (m, 3H), 7.3-7.48 (m, 4H), 7.94 (s, 1H). 13C NMR 
(CDCl3): δ 23.94, 35.30, 35.75, 36.26, 41.15, 46.58, 68.86, 117.02, 123.35, 123.56, 126.00, 130.54, 
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143.72, 151.73, 155.20, 160.87, 164.50. Anal. RP-HPLC Id: tR = 9.84 min (purity 100%), IIIa: tR = 
12.42 min (purity 100%), IVa: tR = 10.78 min (purity 100%). HRMS (EI) m/z calcd for C18H18ClN3O3S: 
391.0757; found: 391.0744. 
 General method D for the synthesis of target compound 20. 4-(4-Chlorophenyl)-1-(4-
(morpholinosulfonyl)phenylsulfonyl)-piperidin-4-ol (20). A solution of 4-(4-chlorophenyl)-4-
piperidinol 2 (0.21 g, 1.00 mmol) and Et3N (0.20 g, 2.00 mmol) in DCM (10 mL) was added to a 
solution of 4-(morpholinosulfonyl)benzene-1-sulfonyl chloride (0.33 g, 1.01 mmol) in DCM (10 mL). The 
reaction mixture was stirred at room temperature for 3 h, quenched with water (20 mL) and the water 
layer was extracted with DCM (3 x 50 mL). The combined organic layers were washed with water (50 
mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure. 
Recrystallization from MeOH/hexane gave 105 mg (68%) of 20 as a white solid. 1H NMR (CDCl3): δ 
1.72-1.85 (m, 2H), 2.08-2.29 (m, 2H), 2.79-2.94 (m, 2H), 3.03-3.15 (m, 4H), 3.69-3.83 (m, 6H), 
7.25-7.41 (m, 4H), 7.90-8.05 (m, 4H). 13C NMR (DMSO-d6): δ 34.66, 41.99, 45.63, 65.04, 68.33, 
126.49, 127.65, 128.45, 130.99, 138.41, 139.63, 147.55. Anal. RP-HPLC Ib: tR = 5.59 min (purity 
100%), IIb: tR = 14.31 min (purity 100%). HRMS (ESI) m/z calcd for C21H25ClN2O6S2: 500.0843; 
found: 500.0865.  
 
Pharmacology 
[125I]CCL5 binding experiments and [3H]inositol phosphate accumulation assays were performed as 
previously described in the literature. 6  
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Chapter 5 
The quest for novel ligands for the constitutively active receptor US28 
 
Janneke W. Hulshof, Henry F. Vischer , Silvina A. Fratantoni, Martine J. Smit, 
Rob Leurs and Iwan J. P. de Esch 
 
Abstract 
In our quest to identify novel ligands for the viral-encoded receptor US28, we 
performed an extensive screening. Compounds from our in-house compounds 
database were selected based on their molecular similarity to structures of 
known ligands acting on US28. The screening of the selected compounds 
resulted in the identification of several inverse agonists, which can be considered 
as new starting points for hit optimization programs. Furthermore, we disclose 
5-(3-(4-methylpiperazin-1-yl)propyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine 
(35) and 2-phenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine (44) as 
the very first nonpeptidergic neutral antagonists acting on a viral-encoded 
receptor. The discovery of novel ligands with unique pharmacological profiles 
gives us unprecedented opportunities to further investigate the role of 
constitutive signaling of US28 during viral infection. 
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Introduction 
Human cytomegalovirus (HCMV) is a DNA virus that encodes homologues of host 
G protein-coupled receptors (GPCRs) for viral replication and persistence. HCMV 
is a widespread pathogen and infection with the virus is associated with different 
pathologies, such as the development of vascular diseases, cancer, chronic 
inflammation and birth defects.1 Moreover, co-infection of the virus with human 
immunodeficiency virus (HIV) has been shown to cause an increased risk of 
disease progression to acquired immunodeficiency syndrome (AIDS) and 
dementia in HIV patients.2  
 
At present, US28 is the most extensively characterized receptor encoded by 
HCMV and many important roles during viral infection have been attributed to 
this GPCR. The receptor shows sequence homology with the CCR1 chemokine 
receptor family3 and can bind several CC chemokines, such as CCL2, CCL3, CCL4 
and CCL5 with high affinity,3-5 suggesting that US28 acts as a chemokine 
scavenger by sequestering these chemokines from the extracellular environment 
via endocytosis. This mode of action putatively represents a mechanism to 
escape immune surveillance after HCVM infection.6-8  
 
Unlike the human chemokine receptors, US28 signals in a constitutively active 
manner through different signaling pathways in both transiently transfected 
COS-7 cells as well as in HCMV-infected cells.9,10 Although constitutive signaling 
seems to be a general characteristic of viral-encoded GPCRs, the biological 
relevance has not been elucidated yet. However, the importance of this ligand-
independent signaling has been demonstrated for the HHV-8 or Kaposi’s 
sarcoma-associated herpesvirus (KSHV) encoded GPCR ORF74. This receptor is 
a viral oncogene that activates multiple intracellular signaling pathways in a 
constitutively active manner resulting in the production and secretion of VEGF 
(vascular endothelial growth factor) and thereby causing cellular transformations 
that can develop into highly vascularized Kaposi’s sarcoma-like lesions in 
transgenic mice.11,12 Interestingly, it has recently been shown that US28 acts as 
a viral oncogene as well, because expression of US28 in NIH-3T3 cells induces a 
transformed phenotype and promotes tumorigenesis in mice.13 The constitutive 
activity of US28 seems to be of importance in the early onset of tumorigenesis 
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as can be deduced from delayed and attenuated tumor formation by the US28-
R129A mutant receptor, which lacks constitutive signaling. Constitutive activity 
can be inhibited by ligands that behave as so-called inverse agonists. The 
discovery of such molecules for US28 will help to unravel the role of US28 in 
viral pathology and cancer.  
 
The identification of small molecules as modulators of protein activity and the 
subsequent hit optimization are key activities in modern drug discovery. During 
the last decade, many hits with the potential to progress to viable drug 
candidates have emerged from high throughput screening (HTS) of corporate 
compound collections.14,15 However, this approach is not always succesful. In a 
HTS campaign hundreds of thousands of compounds are tested, but this 
strategy is expensive and does frequently not lead to new hits that have the 
potential to become optimized. Therefore, other strategies have emerged to 
discover leads, such as the development of focused libraries that are generated 
on the basis of structural information about the ligands and/or the biological 
target or the generation of novel ideas from small molecules reported in the 
literature.16,17  
 
In our quest to identify novel ligands for the viral-encoded receptor US28 we 
have undertaken screening efforts. For this, we have used our own proprietary 
compound collection. We based our selection of compounds on the basis of 
molecular structure of known US28 ligands (Figure 1). So far, only few US28 
ligands have been identified. Recently, VUF2274 (1) was identified as the first 
inverse agonist acting on US2810 and the synthesis and pharmacological 
characterization of an extensive series of analogues revealed the very first 
structure-activity relationships for inverse agonism on US28.18,19 Replacement of 
the 4-hydroxy group of compound 1 into the methylamine group in VUF6966 (2) 
resulted in a 6-fold increase in binding affinity and this compound is, to our 
knowledge, one of the highest affinity inverse agonist acting on US28 currently 
known.19  
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Moreover, several ligands have been reported by Chemocentryx Inc. in the 
patent literature. These molecules were claimed to block dissemination of CMV 
in a host by reversibly inhibiting chemokine binding to US28 in the micromolair 
range, such as a series of piperazinyldibenzothiepins, represented by the 
serotonin receptor antagonists methiothepin (3) and octoclothepin (4) and a 
large series of bicyclic structures, exemplified by VUF6045 (5).20,21 Furthermore, 
a series of benzamides was mentioned to interact with US28, and of this series 
the commercially available dopamine receptor ligand S-(-)-IBZM (6) was the 
only compound of which results were shown.21 Interestingly, all these molecules 
induce a rise in intracellular Ca2+, thereby acting as agonists on US28. 
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Figure 1. Chemical structures of the known US28 ligands 1-6. 
 
In this study, we will disclose the results from our ligand-based screening 
efforts. These novel ligands will give us more insights in the structural 
requirements that are important for binding to US28. 
 
Results and discussion 
The compounds were selected by searching the in-house database for 
compounds bearing structural similarity, i.e. substructure search, of the known 
US28-ligands 1-6. Ligand substructure similarity searches were performed using 
the database management system (ChemFinder Std. 7.0, CambridgeSoft 
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Corporation). Next to the substructure searches, several database compounds 
were selected for screening based on a subjective structural similarity 
assessment after visual inspection.  
 
More than two hundred compounds were screened at a single concentration of 
10 µM for their efficacy by measuring their influence on the [3H]inositol 
phosphate production, whereas the binding affinity was determined by their 
potential to displace [125I]CCL5 binding to US28. A schematic representation of 
the single point measurements is shown in Figure 2. 
 
A. Results of all compounds that show structural 
similarity to compounds 3 and 4. 
B. Results of the compounds selected by a 
subjective structural similarity assessment after 
visual inspection. 
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Figure 2. Schematic representation of all single points measurements. Data are represented as 
percentage of the [125I]CCL5 binding (x-axis) against the percentage of the basal [3H]inositol phosphate  
(IPX) signaling (y-axis). The average of at least three independent experiments is shown. Classification 
of the compounds: green shows the compounds that displace more [125I]CCL5 from the receptor than 
1, but their influence on the basal IPx signaling (inverse agonistic properties) is lower. In the purple 
part the compounds are shown that displace less [125I]CCL5 from the receptor than 1 and that have 
lower inverse agonistic properties. No compounds were found in the yellow or pink part, in which the 
compounds with better inverse agonistic properties than compound 1 would have been found. 
 
As can be seen in Figure 2, several molecules were identified as novel ligands for 
US28. For all compounds that showed more than 50% displacement of 
[125I]CCL5 the IC50 and EC50 values were obtained. Moreover, the in-house 
database was searched for structural analogues of these hits. The results of this 
comprehensive study are summarized in Table 1-5.  
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Firstly, the results of methiothepin (3) and octoclothepin (4) and their analogues 
are shown in Table 1. It is noted that the IC50 value of compound 3 that has 
been previously generated in literature20 by performing radiodisplacement 
studies using a different labeled chemokine, namely [125I]CX3CL1, was 
comparable to the IC50 value generated in our studies with [
125I]CCL5. 
Interestingly, compound 3 shows a 2-fold higher binding affinity than compound 
2 and even a 10-fold higher binding affinity than compound 1.19 Replacement of 
the thiomethylene group of 3 by a chloro atom in compound 4 resulted in an 
affinity comparable to that of compound 1.  
 
In the patent literature compounds 3 and 4 have been demonstrated to act as 
agonists in cytoplasmic calcium mobilization experiments in US28-expressing 
HEK293 cells by inducing a rise in intracellular Ca2+. Surprisingly, in SVEC4-10 
cells these compounds act as inverse agonists by inhibiting the US28-mediated 
constitutive activation of PLC in a dose-dependently manner. To investigate if 
this discrepancy in the different functional assays was dependent on the cell line, 
the influence of methiothepin on the Ca2+ levels in US28-expressing SVEC4-10 
cells was determined as well (See Figure 3).  
 
 
Figure 3. Methiothepin-induced [Ca2+] mobilization in SVEC4-10 cells. Stably US28-expressing (black 
dots) and mock transfected (open dots) cells were loaded with Fluo 4-AM and exposed to 10 µM 
methiothepin. The black arrow indicates the time at which methiothepin (10 µM) was added to the cells. 
Data are normalized to maximum fluorescence signal resulting from addition of Triton X-100 (100%). A 
representative curve of three independent experiments is shown. 
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The applicability of this assay is very limited, because the presence of DMSO 
hampers the Ca2+ measurements and only methiothepin can be dissolved in 
water. Thus, the influence on the Ca2+ efflux cannot be determined for any other 
compound. Intriguingly, in the SVEC4-10 cells methiothepin also shows an 
increase in Ca2+ levels. Therefore, we conclude that methiothepin is a protean 
ligand on US28. Protean ligands are compounds that have multiple functional 
properties on the same receptor measured from the same cells, e.g. inverse 
agonism in one particular pharmacological assay and neutral antagonism in 
another one.23-26 Protean ligands have also been identified for, e.g. the 
histamine H3 receptor,
27,28 the α2A-adrenergic receptor29,30 and the human CB2 
cannabinoid receptor.31 Although protean ligands have been characterized 
pharmacologically, the molecular basis of the mode of action on molecular level 
has not been elucidated yet.24,32 Additionally, the therapeutic potential of 
protean agonists is not clear yet. In theory, it would be possible to obtain tissue 
selectivity of drugs by regulation of receptor function with protean ligands that 
have agonistic properties in one tissue, while being inverse agonists or neutral 
antagonists in other tissue.25  
 
Although the single point measurements of compounds 7 and 10-17 provide us 
with limited pharmacological data, we like to describe some preliminary 
structure-activity relationship (SAR) studies. Clozapine (7) is a dopamine 
antagonist that is widely used as an atypical antipsychotic drug with the 
advantage that it induces a low incidence of undesirable motor side effects. This 
compound exhibits an approximately 10-fold selectivity for D4 versus D2 
dopamine receptors, but it also has a high affinity for a variety of other 
receptors, such as serotonergic receptors (human 5-HT2A, 5-HT2B, and 5-HT2C 
receptors), adrenergic receptors (human α2B and α2C), the histamine H1 and H4 
receptor and the muscarinic M1 receptor.
33-36 Interestingly, compound 7 is also 
able to displace [125I]CCL5 binding from US28 at a concentration of 10 µM. 
Elongation of the R2 group into an ethyl- (8) or butyl moiety (9) results in 
compounds with a binding affinity in the low micromolair range. Nevertheless, 
the inverse agonistic properties of compounds 7-9 on US28 are negligible. 
Interestingly, changing the chloro substituent from the 8- to the 2-position 
(compound 10) is detrimental for the binding affinity.  
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Table 1. Chemical structures and pharmacological properties of compounds 3-4 and 7-17 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 
and EC50 values of at least three independent experiments. 
 
N NR1 R2  
 
S S
S Cl
HN HN
N
Cl
O
N
Cl
S
N
S
N
Cl
Cl
Cl
Cl
A B C D
E F G H  
no. Name R1   R2 IC50 (µM)a EC50 (µM)b 
3 Methiothepin A -CH3 0.41 (0.37 – 0.45) 7.6 (4.5 – 10.7) 
4 Octoclothepin B -CH3 4.9 (1.6 – 8.1) 12.1 (5.6 – 18.6) 
7 Clozapine C -CH3 47% c 11% c 
8 VUF5265 C -CH2CH3 3.8 (2.6 – 5.1) 16% c 
9 VUF5295 C -(CH2)3CH3 4.7 (3.2 – 6.2) 19% c 
10 Loxapine D -CH3 13% c 0% c 
11 VUF6879 E -CH3 19% c 22% c 
12 VUF6876 E -CH2CH3 38% c 0% c 
13 Entumine F -CH3 28% c 0% c 
14 HUF 2118 G -CH3 47% c 0% c 
15 VUF5216 H -CH3 13%c 20% c 
16 VUF5217 H -(CH2)4Ph 47% c 18% c 
17 VUF5218 H -(CH2)4OH 13% c 0%c 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Results of the single 
point measurements at a concentration of 10 µM. 
 
Recently, VUF6879 (11) and VUF6876 (12) have been published in our group as 
histamine H4 receptor ligands.
36 On US28, both compounds are almost 
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completely inactive. Entumine or clothiapine (13) is a drug used for the 
treatment of psychotic disorders, anxiety, drug dependence and alcoholism. Like 
clozapine, this compound has a promiscuous binding profile by interacting with 
many receptors.37 However, the compound does not show any binding affinity 
on US28. Moving the chloro substituent from the 2- to the 8-position as in 
compound 14 results in a slight increase in binding affinity. Compounds 15-17 
have a high flexibility due to their open structure. As can be seen in Table 1, 
there is a slight preference for a ω-phenylbutyl group at the R2 position 
(compare compound 16 with 15 and 17), but in the functional assay all three 
compounds show no or only a small inhibition of the constitutive PLC signaling.  
 
As outlined in Table 2, the database screening reveals the two structurally 
related analogues B83 (18) and C102 (19) as new inverse agonists for US28.  
 
Table 2. Chemical structures and pharmacological properties of compounds 18-27 for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments. 
 
O N R2X
 
 
no. Name X R1 IC50 (µM)a EC50 (µM)b 
18 B83 CH2-CH2 (CH2)7CH3 5.6 (3.4 – 7.8) 4.9 (3.7 – 6.2) 
19 C102 CH2-CH2 (CH2)2Ph 11.9 (8.7 – 15.1) 4.3 (3.5 – 5.1) 
20 C92 CH2-CH2 CH2Ph 10.5 (8.3 – 12.6) 8.8 (5.9-11.7) 
21 A138 CH2-CH2 CH3 15%c 0% c 
22 B143 CH2-CH2 CH2CH3 7% c 0%c 
23 B93 CH2-CH2 
NH2
N OH
 
0% c 0% c 
24 B98 CH2-CH2 
NH
NH
H2N  
34% c 0% c 
25 U238 CH=CH CH(CH3)2 13% c 3% c 
26 B150 CH=CH (CH2)2CH3 18% c 0% c 
27 U261 CH=CH cyclohexyl 8.3 (6.8 – 9.8) 5.8 (3.3 – 8.3) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Result of the single point 
measurements at a concentration of 10 µM. 
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These compounds and some of their analogues were previously synthesized to 
investigate their potential in chronic non-specific respiratory disorders as well as 
allergic conditions.38 Of the analogues mentioned in Table 2, only compound 22 
showed promising in vitro activities in this study. The pharmacological results of 
compounds 18-27 on US28 are depicted in Table 2. Replacement of the octyl 
group of 18 by the phenetyl group in 19 causes the binding affinity to drop 
slightly, and the inverse agonistic properties are comparable. Removal of a CH2 
group between the bridged piperidine moiety and the phenyl ring as in 
compound 20 does not change the affinity on US28. In contrast, small methyl 
and ethyl chains, as in 21 and 22, are not allowed to maintain affinity or 
efficacy. Both the N-hydroxypropionimidamide group in 23 as the ethyl 
guanidine moiety in 24 are not allowed for US28 activity. Compounds 25-27 
differ from the other analogues, due to the presence of a double bond in the 
tricyclic structure. As demonstrated for compounds 21 and 22, the small alkyl 
chains in 25 and 26 are detrimental for both affinity and activity. However, the 
cyclohexyl group in compound 27 is allowed and results in a binding affinity and 
efficacy in the same order as compounds 18-20.  
 
The structures and pharmacological properties of compounds R125 (28), C73 
(29) and their analogues are depicted in Table 3. These compounds have 
comparable binding affinities and efficacies although their tricyclic moieties are 
quite different in respect to the rigidity and the conformation of the two aromatic 
rings. The tricyclic moiety of compound 28 is bended due to the presence of 
three carbon atoms between the two phenyl rings, while the tricyclic ring system 
of 29 is nearly planar, as determined via a conformational analysis study using 
the molecular modelling program MOE (molecular operating environment version 
2004.03, results not shown). Additionally, saturation of the double bond of 29 
as in compound 30 results in a compound with a comparable affinity, and also 
the introduction of an unsaturated bridge between the two phenyl rings in 31 
does not improve the affinity or efficacy. Compounds 32 and 33 both have a m-
trifluoromethyl group in the phenyl ring of the phenethyl group attached to the 
nitrogen atom.  
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Table 3. Chemical structures and pharmacological properties of compounds 28-34 for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments. 
 
no. Name Structure IC50 (µM)a EC50 (µM)b 
28 R125 
NH
 
4.2 (3.6 – 4.8) 39%c 
29 C73 
NH
 
7.0 (5.9 – 8.1) 42% c 
30 A185 
NH
 
5.2 (4.4 – 6.0) 10.9 (6.0 – 15.8) 
31 C162 
NH
 
3.7 (3.2 – 4.2) 5.2 (3.2 – 7.1) 
32 Q113 
NH
F
F
CF3
 
39% c 38% c 
33 F10a 
NH
N
 
5.5 (4.5 – 6.5) 34% c 
34 K15 NH
S
Cl  
 
2.6 (2.0 – 3.2) 21% c 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Results of the single 
point measurements at a concentration of 10 µM. 
 
As can be seen in Table 3, there is a slight preference for the tricyclic system of 
33 compared to the 4,4’-difluorophenyl group in 32. A 2-fold increase in binding 
affinity compared to compound 33 is observed for compound 34, in which the 
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m-trifluoromethyl is replaced by a p-chloro substituent and the two phenyl rings 
of the tricyclic system are connected by a sulphur bridge.  
 
A194 (35) resulted from of the database screening as a potential new lead 
compound on US28. The synthesis of this tricyclic imipramine analogue has been 
previously described in the literature, but no pharmacological data of this 
compound are known.39,40 In this study, compound 35 is 
able to displace [125I]CCL5 binding from US28 in a dose-
dependent manner with an IC50 value of 4.9 µM. However, 
it does not influence the basal signaling of the receptor, 
thereby acting as a neutral antagonist. To our knowledge, 
this compound is the very first small nonpeptidergic 
neutral antagonist acting on a viral-encoded receptor. The 
SAR of 35 and its analogues will be discussed elsewhere (see Chapter 6).  
 
As mentioned earlier, compounds 5 and 6 originated from the patent 
literature.21,22 Unfortunately, the in-house database did not contain any 
analogues of these compounds. However, after visual inspection of the database 
several compounds were selected for screening subjectively inspired by the 
substructure of compound 6, such as J3 (36) and Z193 (37). Structurally 
related compounds of 36 and 37 were found as well and the pharmacological 
evaluation of these compounds resulted in interesting preliminary structure-
activity relationships (Table 4). Enlargement of the cyclopentyl group of 37 with 
one carbon atom as in compound 38 does not influence the affinity or efficacy 
on US28. Additionally, the introduction of an additional CH2 group as in 39 
results in a binding affinity comparable to that of compound 37 and 38, but the 
efficacy of this compound is much lower with only a 26% inhibition of the 
inositol phosphate production at a concentration of 10 µM. In compound 40 the 
amine group is not attached to a rigid ring structure as in compounds 37-39, 
but to the flexible propyl chain resulting in more conformational freedom. This 
results in an activity comparable to that of compounds 37 and 38. Interestingly, 
removal of the chloro atoms from one of the phenyl rings in compound 41 is 
detrimental for US28 affinity. This suggests that 3,4-dichloro substitution in that 
parrticular phenyl ring is of importance.  
N N
N
 
Compound 35. 
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Table 4. Chemical structures and pharmacological properties of compounds 6 and 36-43 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 and 
EC50 values of at least three independent experiments. 
 
no. Name Structure IC50 (µM)a EC50 (µM)b 
36 J3 O
N
 
12.9 (5.4 – 20.4) 10% c 
37 Z193 
NH2
Cl
Cl
 
9.5 (6.8 – 12.3) 11.1 (8.3 – 13.8) 
38 Z172 
Cl
Cl
NH2  
8.5 (6.8 – 10.2) 12.6 (10.0 – 15.1) 
39 Z194 
NH2 Cl
Cl
 
11.8 (11.5 – 12.0) 26% c 
40 Z150 
NH2
Cl
Cl Cl
Cl
 
7.5 (5.0 -10.0) 11.7 (9.3 – 14.1) 
41 Z9 
NH2
Cl
Cl
 
5% c 34% c 
42 Z130 O
Cl
Cl
NH2
 
9.2 (6.3 – 12.0) 10.2 (7.2 – 9.5) 
43 Z131 O
NH2
 
 
8.2 (6.3 – 10.0) 8.4 (7.2 – 9.5) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Results of the single 
point measurements at a concentration of 10 µM. 
 
Compound 42 has a binding affinity and an efficacy in the same range as 
compounds 37 and 38 and replacement of the two chloro atoms in the phenyl 
ring by a t-butyl group at the 4-position in 43 does not result in a compound 
with a higher affinity. 
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Another new group of compounds that resulted from the database screening 
were B191 (44) and B105 (45) and their analogues (Table 5). Of this series, 
compounds 45 and 48-53 were previously synthesized to investigate their 
potential analgesic activity. Although some of these compounds showed 
significant analgesic and sedative effects, none of them was selected for further 
investigation.41 
 
As can be seen in Table 5, most compounds of these series show weak if any 
activity on US28. However, the pharmacological data of compound 44 on US28 
shows that this molecule acted as a neutral antagonist by displacing [125I]CCL5 
binding from US28 with an IC50 value of 10.4 µM without influencing the basal 
signaling of the receptor. Surprisingly, introduction of a chloro substituent at the 
para position of the phenyl ring attached to the cyclic moiety in compound 46 
has a drastic effect on the affinity of the compound. Increasing the flexibility as 
in compound 47 is detrimental for the binding affinity as well. Compound 45 has 
a binding affinity comparable to that of compound 44 and shows a low inhibition 
of the inositol phosphate production. Unfortunately, all tested analogues show a 
low if any activity on US28. Thus, increasing the flexibility as in compounds 48 
and 49, which has one carbon atom less between the phenyl ring and the amine 
group compared to 48, is detrimental for affinity. Additionally, incorporation of 
the nitrogen atom in a 1-methyl-tetrahydroisoquinoline moiety (50) is not 
allowed to maintain affinity. In compounds 51 and 52 the nitrogen atom is 
incorporated in a tetrahydroisoquinoline moiety, but in 51 the 4-chlorophenyl 
group is linked to the amine group by a propyl chain, while in 52 the linker is 
part of a tetrahydroisoquinoline containing tricyclic moiety. Both these 
compounds do not show a significant affinity or efficacy on US28. Removal of 
the chloro substituent in the aromatic ring of compound 52, resulting in 
compound 53, does not improve the activity of the compound either.  
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Table 5. Chemical structures and pharmacological properties of compounds 44-53 for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments. 
 
no. Name Structure IC50 (µM)a EC50 (µM)b 
44 B191 
N
NH
 
10.4 (6.8 – 14.1) 0% c 
45 B105 O
O
N
Cl
 
8.8 (3.5 – 14.1) 23%c 
46 C86 
N
NH
Cl  
26%c 35% c 
47 B126 
N
H
N
Cl
 
3% c 18% c 
48 B73 N
H
Cl
O
O
 
7% c 12% c 
49 B157 NH
Cl
O
O  
0% c 4% c 
50 B115 
O
O
N
Cl  
30% c 12% c 
51 B81 
O
O
N
Cl
 
4% c 0% c 
52 B166 
N
Cl
O
O
 
34% c 32% c 
53 A40 
N
O
O
 
 
31% c 0% c 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production. c Results of the single 
point measurements at a concentration of 10 µM. 
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AG50 (54) was identified as a new inverse agonist 
acting on US28. Compound 54 is a promising ligand with 
IC50 and EC50 values of 12.6 µM (11.5 – 13.8) and 4.7 
µM (4.1 - 5.4 µM). Unfortunately, no analogues of 54 
were present in the database and therefore no 
preliminary indication of SAR can be given.  
 
 
Conclusions 
In summary, we have described our search for new ligands acting on the 
constitutively active viral-encoded receptor US28. This was achieved by a 
ligand-based screening with a selection of compounds from our in-house 
database. The database screen revealed several interesting inverse agonists, 
which can all serve as new starting points for lead optimization programs. 
Several structural diverse novel inverse agonists were discovered. In addition, 
two compounds with a different pharmacological profile were identified, namely 
compounds 35 and 44. Both compounds were able to bind to the receptor with 
IC50 values in the micromolar range, but they did not influence the basal 
signaling of the receptor, thereby acting as neutral antagonists on US28. Thus, 
we identified the very first neutral antagonists on the viral-encoded receptor 
US28. Interestingly, the availability of inverse agonists, that are able to inhibit 
the constitutive signaling of the receptor, and neutral antagonists, that do not 
influence the basal signaling, gives us the possibility to further investigate the 
significance of constitutive US28-signaling and the role of the receptor during 
HCMV infection.  
 
Experimental 
Compounds 3, 4, 6, 7 and 10 were purchased from Sigma-Aldrich Co. (USA). Compounds 11 and 12 
were recently reported in the literature.36 Compounds 13 and 14 were kindly donated by Dr. Aebischer 
from the Sandoz research institute in Bern. The purity of all compounds from the in-house database 
was ≥95%, as determined via LC-MS measurements. Transient and stable expression of US28, the 
[125I]CCL5 binding experiments and the [3H]inositol phosphate accumulation assay were performed as 
previously described.19 
 
S
S
HN
NH
O
O
F
F
54
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Chapter 6 
Identification of a molecular determinant that leads to neutral 
antagonism or inverse agonism on US28 
 
Janneke W. Hulshof, Henry F. Vischer , Saskia Hulscher, Iwan J. P. de Esch, 
Martine J. Smit and Rob Leurs 
 
Abstract 
Many viruses encode constitutively active G protein-coupled receptors to alter 
intracellular signaling pathways in the host, thereby changing the normal cellular 
programming. Blocking these viral-encoded receptors and inhibiting their 
constitutive signaling could be a new strategy for the development of 
therapeutics against viral-induced pathologies. Currently, the human 
cytomegalovirus encoded receptor US28 is the only viral-encoded GPCR for 
which small non-peptide inhibitors have been identified. In this study, we 
describe the synthesis and pharmacological characterization of novel inverse 
agonists acting on US28. Moreover, we report the discovery of a neutral 
antagonist for the viral-encoded receptor and we show how we can modulate the 
functional activity of this molecule by the introduction of small structural 
modifications. These ligands with different functional activities can help us to 
investigate the importance of US28 signaling in viral pathogenesis and in the 
future these molecules may serve as putative leads for innovative anti-viral 
intervention. 
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Introduction 
Large DNA viruses, e.g. herpes- and poxviruses, have genes that encode G 
protein-coupled receptors that help to exploit the host cell for viral reproduction 
and survival.1,2 These viral genes may have been pirated from the host genome 
during the long co-evolution of virus and host as they bear great resemblance to 
the cellular host proteins in structure and/or function. Interestingly, most viral-
encoded GPCRs show a high sequence identity with human chemokine receptors, 
but compared to their mammalian homologues many of these viral-encoded 
chemokine receptors activate different signaling pathways in a ligand-
independent manner.3-5 More and more information about vGPCRS with regards 
to their signal transduction pathways and chemokine binding properties has 
been acquired, but the exact role of these receptors during the viral life cycle 
and viral pathogenesis has not been elucidated yet. However, increasing 
evidence suggests that they might play an essential role in virus-associated 
diseases and may therefore represent interesting and challenging new drug 
targets for a novel class of anti-viral therapy.4  
 
One of these virally encoded GPCRs is the human cytomegalovirus (HCMV) 
encoded constitutively active receptor US28.6 HCMV is highly species-specific β-
herpesvirus that persists lifelong in the host in a latent form without any clinical 
symptoms. However, primary infection or reactivation of the virus in 
immunocompromised hosts, such as premature neonates, transplant recipients 
or acquired immunodeficiency syndrome (AIDS) patients, can cause severe and 
even fatal disorders.7,8  
Infection with HCMV is suggested to be associated with vascular diseases,9-11 
inflammatory and autoimmune diseases as well as cancer.12 Interestingly, US28 
is proposed to have an important role in the HCMV-mediated development of 
vascular diseases due to the US28-induced migration of smooth muscle cells 
after infection. This migration towards the vascular intima is a typical 
characteristic of the formation of atherosclerotic and restenotic lesions.13 In 
people infected with human immunodeficiency virus (HIV), co-infection with 
HCMV has been shown to cause an increased risk of disease progression to AIDS 
and dementia.14 US28 is also suggested to play a role in the relationship 
between HCMV and HIV, because the vGPCR can act as a co-receptor for HIV-1 
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entry into cells in vitro.15 Moreover, a potential symbiotic relationship between 
HCMV and HIV-1 has been suggested, because HIV-1 can establish the 
immunosuppression needed for the emergence of HCMV from latency and 
maximal HCVM replication, while HCMV facilitates HIV-1 infection through US28 
and provides an additional mechanism for cell entry by HIV-1.16  
 
US28 can bind several inflammatory CC chemokines, such as CCL2, CCL3, CCL4, 
CCL5, and CCL7, as well as the only member of the CX3C chemokine family, 
namely CX3CL1, with high affinity.17-20 This large spectrum chemokine binding 
profile suggests that US28 could act as a chemokine scavenger by removing the 
CC chemokines from the extracellular environment, thereby helping to overturn 
the immune system of the host.21,22 Moreover, US28 constitutively activates 
different signaling pathways, including phospholipase C, NF-κB, cAMP-response 
element binding protein (CREB) and nuclear factor activated T cell (NFAT). Via 
these pathways the virus alters the normal homeostasis of the cell for its own 
benefit. 5,23-25 In view of the potential role of US28 during viral infection, small 
molecules that inhibit the basal signaling of the receptor and block chemokine or 
HIV binding to US28 are considered promising therapeutics against HCMV-
mediated disorders.5  
 
Currently, US28 is the only viral-encoded GPCR for which small nonpeptidergic 
ligands have been identified. Several molecules that inhibit chemokine binding to 
US28 have been reported in the patent literature, e.g. the non-selective 5-
hydroxytryptamine (5-HT) receptor antagonist methiothepin was reported to 
bind to US28 in a reversible manner with an IC50 value of 0.3 µM. Moreover, this 
compound was shown to act as an agonist in cytoplasmic calcium mobilization 
experiments by inducing a rise in intracellular Ca2+.26 Next to this, we identified 
VUF2274 (1) as the very first inverse agonist acting on a virally encoded GPCR 
(Figure 1), i.e. this molecule is able to completely block the constitutive 
signaling of the receptor. Moreover, it has been shown that compound 1 inhibits 
the US28-mediated HIV-1 entry in cells.27 Recently, the synthesis of an 
extended series of analogues of compound 1 was reported and the first 
structure-activity relationships for inverse agonism on a viral-encoded 
chemokine receptor were elucidated.28,29  
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Figure 1. Chemical structure of methiothepin and compound 1-3. 
 
In our search for novel ligands acting on US28, a large number of compounds 
from our in-house compound collection was screened for their binding affinity 
and inverse agonistic properties (Chapter 5). Several interesting ligands with 
different pharmacological profiles have been found, such as the novel inverse 
agonist 2 and the very first nonpeptidergic neutral antagonist acting on US28, 
namely compound 3.  
 
Many GPCRs exist in one of two main conformers of the receptor, namely the 
inactive state R or the active state R* (Figure 2).30 The active state is considered 
to be responsible for G protein activation, while the inactive state is not coupled 
to G proteins. The equilibrium between the active and the inactive state 
determines the level of the basal signaling.31-33 Agonists are molecules that bind 
to the receptor and stabilize or increase the amount of receptors in the active 
state. Inverse agonists are able to reduce the constitutive basal signaling of a 
receptor by stabilizing or enriching the number of receptors in the inactive 
state.34 In contrast, neutral antagonists are able to bind to the receptor without 
altering the equilibrium between the active and inactive states of the receptor, 
and by doing so, having no influence on the basal singaling. These antagonists 
are important tools for ligand classification, because compounds with these 
characteristics that competitively bind to the receptor as well, will act as 
functional antagonists to compounds with agonistic or inverse agonistic 
properties.35 
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Figure 2. Three simple models for GPCR systems. a. The classical view of receptor binding and 
activation shows agonist (A) binding to an inactive (R) receptor to form a complex (AR). This complex 
isomerizes the receptor to the active state (R*) due to the efficacy of the agonist. b. Activation of the 
receptor by an agonist (A) is followed by topographically distinct binding of the active receptor to the G 
protein (G). The response follows from the ternary AR*G complex. c. The extended ternary complex 
permits allows the for the spontaneous formation of an active-state receptor (R*) in absence of an 
agonist. The active receptor R* can interact with, and activate, a G protein. Activation of the receptor 
from R to R*, which can happen spontaneously or through ligand binding, modifies the affinity of the 
receptor for the G protein by the factors β and γ. Adapted from Kenakin et al.36 
 
In this study, we describe the synthesis and pharmacological characterization of 
several analogues of compounds 2 and 3 to investigate the structure-activity 
relationships of these ligands. Moreover, we show how the synthesis of hybrid 
compound 4a, which contains structural features of both inverse agonist 1 and 
neutral antagonist 3, resulted in the discovery of a molecular determinant that 
leads to neutral antagonism or inverse agonism for US28. Thus, the functional 
activity of ligands on US28 can be modulated by subtle structural changes. 
These insights will enable the design of molecules with different efficacies to 
investigate the significance of US28 signaling in viral pathogenesis. 
 
Chemistry 
Bromide intermediate 5, which was synthesized in a quantitative yield by an 
acid-catalysed condensation of diphenylmethanol with 2-bromoethanol with 
azeotropic removal of water,37 was reacted with 4-(4-chlorophenyl)piperidin-4-ol 
6 in the microwave in the presence of NaI, Na2CO3 and CH3CN to give compound 
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7 (Scheme 1). Compound 8 (Table 1) was synthesized in an analogue manner 
by the alkylation of the commercially available 4,4'-(4-chlorobutane-1,1-
diyl)bis(fluorobenzene) with piperidine 6. 
 
OH
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Cl
Cl
b
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7  
 
Scheme 1. Synthetic pathway for the synthesis of compound 7. Reagents and conditions: (a) p-TSA, 
2-bromoethanol, toluene, reflux; (b) NaI, Na2CO3, CH3CN, microwave (15 min, 160 °C). 
 
The synthesis of compounds 4a-4d is outlined in Scheme 2.  
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Scheme 2. Synthetic pathway for the synthesis of 4a-4d. Reagents and conditions: (a) LiAlH4, THF, 
reflux; (b) 1-bromo-3-chloropropane, Na2CO3, microwave (15 min, 200 °C); (c) NaI, Na2CO3, CH3CN, 
microwave (15 min, 160 °C) or NaI, Na2CO3, CH3CN, reflux; (d) AlCl3, LiAlH4, THF. 
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Reduction38 of 11,12-dihydrodibenzo[b,f]azocin-6(5H)-one 9 with LiAlH4 resulted 
in 5,6,11,12-tetrahydrodibenzo[b,f]azocine 10, which was alkylated with 1-
bromo-3-chloropropane in the microwave (15 min, 200 °C) to yield intermediate 
11. N-alkylation of piperidine moieties 6, 12 and 13 with chloride 11 afforded 
target compounds 4a, 4d and intermediate 4b respectively. The 3-substituted 
piperidine moiety 12 was synthesized by a Grignard reaction of BOC-protected 
piperidin-3-one with 4-chlorophenyl magnesium bromide followed by a 
deprotection under acidic conditions.39 Piperidine moiety 13 was synthesized 
starting from bis(2-chloroethyl)amine hydrochloride as previously described in 
the literature.29,40 The nitrile group of intermediate 4b was reduced in the 
presence of AlCl3 and LiAlH4 to yield target compound 4c.  
 
ClN
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NH
R1
R2
NN
R1
R2
OH
Cl
b, cR2NH2R1 +
d
18a R1 = H; R2 = H
18b R1 = Cl; R2 = H
18c R1 = H; R2 = Cl
16a R1 = H; R2 = H
16b R1 = Cl; R2 = H
16c R1 = H; R2 = Cl
17a R1 = H; R2 = H
17b R1 = Cl; R2 = H
17c R1 = H; R2 = Cl
14a R1 = Cl
14b R1 = H
O
15a R1 = H
15b R1 = Cl
a
 
 
Scheme 3. Synthetic pathway for the synthesis of 18a-18c. Reagents and conditions: (a) NaBH(OAc)3, 
CH3COOH, DCE; (b) NaNH2, toluene, reflux; (c) 1-bromo-3-chloropropane, reflux; (d) 6, NaI, Na2CO3, 
CH3CN, microwave (15 min, 160 °C). 
 
Amines 16a-c were deprotonated with NaNH2 in toluene at reflux temperature 
followed by an alkylation with 1-bromo-3-chloropropane to give intermediates 
17a-c, which were reacted with piperidine 6 in the presence of NaI, Na2CO3, and 
CH3CN (Scheme 3). Unsubstituted amine 16a was commercially available, and 
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amines 16b and 16c, which were used for the synthesis of compounds 18b and 
18c, were synthesized in a quantitative yield via a reductive amination reaction 
with the corresponding anilines 14a-b and benzaldehydes 15a-b in the 
presence of sodium triacetoxyborohydride and acetic acid in DCE. 
 
Rigid tricyclic analogue 24 was synthesized as depicted in Scheme 4. 
Intermediate 20 was synthesized by the reaction of 2-(2-iodophenyl)acetic acid 
19 with 4-(methylthio)benzenethiol in the presence of KOH, Cu and water.41 The 
ring closure to the tricyclic system of 21 was performed by a Friedel-Crafts 
acylation of 20 with PPA in toluene.42 Reduction of the carbonyl group of 21 with 
NaBH4 in MeOH resulted in alcohol 22, which was reacted with BF3·(Et)2O and 2-
bromoethanol in toluene to give bromide 23.43 N-akylation of piperidine 6 with 
23 yielded target compound 24. 
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Scheme 4. Synthetic pathway for the synthesis of 24. Reagents and conditions: (a) Cu, KOH, water, 
reflux; (b) PPA, toluene, reflux; (c) NaBH4, MeOH; (d) BF3·(Et)2O, 2-bromoethanol, toluene; (e) 6, NaI, 
Na2CO3, CH3CN, reflux. 
 
Results and discussion 
Screening of our in-house compound collection (Chapter 5) revealed two 
interesting novel hits, namely L118 (2) and A194 (3). In this study, both 
compounds were able to displace more than 50% of [125I]CCL5 from US28 at a 
concentration of 10 µM. Both compounds were re-screened by evaluating their 
ability to dose-dependently displace [125I]CCL5 binding to US28 and by 
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determining their inverse agonistic properties by investigating their potential to 
inhibit the constitutive inositol phosphate production in US28-expressing SVEC4-
10 cells.  
 
Compounds 2 and 3 were able to bind to US28 with IC50 values of 2.3 and 4.9 
µM, respectively. Interestingly, compound 2 acts as an inverse agonist on US28 
by inhibiting the ligand-independent signaling of the receptor. In contrast, 
compound 3 did not influence the basal signaling of the receptor, thereby acting 
as a neutral antagonist. This is the very first report of a small nonpeptidergic 
molecule acting as a neutral antagonist on a viral-encoded receptor, namely 
US28. To further investigate a possible correlation between the structures of the 
ligands and their functional activity on US28, several analogues of 2 and 3 were 
obtained from our in-house database or synthesized. All compounds were 
evaluated for their binding properties by their ability to displace [125I]CCL5 
binding to US28 in a dose-dependent manner. The inverse agonistic properties 
were determined for a selection of compounds. 
 
Table 1. Chemical structures and pharmacological properties of compounds 1, 2, 7 and 8 for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 
and EC50 values of at least three independent experiments. 
 
X
N
OH
Cl
R2
R2
R1
 
 
no. Code R1 R2 X IC50 (µM)a EC50 (µM)b 
1 VUF2274 CN H CH2 4.9 (4.4 - 5.5) 6.3 (5.9 – 6.8) 
2 L118 H F O 2.3 (1.5 – 3.2) 4.6 (2.5 - 4.0) 
7 VUF6999 H H O 2.1 (1.8 – 2.4) 3.5 (1.7 – 5.4) 
8 VUF6968 H F CH2 3.0 (2.5 – 3.5) 5.2 (3.2 – 7.2) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production.  
 
Structural analogues of L118 (2) 
To study the importance of the fluoro atoms in the phenyl rings of 2 and the 
oxygen atom in the linker between the diphenyl group and the piperidine moiety 
in this molecule, compounds 7 and 8 were synthesized (Table 1). In our 
Chapter 6 
140 
previous study28 it was demonstrated that chloro substitution at the para 
position of both rings of the diphenyl group resulted in a decrease of affinity 
compared to reference compound 1. However, the introduction of the two fluoro 
atoms in 8 causes an increase in affinity compared to lead compound 1 and an 
affinity comparable to that of compound 2. Moreover, removal of the fluoro 
atoms, resulting in compound 7, does not change affinity or efficacy on US28. 
 
Table 2. Chemical structures and pharmacological properties of compounds 3, 4a, 4c-d and 25-27 
for the HCMV-encoded receptor US28. The values are represented as the mean and the interval of the 
IC50 and EC50 values of at least three independent experiments. 
 
N
X
R2
 
 
no. Code X         R1 IC50 (µM)a EC50 (µM)b 
3 A194 CH2 N N
 
4.9 (2.8 – 7.1) 3% ± 15 
25 B82 CH2 N N
OH  
1.6 (1.3 – 1.9) 0% ± 6 
26 A190 C(=O) N N
 
> 100 0% ± 16 
27 B78 C(=O) N N
OH  
> 100 0% ± 5 
4a VUF10000 CH2 N Cl
OH
 
0.7 (0.6 – 0.9) 4.7 (2.8 – 6.6) 
4c VUF10253 CH2 
N Cl
H2N
 
1.6 (1.0 – 2.2) 7.6 (4.8 – 10.5) 
4d VUF10347 CH2 
N
OH
Cl
 
 
 
0.9 (0.7 – 1.0) 3.9 (3.6 – 4.2) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production.  
 
Structural analogues of A194 (3) 
To investigate the effect of the structure on the functional activity of the 
receptor, analogues of compound 3 were evaluated on US28 (Table 2 and 3). 
Firstly, several molecules were taken from our in-house library and 
pharmacologically analyzed (compounds 25-27). Replacement of the N-methyl 
group of 3 by an ethanol group in 25 results in a 3-fold increase in affinity, but 
the antagonistic properties are maintained. Interestingly, changing the basic 
properties of the nitrogen atom of both compounds 3 and 25 by the introduction 
A molecular determinant that leads to neutral antagonism or inverse agonism 
   141
of an amide group in compounds 26 and 27 causes a significance decrease in 
binding affinity.  
 
It was previously discovered that a 4-phenylpiperidine moiety is essential for 
inverse agonism on US28.28 Thus, the N-methylpiperazine group of 3 was 
replaced by the 4-(4-chlorophenyl)piperidin-4-ol moiety of lead compound 1, 
resulting in compound 4a, leading to the anticipated recovery of the inverse 
agonistic properties (Figure 3). Intriguingly, this structural modifcation has a 
great influence on the functional activity of the ligands and reveals a molecular 
determinant that leads to neutral antagonism or inverse agonism. Moreover, 
hybrid compound 4a has a 7-fold higher binding affinity than that of lead 
compound 1 or neutral antagonist 3.  
 
N
N N
N
N
OH
Cl
3
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N
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Figure 3. Chemical structures of inverse agonist 1, neutral antagonist 3 and hybrid compound 4a.  
 
It is known for many GPCRs that small structural modifications can cause 
dramatic changes in the functional activities on the receptor.44,45 It is shown for 
constitutively active receptors that inverse agonists can activate molecular 
switches that are essential to give a conformational rearrangement that leads to 
the inverse agonistic effect of these ligands.34,46 Apparently, the structures of 
compounds 3 and 25 cannot induce the conformational change necessary to 
stabilize or enrich the number of receptors in the inactive state. Thus, these 
compounds do not modulate the basal signaling of the receptor, thereby acting 
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as neutral antagonists. In contrast, the structure of compound 4a is able to 
induce the conformational change to inactivate the receptor, thereby inhibiting 
the basal signaling of the receptor. Thus, the cyclic amine group attached to the 
propyl linker can be considered as an interesting molecular determinant for the 
modulation of the functional activity of ligands acting on US28. 
 
Previously, it was shown that a methylamine group at the 4-position of the 
piperidine ring resulted in a 6-fold increase in binding affinity compared to lead 
compound 1 (Chapter 3).29 Thus, the 4-hydroxy group of compound 4a was 
replaced by a methylamine group, resulting in compound 4c. However, this 
structural modification did not cause an increase in the binding affinity and 
efficacy on US28. Introduction of a chiral center by moving the hydroxy group 
and the 4-chlorophenyl substituent to the 3-position of the piperidine ring, as in 
compound 4d, did not improve the binding affinity and efficacy on US28 either.  
 
To investigate the significance of the rigid tricyclic structure of compound 4a 
several flexible analogues were synthesized (Table 3). The more rigid system 
in compound 4a proofs to be of importance for affinity, because removal of the 
ethylene bridge between the two phenyl rings as in open analogue 18a causes 
a more than 10-fold decrease in binding affinity. Introduction of a chloro atom 
at the 4-position of one of the phenyl rings, resulting in compounds 18b and 
18c, shows an interesting regioselectivity. The efficacies of both compounds 
are comparable, but the position of the chloro atom in compound 18b was 
preferred, resulting in a 3-fold higher binding affinity compared to compound 
18c. To investigate the influence of the tricyclic system of methiothepin, 
compound 24 was synthesized. Unfortunately, this compound shows an almost 
18-fold decrease of binding affinity compared to compound 4a.  
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Table 3. Chemical structures and pharmacological properties of compounds 4a, 4c, 18a-18c and 24 
for the HCMV-encoded receptor US28. The values are represented as the mean and the interval of the 
IC50 and EC50 values of at least three independent experiments. 
 
N
R2
Cl
R1
 
 
no. Code R1 R2 IC50 (µM)a EC50 (µM)b 
4a VUF10000 N
 
OH 0.7 (0.6 – 0.9) 4.7 (2.8 – 6.6) 
4c VUF10253 N
 
CH2NH2 1.6 (1.0 – 2.2) 7.6 (4.8 – 10.5) 
18a VUF10254 
N
 
OH 4.1 (2.8 – 5.4) 3.0 (2.8 – 6.0) 
18b VUF10257 
NCl
 
OH 1.8 (1.4 – 2.1) 5.0 (3.9 – 6.2) 
18c VUF10258 
N
Cl
 
OH 5.7 (4.3 – 7.1) 5.5 (5.0 – 6.0) 
24 VUF10255 
O
S
S
 
 
OH 12.4 (11.2 – 13.5) 7.1 (4.9 – 9.3) 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production.  
 
Conclusions 
Screening of a selection of compounds from our in-house database resulted in 
the identification of compound 2 and 3 as new starting points for hit 
optimization programs. While compound 2 was shown to have inverse agonistic 
properties on US28, molecule 3 was identified as the very first neutral 
antagonist acting on a viral-encoded receptor, namely US28. In this study, we 
report the synthesis and SAR of a series of analogues of compounds 2 and 3 and 
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we studied the effect of the structure of the ligands on the functional activity on 
the receptor. Remarkably, replacement of the piperazine moiety of compound 3 
by a 4-(4-chlorophenyl)piperidin-4-ol group as in compound 4a resulted in 
complete recovery of the inverse agonistic properties. Thus, the nature of the 
nitrogen containing ring system attached to the propyl chain can be considered 
as a molecular determinant for the regulation of the functional activity of this 
series of ligands. Antagonists are important tools to study receptor 
pharmacology, because these ligands act as functional antagonists to 
compounds with agonistic or inverse agonistic properties. 
 
Experimental section 
General procedures.  
THF and DCM were freshly distilled from lithium aluminium hydride. All reactions were performed under 
an atmosphere of dry nitrogen. Microwave reactions were performed in a CEM Explorer single mode MW 
reactor equipped with auto sampler. 1H NMR and 13C NMR spectra were recorded on a Bruker AC-200 
(200 MHz) spectrometer unless otherwise stated. J.T. Baker silica gel was used for flash 
chromatography. HRMS mass spectra were recorded on a Finnigan MAT 900 mass spectrometer. 
Analytical HPLC-MS analyses were conducted using a Shimadzu LC-8A preparative liquid chromatograph 
pump system with a Shimadzu SPD-10AV UV-VIS detector set at 254 nm, with the MS detection 
performed with a Shimadzu LCMS-2010 liquid chromatograph mass spectrometer. The analyses were 
performed using the following conditions; condition I: a Xbridge(C18)5um column (100 mm x 4.9 mm) 
with 70% MeOH - 30% H2O-0.1% formic acid (Method Ia); 60% MeOH - 40% H2O-0.1% formic acid 
(Method Ib) or 50% MeOH - 50% H2O-0.1% formic acid (Method Ic). Flow rate = 1.0 mL/min. Total run 
time 15 min unless otherwise stated. Condition II: a Xbridge(C18)5um column (100 mm x 4.9 mm) 
with 50% CH3CN - 50% H2O-0.1% formic acid (Method IIa); 40% CH3CN - 60% H2O-0.1% formic acid 
(Method IIb), 35% CH3CN - 65% H2O-0.1% formic acid (Method IIc), 30% CH3CN - 70% H2O-0.1% 
formic acid (Method IId) or 25% CH3CN - 75% H2O-0.1% formic acid (Method IIe). Flow rate = 1.0 
mL/min. Total run time 20 min. Compounds that were isolated as fumaric acid salts all showed an extra 
peak around two minutes. Fumaric acid blancs were used to determine the tR of fumaric acid. Purities 
calculated are based on RP HPLC-UV peak surface area of the compounds (disregarding the fumaric acid 
peak). Compounds 2, 3 and 25-27 were taken from our in-house database. 
 1-(2-(bis(4-Fluorophenyl)methoxy)ethyl)-4-(4-chlorophenyl)-piperidin-4-ol maleate 
(2). This compound was obtained from our in-house database. 1H NMR (CDCl3): δ 1.80-2.01 (m, 2H), 
2.32-2.55 (m, 2H), 3.16-3.56 (m, 7H), 3.82 (t, J = 4.8 Hz, 2H), 5.32 (s, 1H), 6.16 (s, 2H), 6.92-7.00 
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(m, 4H), 7.19-7.39 (m, 10H). 13C NMR (MeOH-d4): δ 36.23, 48.60, 57.24, 63.76, 69.12, 84.13, 116.14, 
116.57, 127.48, 129.54, 129.97, 130.14, 134.29, 136.72, 138.65, 138.71, 146.97, 161.34, 166.21, 
170.89. Anal. RP-HPLC Ib: tR = 9.63 min (purity 99%), IIa: tR = 8.18 min (purity 100%), IIb (total run 
time 30 min): tR = 21.49 min (purity 98%). HRMS (ESI) m/z calcd for C27H28ClF2NO: 457.1620; found: 
457.1607. 
 5-(3-(4-Methylpiperazin-1-yl)propyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine 
trihydrochloride (3). This compound was obtained from our in-house database. 1H NMR (MeOH-d4): δ 
2.08-2.33 (m, 2H), 3.00 (s, 3H), 3.13-3.79 (m, 14H), 3.31 (s, 2H), 3.87 (t, J = 8.1 Hz, 2H), 6.99 (d, J 
= 4.0 Hz, 1H), 7.10-7.41 (m, 7H). 13C NMR (MeOH-d4, 400 MHz): δ 22.45, 32.47, 34.57, 43.35, 50.03, 
51.75, 54.89, 55.85, 61.00, 125.20, 127.89, 128.84, 130.90, 130.96, 131.65, 132.72, 133.83, 136.01, 
138.00, 142.10. Anal. RP-HPLC Ic: tR = 6.84 min (purity 100%), IIe: tR = 6.14 min (purity 97%). 
HRMS (EI) m/z calcd for C23H31N3: 349.2518; found: 349.2506. 
 General method A. 1-(2-(Benzhydryloxy)ethyl)-4-(4-chlorophenyl)piperidin-4-ol 
fumarate (7). 5 (0.58 g, 1.99 mmol), which was synthesized following a method previously 
described,37 4-(4-chlorophenyl)piperidin-4-ol 6 (0.51 g, 2.41 mmol), NaI (0.30 g, 2.00 mmol), Na2CO3 
(0.42 g, 3.96 mmol) and 3 mL CH3CN were added in a 10 mL microwave vessel and this was reacted 
during 15 minutes in the microwave at a temperature of 160 °C (settings: ramp time 5 min, hold time 
15 min, power 200 watt, pressure 17.2 bar). The solvent was removed in vacuo and the residue was 
diluted with water (20 mL), followed by an extraction with DCM (3 x 15 mL). The combined organic 
layers were washed with water (3 x 40 mL) and brine (40 mL), dried over anhydrous MgSO4, filtered, 
and evaporated in vacuo. Purification by flash chromatography (0-50% EtOAc in DCM) gave 480 mg 
(57%) of the free base as an oil. This was dissolved in EtOAc and acidified by the addition of a 
saturated solution of fumaric acid in Et2O. The fumaric salt was isolated by filtration and recrystallized 
from MeOH/Et2O to give 281 mg (52%) of 7 as a white solid. 1H NMR (CDCl3): δ 1.60-1.81 (m, 2H), 
2.08-2.43 (m, 2H), 2.84-3.25 (m, 6H), 3.65-3.78 (m, 2H), 5.28 (s, 1H), 6.63 (s, 2H), 7.11-7.36 (m, 
14H). 13C (CDCl3): δ 36.29, 49.42, 56.91, 64.68, 69.54, 84.64, 126.57, 127.30, 128.09, 128.89, 
134.06, 135.30, 141.78, 148.74, 169.53. Anal. RP-HPLC Ib: tR = 8.60 min (purity 100%), IId: tR = 
12.13 min (purity 100%). HRMS (ESI) m/z calcd for C26H28ClNO2: 421.1808; found: 421.1803. 
 General method B. 1-(4,4-bis(4-Fluorophenyl)butyl)-4-(4-chlorophenyl)piperidin-4-ol 
(8). A solution of 4,4'-(4-chlorobutane-1,1-diyl)bis(fluorobenzene) (0.56 g, 1.99 mmol), 4-(4-
chlorophenyl)piperidin-4-ol 6 (0.51 g, 2.41 mmol), NaI (0.30 g, 2.00 mmol) and Na2CO3 (0.43 g, 4.06 
mmol) in CH3CN (20 mL) was refluxed overnight. The solvent was removed in vacuo, the residue was 
diluted with water (50 mL) and extracted with DCM (3 x 30 mL). The combined organic layers were 
washed with water (3 x 50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered and 
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evaporated in vacuo. Purification by flash chromatography (0-100% EtOAc in DCM) and recrystallization 
from EtOAc gave 853 mg (94%) of 8 as a white solid. 1H NMR (CDCl3): δ 1.48-1.72 (m, 5H), 1.92-2.24 
(m, 4H), 2.30-2.55 (m, 4H), 2.69-2.85 (m, 2H), 3.86 (t, J = 7.8 Hz, 1H), 6.90-7.43 (m, 12H). 13C 
(CDCl3): δ 25.76, 34.27, 38.71, 49.83, 50.14, 58.92, 71.41, 115.57, 115.78, 126.47, 128.82, 129.43, 
129.51, 133.22, 140.86, 140.89, 147.16, 160.54, 162.97. Anal. RP-HPLC Ib: tR = 8.78 min (purity 
100%), IIb: tR = 13.99 min (purity 100%). HRMS (EI) m/z calcd for C27H28ClF2NO: 455.1827; found: 
455.1826. 
 General method C. 1-(3-((4-chlorobenzyl)(phenyl)amino)-propyl)-4-(4-chlorophenyl)- 
piperidin-4-ol fumarate (18c). (i) A solution of aniline 14b (1.82 mL, 20.0 mmol), 4-
chlorobenzaldehyde 15b (2.35 mL, 20.0 mmol) and CH3COOH (1.14 mL, 19.9 mmol) in DCE (100 mL) 
was stirred for 24h at room temperature and NaBH(OAc)3 (6.36 g, 30.0 mmol) was added. The reaction 
mixture was stirred for another 18h, quenched with 5% Na2CO3 (100 mL) and the water layer was 
extracted with DCM (3 x 100 mL). The combined organic layers were washed with brine (150 mL), dried 
over anhydrous Na2SO4, filtered and evaporated in vacuo to give 4.42 g (100%) of 16c as a brown 
solid. 1H NMR (CDCl3): δ 4.06 (br s, 1H), 4.29 (s. 2H), 6.51-6.58 (m, 2H), 7.07-7.14 (m, 2H), 7.24-
7.36 (m, 5H). 
(ii) NaNH2 (0.39 g, 10.0 mmol) was added to a solution of 16c (1.09 g, 5.01 mmol) in toluene (15 mL) 
and this was refluxed for 18h. 1-Bromo-3-chloropropane (2.5 mL, 25.3 mmol) was added and the 
reaction mixture was refluxed for another 18h. Water (25 mL) was added and the water layer was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water (3 x 30 mL) 
and brine (40 mL), dried over anhydrous Na2SO and filtered. After evaporation under reduced pressure, 
the residue was purified by flash chromatography (5% DCM in hexane) to give 142 mg (10%) of 17c as 
a light yellow oil. 1H NMR (CDCl3): δ 1.98-2.18 (m, 2H), 3.45-3.68 (m, 4H), 4.50 (s, 2H), 6.51-6.75 (m, 
3H), 7.03-7.28 (m, 6H). 
(iii) Following method B using 17c gave 142 mg of the free base as an oil. This was converted to the 
fumaric salt as described for 7 to give 178 mg (63%) of 18c as a white solid. 1H NMR (MeOH-d4): δ 
1.81-1.93 (m, 2H), 1.97-2.17 (m, 2H), 2.19-2.39 (m, 2H), 2.98-3.39 (m, 6H), 3.50 (t, J = 7.2 Hz, 2H), 
4.54 (s, 2H), 6.59-6.30 (m, 4H), 7.02-7.51 (m, 11H).13C (MeOH-d4): δ 23.81, 36.88, 49.57, 50.09, 
55.21, 55.84, 69.75, 114.39, 118.29, 127.48, 129.44, 129.58, 129.61, 130.30, 133.52, 134.07, 
137.00, 139.26, 147.47, 149.37, 173.62. Anal. RP-HPLC Ib: tR = 4.87 min (purity 100%), IIb: tR = 
3.89 min (purity 100%). HRMS (EI) m/z calcd for C27H30Cl2N2O: 468.1735; found: 468.1721. 
 4-(4-chlorophenyl)-1-(3-(11,12-dihydrodibenzo[b,f]azocin-5(6H)-yl)propyl)piperidine-
4-ol fumarate (4a). Following method A using 11 (0.29 g, 1.01 mmol) gave 289 mg of the free base 
as an oil. This was converted to the fumaric salt as described for 7 and recrystallized from MeOH/Et2O 
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to give 199 mg (38%) of 4a as white crystals. 1H NMR (CDCl3): δ 1.50-1.92 (m, 5H), 2.09-2.36 (m, 
2H), 2.41-2.70 (m, 4H), 2.78-3.34 (m, 8H), 4.11 (s, 2H), 6.69 (s, 2H), 6.72-7.35 (m, 12H). 13C 
(CDCl3): δ 23.15, 33.28, 34.22, 35.92, 48.11, 51.14, 55.08, 60.96, 69.57, 119.32, 122.17, 125.91, 
126.82, 127.15, 128.39, 128.79, 129.73, 131.08, 132.94, 135.45, 136.06, 137.65, 141.83, 145.37, 
150.02, 171.33. Anal. RP-HPLC Ib (total run time 20 min): tR = 14.43 min (purity 100%), IIc: tR = 
11.35 min (purity 97%). HRMS (EI) m/z calcd for C29H33ClN2O: 460.2281; found: 460.2284. 
 (4-(4-chlorophenyl)-1-(3-(11,12-dihydrodibenzo[b,f]azocin-5(6H)-yl)propyl)piperidin-
4-yl)methanamine fumarate (4c). (i) Following method B using 11 and 4-(4-chlorophenyl)-
piperidine-4-carbonitrile hydrochloride 13, which was synthesized as previously described in the 
literature,29 afforded 675 mg of 4b as a light yellow oil. The crude product was used without further 
purification.  
(ii) AlCl3 (0.37 g, 2.78 mmol) was added portion wise to a suspension of LiAlH4 (0.11 g, 2.90 mmol) in 
THF (10 mL) at 0 °C and this was stirred for 5 min followed by the drop wise addition of a solution of 4b 
(675 mg, 1.44 mmol) in THF (5 mL). The reaction mixture was allowed to warm to room temperature, 
stirred overnight, cooled with an ice bath and quenched with a saturated solution of Na2CO3 in water 
until the foaming stopped. Subsequently, the suspension was filtered, the filtrate was dried over 
anhydrous MgSO4, filtered again and evaporated in vacuo. Purification by flash chromatography (5% 
Et3N in EtOAc) afforded 183 mg (39%) of the free base as an oil. This was converted to the fumaric salt 
as described for 7 to give 199 mg (24%) of 4c as a light brown solid. 1H NMR (CDCl3/DMSO-d6): δ 
1.54-1.75 (m, 2H), 1.82-1.93 (m, 2H), 2.05-2.18 (m, 4H), 2.27-2.39 (m, 2H), 2.59-2.68 (m, 2H), 2.86 
(s, 2H),2.92-2.99 (m, 2H), 3.03-3.19 (m, 6H), 4.11 (s, 2H),6.60 (s, 2H), 6.73 (t, J = 7.3 Hz, 1H), 
6.89-7.04 (m, 6H), 7.11-7.39 (m, 5H). 13C NMR (CDCl3/DMSO-d6): δ 24.06, 31.36, 32.79, 33.75, 
38.67, 48.42, 50.68, 54.91, 60.22, 119.50, 121.68, 125.47, 126.33, 126.68, 128.51, 128.59, 128.79, 
129.20, 130.57, 131.95, 134.13, 135.82, 137.06, 141.06, 146.64, 149.77. Anal. RP-HPLC Ib: tR = 4.43 
min (purity 99%), Ic (total run time 20 min): tR = 14.35 min (purity 100%), IIe (total runtime 30 min): 
tR = 21.45 min (purity 96%). HRMS (EI) m/z calcd for C30H36ClN3: 473.2598; found: 473.2579. 
 3-(4-Chlorophenyl)-1-(3-(11,12-dihydrodibenzo[b,f]azocin-5(6H)-yl)propyl)piperidin-3-
ol fumarate (4d). Following method A using 11 (0.18 g, 0.63 mmol) and 3-(4-chlorophenyl)piperidin-
3-ol 12 (0.11 g, 0.52 mmol), which was synthesized as described in the literature,39 gave 77 mg of the 
free base as an oil. This was converted to the fumaric salt as described for 7 to give 50 mg (17%) of 
4d as a white solid. 1H NMR (MeOH-d4): δ 1.76-2.29 (m, 6H), 2.79-3.10 (m, 5H), 2.91 (s, 2H), 3.13-
3.39 (m, 6H), 4.13 (s, 2H), 6.69 (s, 2H), 6.79-7.12 (m, 8H), 7.37-7.49 (m, 4H). 13C NMR (MeOH-d4): δ 
20.44, 23.57, 34.56, 34.75, 35.80, 52.18, 53.72, 56.81, 61.36, 62.93, 71.47, 121.23, 124.28, 127.22, 
127.77, 128.10, 128.49, 129.67, 129.94, 130.90, 132.24, 134.91, 136.16, 138.21, 139.02, 143.20, 
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144.30, 151.23, 171.08. Anal. RP-HPLC Ib (total run time 20 min): tR = 6.78 min (purity 99%), IIa 
(total run time 30 min): tR = 14.64 min (purity 98%). HRMS (EI) m/z calcd for C29H33ClN2O: 460.2281; 
found: 460.2283. 
 5-(3-Chloropropyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine (11).  
5,6,11,12-Tetrahydrodibenzo[b,f]azocine 10 (0.42 g, 2.01 mmol), which was synthesized as previously 
described in the literature,38 and Na2CO3 (0.42 g, 3.96 mmol) were added in a 10 mL microwave vessel 
and 1-bromo-3-chloropropane (3 mL) was added. This solution was reacted in the microwave for 15 
min at a temperature of 200 °C (settings: ramp time 5 min, hold time 15 min, power 200 watt, 
pressure 17.2 bar) and filtered. The solvent was evaporated in vacuo and the residue was purified by 
flash chromatography (15% DCM in hexane) to give 228 mg (40%) of 11 as a colourless oil. 1H NMR 
(CDCl3): δ 1.85-1.98 (m, 2H), 3.04-3.48 (m, 8H), 4.15 (s, 2H), 6.80-7.24 (m, 8H). 
 1-(3-(Benzyl(phenyl)amino)propyl)-4-(4-chlorophenyl)piperidin-4-ol hemifumarate 
(18a). Following method C starting with N-benzylaniline gave 331 mg of the free base as an oil. This 
was converted to the fumaric salt as described for 7 and recrystallized from MeOH/Et2O to give 261 mg 
(24% over two steps) of 18a as white crystals. 1H NMR (CDCl3/DMSO-d6): δ 1.53-1.72 (m, 2H), 1.74-
1.97 (m, 2H), 2.00-2.21 (m, 2H), 2.41-2.70 (m, 4H), 2.82-3.01 (m, 2H), 3.26-3.48 (t, J = 7.4 Hz, 2H), 
4.42 (s, 2H), 6.49-6.88 (m, 5H), 6.98-7.42 (m, 11H). 13C NMR (CDCl3/DMSO-d6): δ 22.90, 36,45, 
48.43, 54.32, 54.76, 69.23, 112.30, 116.32, 126.13, 126.43, 126.61, 128.02, 128.34, 129.04, 135.15, 
138.49, 146.62, 148.14, 170.21. Anal. RP-HPLC Ib: tR = 10.01 min (purity 100%), IIb (total run time 
30 min): tR = 8.05 min (purity 100%), IIb (total run time 30 min): tR = 18.22 min (purity 100%). 
HRMS (EI) m/z calcd for C27H31ClN2O: 434.2125; found: 434.2113. 
 1-(3-(Benzyl(4-chlorophenyl)amino)propyl)-4-(4-chlorophenyl)piperidin-4-ol 
hemifumarate (18b). Following method A starting with benzaldehyde and 4-chloroaniline gave 105 
mg of the free base as an oil. This was converted to the fumaric salt as described for 7 and 
recrystallized from Et2O/MeOH to give 112 mg of 18b as white crystals (6% over 3 steps) 
1H NMR (CDCl3/DMSO-d6): δ 1.61-2.05 (m, 4H), 2.13-2.37 (m, 2H), 2.53-2.86 (m, 2H), 2.99-3.12 (m, 
2H), 3.37 (t, J = 7.1 Hz, 2H), 4.44 (s, 2H), 6.46-6.68 (m, 2H), 6.72 (s, 2H), 7.02-7.39 (m, 11H). 13C 
NMR (CDCl3/DMSO-d6): δ 22.64, 36.16, 48.38, 48.70, 54.54, 69.37, 113.62, 121.22, 126.02, 126.40, 
126.86, 128.26, 128.49, 128.88, 132.73, 135.35, 137.92, 145.84, 146.72, 170.93. Anal. RP-HPLC Ib : 
tR = 5.03 min (purity 100%), IIa (total run time 30 min): tR = 14.46 min (purity 98%). HRMS (EI) m/z 
calcd for C27H30Cl2N2O: 468.1735; found: 468.1718. 
 4-(4-Chlorophenyl)-1-(2-(8-(methylthio)-10,11-dihydro-dibenzo[b,f]thiepin-10-yloxy)-
ethyl)piperidin-4-ol fumarate (24). (i) 4-(Methylthio)benzenethiol (5.24 g, 20.0 mmol) was added 
to a solution of 2-(2-iodophenyl)acetic acid 19 (3.12 g, 20.0 mmol) and KOH (4.49 g, 80.0 mmol) in 
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water (60 mL). After the addition of Cu (205 mg), the reaction mixture was refluxed for 48h, cooled to 
room temperature and filtered. The filtrate was acidified with 1.0 M HCl, filtered and the residue was 
dried under vacuum to yield 4.83 g (83%) of 2-(2-(4-(methylthio)phenylthio)phenyl)acetic acid 20 as a 
pink solid. 1H NMR (CDCl3): δ 2.43 (s, 3H), 7.12-7.35 (m, 8H). 
(ii) PPA (50.0 g) was added to a solution of 20 (4.83 g, 16.6 mmol) in toluene (30 mL) and the reaction 
mixture was heated and refluxed for 18h. Water (50 mL) was added, the organic layer was separated 
and the water layer was extracted with EtOAc (3 x 30 mL). The combined organic extracts were washed 
with 5% NaOH (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated in 
vacuo to give 3.50 g (77%) of 8-(methylthio)dibenzo[b,f]thiepin-10(11H)-one 21 as a brown oil. 1H 
NMR (CDCl3): δ 2.46 (s, 3H), 4.36 (s, 2H), 7.13-7.64 (m, 6H), 8.02 (d, J = 2.3 Hz, 1H). 
(iii) A solution of 21 (3.50 g, 12.8 mmol) and NaBH4 (1.01 g, 26.7 mmol) in MeOH (100 mL) was stirred 
overnight at room temperature. The reaction mixture was evaporated in vacuo, water was added (50 
mL) and the water layer was extracted with Et2O (3 x 25 mL). The combined organic extracts were 
washed with water (3 x 50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered and 
evaporated in vacuo to give 3.14 g (89%) of 8-(methylthio)-10,11-dihydrodibenzo[b,f]thiepin-10-ol 22 
as a brown solid. 1H NMR (CDCl3): δ 2.44 (s, 3H), 3.31-3.49 (m, 1H), 3.69-3.78 (m, 1H), 5.49 (br s, 
1H), 6.95-7.49 (m, 7H). 
(iv) BF3·(Et)2O (1.60 mL, 12.6 mmol) was added drop wise to a solution of 22 (3.14 g, 11.4 mmol) and 
2-bromoethanol (1.22 mL, 17.2 mmol) in toluene (30 mL) and the reaction mixture was stirred for 1h. 
Water (25 mL) was added and the water layer was extracted with EtOAc (3 x 20 mL). The combined 
organic extracts were washed with water (25 mL), 5% NaOH (2 x 25 mL) and brine (25 mL), dried over 
anhydrous Na2SO4, filtered and evaporated in vacuo to give 3.37 g of 11-(2-bromoethoxy)-2-
(methylthio)-10,11-dihydrodibenzo[b,f]thiepine 23 as a brown oil. The crude product was used without 
further purification. 
(v) Following method B using crude 23 (0.57 g, 1.49 mmol) and 4-(4-chlorophenyl)piperidin-4-ol 9 
(0.21 g, 1.00 mmol) gave 88 mg of a light yellow oil. This was converted to the fumaric salt as 
described for 7 to give 101 mg (16%) of 24 as a white solid. 1H NMR (CDCl3/DMSO-d6): δ 1.67-1.80 
(m, 2H), 2.21-2.57 (m, 5H), 2.78-3.31 (m, 6H), 3.42-3.62 (m, 2H), 3.78-3.99 (m, 2H), 5.22-5.33 (m, 
1H), 6.73 (s, 2H), 7.00-7.41 (m, 12H). 13C NMR (CDCl3/DMSO-d6): δ 15.53, 35.91, 38.84, 48.92, 
49.19, 56.61, 64.57, 68.79, 77.22, 125.02, 125.61, 126.28, 127.43, 128.16, 129.64, 130.97, 131.39, 
131.82, 132.58, 133.66, 134.94, 137.86, 138.80, 142.22, 146.10, 169.42. Anal. RP-HPLC Ia: tR = 7.76 
min (purity 99%), IIa (total run time 30 min): tR = 19.48 min (purity 97%). HRMS (EI) m/z calcd for 
C28H30ClNO2S2: 511.1406; found: 511.1405. 
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 2-(4-(3-(11,12-Dihydrodibenzo[b,f]azocin-5(6H)-yl)propyl)-piperazin-1-yl)ethanol 
dimaleate (25). This compound was obtained from our in-house database. 1H NMR (MeOH-d4): δ 
1.79-1.85 (m, 2H), 2.72 (t, J = 7.7 Hz, 2H), 2.86-3.11 (m, 12H), 3.20-3.41 (m, 4H), 3.74 (t, J = 5.3 
Hz, 2H), 4.19 (s, 2H), 6.27 (s, 4H), 6.86-6.90 (m, 1H), 6.98- 7.11 (m, 7H). 13C NMR (MeOH-d4): δ 
24.93, 34.62, 35.62, 51.78, 52.07, 52.13, 56.21, 57.96, 59.73, 62.80, 121.62, 124.56, 127.16, 
128.05, 128.56, 130.17, 130.17, 130.89, 132.32, 134.52, 138.50, 143.12, 170.06. Anal. RP-HPLC Ic: 
tR = 4.56 min (purity 100%), IId: tR = 4.00 min (purity 100%). HRMS (EI) m/z calcd for C24H33N3O: 
379.2624; found: 379.2619. 
 1-(11,12-Dihydrodibenzo[b,f]azocin-5(6H)-yl)-3-(4-methylpiperazin-1-yl)propan-1-one 
dihydrochloride trihydrate (26). This compound was obtained from our in-house database. 1H NMR 
(MeOH-d4): δ 2.32-2.51 (m, 1H), 2.62-3.04 (m, 6H), 3.12-3.38 (m, 6H), 4.44-4.65 (m, 6H), 4.20 (d, J 
= 14.7 Hz, 1H), 5.68 (d, J = 14.7 Hz, 1H), 6.94-7.28 (m, 8H). 13C NMR (MeOH-d4): δ 30.40, 32.25, 
35.64, 43.31, 50.15, 51.10, 53.83, 54.25, 127.35, 129.18, 129.20, 129.81, 130.28, 130.61, 131.20, 
132.73, 135.50, 140.22, 141.05, 141.78, 170.58. Anal. RP-HPLC Ic: tR = 4.11 min (purity 100%), IId: 
tR = 3.85 min (purity 100%). HRMS (EI) m/z calcd for C23H29N3O: 363.2311; found: 363.2307. 
 1-(11,12-Dihydrodibenzo[b,f]azocin-5(6H)-yl)-3-(4-(2-hydroxyethyl)piperazin-1-yl)-
propan-1-one dimaleate (27). This compound was obtained from our in-house database. 1H NMR 
(MeOH-d4): δ 2.11-2.51 (m, 1H), 2.75-2.98 (m, 8H), 3.02-3.33 (m, 10H), 3.80 (t, J = 5.2 Hz, 2H), 
4.17 (d, J = 14.7 Hz, 1H), 5.68 (d, J = 14.6 Hz, 1H), 6.28 (s, 4H), 6.99-7.19 (m, 8H).13C NMR (MeOH-
d4): δ 32.18, 32.34, 35.61, 51.31, 52.49, 53.67, 54.17, 57.08, 59.53, 127.34, 128.98, 129.13, 129.66, 
130.11, 130.58, 131.16, 132.57, 134.38, 135.67, 140.82, 140.96, 141.69, 170.00, 172.34. Anal. RP-
HPLC Ic: tR = 3.86 min (purity 100%), IIe: tR = 6.00 min (purity 100%). HRMS (EI) m/z calcd for 
C24H31N3O2: 393.2416; found: 393.2408. 
 
Pharmacology 
[125I]CCL5 binding experiments and [3H]inositol phosphate accumulation assays were performed as 
previously described in the literature.29  
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Novel 2-benzyl-2,3-dihydro-1H-inden-1-amines as inverse agonists for 
the chemokine receptor US28 
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P. de Esch, Martine J. Smit and Rob Leurs 
 
Abstract 
Screening of our in-house compound collection afforded 1a {2-(2,4-
dichlorobenzyl)-2,3-dihydro-1H-inden-1-amine} as a novel inverse agonist 
acting on the human cytomegalovirus-encoded receptor US28. The structure of 
compound 1a provided some interesting points for lead optimization. Firstly, the 
influence of the two chloro substituents was investigated by the introduction of 
different substitutions in the benzyl group of 1a. Secondly, a series of analogues 
with various cyclic ring systems or small groups attached to the amine group 
were synthesized. Pharmacological characterization of these analogues revealed 
that 2,4-dichloro substitution in the benzyl group is preferred. All compounds 
with other substitution patterns in the benzyl ring were found to be less potent. 
Moreover, incorporation of the nitrogen atom of 1a into different ring systems, 
namely a 4-(4-chlorophenyl)piperidin-4-ol moiety, a piperidine ring or a N-
methylpiperazine group, is allowed in the structure. 
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Introduction 
G protein-coupled receptors are a large family of cell-surface proteins that play 
important roles in the signal transduction in cells by the transmission of 
extracellular signals into intracellular responses. The GPCR family has emerged 
as one of the most important targets for therapeutic intervention, and currently 
many known marketed drugs are targeted on GPCRs.1 Several herpesviruses 
have pirated cellular GPCR-encoding genes and modified their functional 
properties for their own benefit. Especially chemokine receptors have been 
pirated from their host to be incorporated in the viral genome to affect 
chemokine signaling to guarantee replication and survival of the virus. Only a 
couple of these viral GPCRs (vGPCRs) have so far been demonstrated to be 
functional chemokine receptors in respect of signal transduction and chemokine 
binding properties.2 In contrast to their mammalian homologues, several of 
these vGPCRs activate various signaling pathways in a constitutively active 
manner. This ligand-independent signaling of several vGPCRs and the putative 
roles of chemokines and chemokine receptors in inflammatory diseases and 
tumour metastasis indicates that viral-encoded chemokine receptors may play 
an important role in virus-associated diseases.3,4  
 
The genome of human cytomegalovirus (HCMV) encodes several GPCRs,5-7 of 
which US28 is currently the most extensively characterized. Infection with HCMV 
has been associated with vascular diseases,8 severe birth defects,9 inflammatory 
and autoimmune diseases10 as well as cancer.11,12 The exact role of US28 during 
viral infection has not been elucidated yet, but the receptor has been shown to 
exhibit several interesting pharmacological features. The 30% amino acid 
sequence homology13 of US28 with the human CCR1 chemokine receptor 
suggests that the virus exploits chemokine signal transduction pathways to 
intervene in the host immune system through chemokine mimicry.14 US28 can 
bind a number of inflammatory CC chemokines13,15,16 and eliminates them 
efficiently from the extracellular environment via constitutive receptor 
internalization, thereby escaping immune surveillance.17,18 Moreover, the high 
affinity binding of the membrane-bound CX3C chemokine CX3CL1 is suggested 
to play a role in the cell to cell transfer of HCMV.19 Another potential way of 
spreading the virus through the human body is via the migration of vascular 
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smooth muscle cells by US28 upon binding of the CC chemokines CCL2 and 
CCL5.20 The migration of smooth muscle cells plays a significant role in the 
formation of atherosclerotic and restenotic lesions, thereby providing a possible 
link between HCMV and the development of vascular diseases. Additionally, 
US28 is suggested to play a role in the dissemination of the HIV-1 virus through 
the body by its in vitro co-receptor activity.21 Recently, it was discovered that 
US28 might act as a viral oncogene by causing transformations and promoting 
tumorigenesis in mice.22 The constitutive signaling of US28 was shown to be of 
importance in the early beginning of tumor formation. Mice that were injected 
with NIH-3T3 cells stably transfected with the US28-R129A mutant receptor, 
which lacks constitutive signaling, showed a delayed and attenuated tumor 
formation, further emphasizing the physiological relevance of the ligand-
independent signaling after viral infection. 
 
In summary, US28 has been shown to display many interesting features in vitro, 
thereby providing a causative link between US28 and several diseases resulting 
from infection with HCM. However, the lack of in vivo models hampers the 
analysis of the function of US28 in physiological relevant systems so far.  
 
To further investigate the relevance of the constitutive signaling of US28 during 
viral infection we were aiming to identify inverse agonists that are able to inhibit 
the ligand-independent signaling of the receptor. These molecules are valuable 
tools in elucidating the role of US28 in the aforementioned pathologies related to 
HCMV infection. Previously, VUF2274 was identified as the very first inverse 
agonist acting on the viral-encoded receptor US28 with IC50 and EC50 values of 
4.9 and 3.2 µM (Figure 1).23  
 
Cl
Cl
NH2
1a
N
OH
Cl
CN
VUF2274  
 
Figure 2. Chemical structures of VUF2274 and hit compound 1a. 
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Interestingly, this molecule was able to inhibit the US28-mediated HIV entry in 
cells when cotransfected with CD4. Subsequent lead optimization of VUF2274 
resulted in the disclosure of the very first structure-activity relationships for 
inverse agonism on US28.24,25 Novel chemotypes could provide new 
opportunities for the development of potent and selective inverse agonists, 
eventually leading to promising therapeutics for clinical anti-viral intervention. 
Thus, a selection of our in-house compound collection was screened (Chapter 5) 
and this resulted in the identification of Z193 (1a) as a novel inverse agonists 
for the HCMV-encoded receptor US28 (Figure 1). In this study, a series of 
analogues of compound 1a was synthesized to explore the first structure-
activity relationships for the interaction of these promising novel inverse 
agonists targeting the HCMV-encoded receptor US28.  
 
Chemistry 
A general synthetic route for the preparation of compounds 1a-1n is outlined in 
Scheme 1. The substituted 2-(phenylmethylene)-2,3-dihydro-1H-inden-1-ones 3 
were synthesized in high yields by treating indanones 2 with the appropriate 
substituted benzaldehydes in a saturated solution of K2CO3 in EtOH.
26 Reduction 
of both the carbonyl group as well as the double bond of intermediates 3 in one 
pot with lithium aluminium hydride was not successful. Therefore, hydrogenation 
of the double bond and subsequent reduction of the carbonyl group with sodium 
borohydride afforded the substituted 2-benzyl-2,3-dihydro-1H-inden-1-ols 4 as 
1:1 mixture of both diastereomers in moderate to high yields. Intermediates 4 
were converted to the corresponding 1-azido-2-benzyl-2,3-dihydro-1H-indenes 
5 in the presence of diphenyl phosphorazidate (DPPA) and 2,3,4,6,7,8,9,10-
octahydropyrimidol[1,2-a]azepine (DBU) in THF.27,28 For some of the azide 
intermediates it was possible to separate the two diasteromers via column 
purification. Hydrogenation of the azide group with palladium on activated 
carbon afforded target compounds 1a-1h (Method A). The separation of the two 
diastereomers could not be accomplished after the last step of the synthesis 
route.  
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Scheme 1. Synthetic pathway for the synthesis of 1a-1n. Reagents and conditions: (a) K2CO3, EtOH; 
(b) 10% Pd/C, H2, MeOH; (c) NaBH4, MeOH; (d) DPPA, DBU, THF; (e) 10% Pd/C, H2, MeOH; (f) SOCl2, 
DCM; (g) Amine, NaI, CH3CN, 90°C. 
 
Treatment of 2-benzyl-2,3-dihydro-1H-inden-1-ol derivatives 4 with thionyl 
chloride gave a 1:1 mixture of the two diastereomers of 1-chloro-2-(2,4-
dichlorobenzyl)-2,3-dihydro-1H-indenes 6 in a quantitative yield. Alkylation of 
chloro derivatives 6 with the appropriate amine groups in the presence of NaI, 
Na2CO3, and CH3CN at reflux temperature or in the microwave, as described in 
Chapter 3, gave mainly elimination of HCl.25 However, N-alkylation of the 
different commercially available amines with chloro intermediates 6 was 
successful by heating the corresponding amine in CH3CN to reflux temperature 
in the presence of Na2CO3 and NaI and subsequent addition of the appropriate 
chloride 6 when reflux temperature was reached. This resulted in the synthesis 
of target compounds 1i-n in moderate to low yields (Method B). This synthesis 
route resulted in the formation of only one diastereomer of the desired 
compounds. Most likely, the nucleophiles, e.g. N-methylpiperazine, are sterically 
less hindered if they approach the 5-membered ring of intermediates 6 opposite 
the 2,4-dichlorobenzyl group, as in (1R,2S)-6 and (1S,2R)-6. This SN2 
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substitution reaction gives inversion of configuration, resulting in the formation 
of (1R,2R)-1m and (1S,2S)-1m. Approach of the amine from the other side, as 
in (1R,2R)-6 and (1S,2S)-6, is less favourable, giving presumably elimination of 
HCl instead of reaction to the desired product. Unfortunately, additional 2D NMR 
studies to characterize the different diastereomers were not successful and could 
not be used to prove the hypothesis.  
 
Results and discussion 
To identify novel inverse agonist for US28, a selection of compounds from our 
in-house database was screened for their ability to modulate the basal signaling 
of the receptor. This resulted in the identification of compound 1a as a novel 
nonpeptidergic inverse agonist acting on US28. Starting from this, a series of 
analogues of compound 1a were synthesized, which were evaluated for their 
potential to dose-dependently displace [125I]CCL5 binding to US28. The inverse 
agonistic properties of a selection of compounds were investigated by testing 
their potential to inhibit the US28-mediated constitutive inositol phosphate 
production in SVEC4-10 cells.  
 
Table 1. Chemical structures and pharmacological properties of compounds 1a-1h for the HCMV-
encoded receptor US28. The values are represented as the mean and the interval of the IC50 and EC50 
values of at least three independent experiments. 
 
NH2
R  
 
no. Code or VUF number R IC50 (µM)a EC50 (µM)b 
1a Z193 2,4-Cl2 9.5 (6.8 – 12.3) 11.1 (8.3 – 13.8) 
1b VUF10482 2,4-Me2 17.7 (14.5 – 20.9) 13.7 (9.1 – 18.2) 
1c VUF10481 2,4-(OMe)2 > 100 > 100 
1d VUF10486 2-OMe 37.3 (28.8 – 45.7) 42.7 (41.7 – 43.7) 
1e VUF10478 4-OMe > 100 > 100 
1f VUF10476 3-Me-4-OMe 59.7 (50.1 – 69.2) 16.4 (14.1 – 18.6) 
1g VUF10480 4-NH(C=O)CH3 > 100 > 100 
1h VUF10477 H 80.6 (32.4 – 128.8) > 100 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production.  
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The influence of the substitution pattern of the benzyl group was investigated in 
compounds 1b-1h (Table 1). Interestingly, all the compounds with variations in 
the benzyl group, including the unsubstituted analogue 1h, are found to be less 
potent. Replacements of the electron donating chloro substituents of 1a by 
electron releasing methyl groups (1b) results in a small decrease in binding 
affinity. However, introduction of the two methoxy groups in compound 1c is not 
allowed to maintain affinity or efficacy on US28. To investigate the influence of 
the position of the methoxy groups compounds 1d and 1e were synthesized. 
Introduction of a methoxy group at the ortho position of the phenyl ring (1d) 
only causes a 3-fold drop in binding affinity and efficacy compared to lead 
compound 1a, while a methoxy group in the para position results in a complete 
loss of activity for the receptor. Interestingly, introduction of an additional 
methyl group at the meta position of the phenyl ring results in a partial recovery 
of the binding affinity, while the efficacy is comparable to lead compound 1a.  
 
The influence of an acetamide group at the para position of the phenyl ring was 
investigated by the synthesis of analogue 1f. As can be seen in Table 1, it 
seems that this substituent is not permitted at this position. Removal of all 
substituents in the phenyl ring (1h) is not beneficial for activity either, as this 
compound has a more than 7-fold lower binding affinity than lead compound 1a. 
Taken together, several analogues were synthesized to optimize the substitution 
pattern in the benzyl group of lead compound 1a, but all variations in this part 
of the molecule did not improve the binding affinity or activity on US28. 
 
To study the importance of the amine group of hit compound 1a, different cyclic 
ring systems or small groups were introduced (Table 2). Introduction of the 
unsaturated tetrahydropyridine moiety in 1i results in a complete loss of affinity 
and activity, while incorporation of the nitrogen atom into other ring systems, 
e.g. in a 4-(4-chlorophenyl)piperidin-4-ol moiety (1j) or a piperidine ring (1k) 
leads to a binding affinity comparable to compound 1a. Previously, the same 
effect in binding affinity between 4-(4-chlorophenyl)piperidin-4-ol substitution 
and a tetrahydropyridine moiety was observed in VUF2274 analogues.24 
Interestingly, small improvements in efficacy are observed for both 1j and 1k 
compared to lead compound 1a. 
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Table 2. Chemical structures and pharmacological properties of compounds 1a and 1i-1n for the 
HCMV-encoded receptor US28. The values are represented as the mean and the interval of the IC50 
and EC50 values of at least three independent experiments. 
 
R
Cl
Cl  
 
no. Code or VUF number          R1 IC50 (µM)a EC50 (µM)b 
1a Z193 NH2  
9.5 (6.8 – 12.3) 11.1 (8.3 – 13.8) 
1i 10385 N Cl
 
> 100 > 100 
1j 10384 N Cl
OH
 
11.0 (10.0 – 12.0) 6.0 (4.0 – 7.9) 
1k 10356 N
 
13.4 (11.2 – 15.5) 2.6 (2.1 – 3.0) 
1l 10357 N N
 
> 100 > 100 
1m 10386 N N
 
8.1 (6.6 – 9.5) 12.1 (9.1 – 15.1) 
1n 10419 
NH  
 
> 100 > 100 
a [125I]CCL5 displacement. b Inhibition of [3H]inositol phosphate production.  
 
Introduction of the N-phenylpiperazine moiety in analogue 1l is detrimental for 
the binding affinity and efficacy, while the smaller N-methylpiperazine group in 
1m results in a compound with an activity comparable to compound 1a. 
Attachment of a benzyl group to the nitrogen atom as in 1n is not allowed to 
maintain binding affinity or efficacy on the receptor. 
 
In summary, incorporation of the nitrogen atom of 1a into several ring systems, 
such as a 4-(4-chlorophenyl)piperidin-4-ol group, a piperidine ring or a N-
methylpiperazine moiety, is permitted in the structure. In contrast, the 
introduction of the tetrahydropyridine moiety in 1i, the N-phenylpiperazine 
group in 1l and the benzyl substitution in 1n are not allowed and cause a 
complete drop in affinity anf efficacy. 
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Conclusions 
Screening of our in-house compound collection resulted in the identification of 
Z193 (1a) as a novel scaffold for inverse agonism on the viral-encoded receptor 
US28. To explore the first structure-activity relationships of these novel 2-
benzyl-2,3-dihydro-1H-inden-1-amines different analogues were synthesized 
and pharmacologically evaluated. This hit optimization of 1a revealed that 2,4-
dichloro substitution in the benzyl group is prefered, as all compounds with 
other variations in the substitution pattern were found to be less potent. 
Moreover, incorporation of the nitrogen atom of 1a into a 4-(4-
chlorophenyl)piperidin-4-ol moiety, a piperidine ring or a N-methylpiperazine 
group, is allowed to maintain affinity and efficacy. These ligands possess an 
interesting new scaffold for inverse agonism on US28 and may provide useful 
information about ligand-receptor interactions that are important for binding and 
efficacy on the receptor. 
 
Experimental section 
General procedures. THF and DCM were freshly distilled from lithium aluminium hydride. All reactions 
were performed under an atmosphere of dry nitrogen. Microwave reactions were performed in a CEM 
Explorer single mode MW reactor equipped with auto sampler. 1H NMR and 13C NMR spectra were 
recorded on a Bruker AC-200 (200 MHz) spectrometer. J.T. Baker silica gel was used for flash 
chromatography. HRMS mass spectra were recorded on a Finnigan MAT 900 mass spectrometer by 
electron ionization (EI) mass spectrometry or on a Shimadzu IT TOF (ion trap – time-of flight) mass 
spectrometer by electron spray ionization (ESI) mass spectrometry. Melting points were measured on a 
MPA100 OptiMelt automated melting point system apparatus and were uncorrected. Analytical HPLC-MS 
analyses were conducted using a Shimadzu LC-8A preparative liquid chromatograph pump system with 
a Shimadzu SPD-10AV UV-VIS detector set at 254 nm, with the MS detection performed with a 
Shimadzu LCMS-2010 liquid chromatograph mass spectrometer. The analyses were performed using 
the following conditions; condition I: a Xbridge(C18)5um column (100 mm x 4.9 mm) with 60% MeOH 
- 40% H2O-0.1% formic acid (Method Ia); 50% MeOH - 50% H2O-0.1% formic acid (Method Ib), 40% 
MeOH - 50% H2O-0.1% formic acid (Method Ic) or 30% MeOH - 70% H2O-0.1% formic acid (Method 
Id). Flow rate = 1.0 mL/min. Total run time 15 min unless otherwise stated. Condition II: a 
Xbridge(C18)5um column (100 mm x 4.9 mm) with 50% CH3CN - 50% H2O-0.1% formic acid (Method 
IIa); 40% CH3CN - 60% H2O-0.1% formic acid (Method IIb) or 30% CH3CN - 70% H2O-0.1% formic 
acid (Method IIc). Flow rate = 1.0 mL/min. Total run time 20 min. Condition III: a Xbridge(C18)5um 
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column (100 mm x 4.9 mm) with 60% CH3CN - 40% H2O with 10 % NH4HCO3/NH4OH buffer pH 8 
(Method IIIa) or 50% CH3CN - 50% H2O-0.1% formic acid (Method IIIb). Flow rate = 1.0 mL/min. Total 
run time 20 min. Compounds that were isolated as fumaric acid salts all showed an extra peak around 
two minutes. Fumaric acid blancs were used to determine the tR of fumaric acid. Purities calculated are 
based on RP HPLC-UV peak surface area of the compounds (disregarding the fumaric acid peak). 
Compound 1a was taken from our in-house database. 
 General method A for the synthesis of target compounds 1a-1h. 2-(2,4-Dimethylbenzyl)-
2,3-dihydro-1H-inden-1-amine hydrochloride (1b). (i) 2,4-Dimethylbenzaldehyde (1.67 g, 10.0 
mmol) and 1-indanone (1.33 g, 10.0 mmol) were added to a saturated solution of anhydrous K2CO3 in 
EtOH (25 mL).The resulting reaction mixture was stirred vigorously for 24 h, 37% HCl (2 mL) was 
added and the solvent was evaporated in vacuo. Water (50 mL) was added and the water layer was 
extracted with DCM (3 x 25 mL). The combined organic extracts were washed with brine (50 mL), dried 
over anhydrous Na2SO4, filtered and evaporated in vacuo. The residue was recrystallized from EtOH to 
give 1.95 g (79%) of 2-(2,4-dimethylbenzylidene)-2,3-dihydro-1H-inden-1-one as white crystals. 1H 
NMR (CDCl3): δ 2.33 (s, 3H), 2.43 (s, 3H), 3.95 (s, 2H), 6.98-7.11 (m, 2H), 7.31-7.60 (m, 3H), 7.80-
7.95 (m, 2H). 
(ii) A suspension of 2-(2,4-dimethylbenzylidene)-2,3-dihydro-1H-inden-1-one (1.14 g, 5.49 mmol) and 
10% Pd/C (5 mg) in MeOH (10 mL) was hydrogenated with H2 (atmospheric pressure) for 18 h. The 
reaction mixture was filtrated over Hyflo and the residue was washed with EtOH. The filtrate was 
evaporated in vacuo to give 2-(2,4-dimethylbenzyl)-2,3-dihydro-1H-inden-1-one in a quantitative yield. 
1H NMR (CDCl3): δ 2.28 (s, 3H), 2.30 (s, 3H), 2.41-2.59 (m, 1H), 2,72-3.05 (m, 2H), 3.10-3.22 (m, 
1H), 3.37 (dd, J = 10.4 Hz and 3.9 Hz, 1H), 6.81-7.01 (m, 3H), 7.25-7.41 (m, 2H), 7.54 (d, J = 7.5 
Hz, 1H), 7.77 (d, J = 7.6 Hz, 1H). 
(iii) A solution of 2-(2,4-dimethylbenzyl)-2,3-dihydro-1H-inden-1-one (1.15 g, 4.59 mmol) and NaBH4 
(0.17 g, 4.59 mmol) in MeOH (10 mL) was stirred overnight at room temperature. The reaction mixture 
was evaporated in vacuo, water was added (25 mL) and the water layer was extracted with EtOAc (3 x 
20 mL). The combined organic extracts were washed with water (3 x 25 mL) and brine (25 mL), dried 
over anhydrous Na2SO4, filtered and evaporated in vacuo to give a quantitative yield of 2-(2,4-
dimethylbenzyl)-2,3-dihydro-1H-inden-1-ol as a 1:1 mixture of two diastereomers. 1H NMR (CDCl3): δ 
1.70 (br s, 1H), 2.30 (s, 6H), 2.35-2.88 (m, 3H), 2.98-3.12 (m, 2H), 4.83-5.01 (m, 1H), 6.89-7.01 (m, 
2H), 7.04-7.41 (m, 6H). 
(iv) A solution of 2-(2,4-dimethylbenzyl)-2,3-dihydro-1H-inden-1-ol (1.15 g, 4.59 mmol) and DPPA 
(1.39 mL, 6.41 mmol) in THF (10 mL) was stirred for 10 min, cooled to 0 °C and DBU (0.98 mL, 6.42 
mmol) was added in a drop wise manner. The reaction mixture was allowed to warm to room 
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temperature and stirred for 18 h. The solvent was evaporated in vacuo, water (25 mL) was added and 
the water layer was extracted with Et2O (3 x 15 mL). The combined organic extracts were washed with 
brine (25 mL), dried over anhydrous Na2SO4, filtered and evaporated in vacuo. Purification by column 
chromatography (hexane) afforded 763 mg (60%) of 1-azido-2-(2,4-dimethylbenzyl)-2,3-dihydro-1H-
indene as a 1:1 mixture of two diastereomers. 1H NMR (CDCl3): δ 2.29 (s, 3H), 2.30 (s, 3H), 2.51-2.84 
(m, 4H), 2.90-3.11 (m, 1H), 4.52 and 4.70 (d, J = 4.7 and 5.0 Hz, 1H), 6.87-7.03 (m, 3H), 7.11-7.39 
(m, 4H). 
(v) A solution of 1-azido-2-(2,4-dimethylbenzyl)-2,3-dihydro-1H-indene (0.76 g, 2.74 mmol) and 10% 
Pd/C (3 mg) in MeOH (10 mL) was hydrogenated with H2 (atmospheric pressure) for 3 days. The 
reaction mixture was filtrated over Hyflo, the residue was washed with EtOH and the filtrate was 
evaporated in vacuo. Purification by flash chromatography (2% Et3N in hexane) gave 646 mg of the 
free base. This was dissolved in a solution of HCl gas in EtOH and the solvent was evaporated in vacuo. 
The hydrochloride salt was isolated by filtration and recrystallized from Et2O/MeOH to give 665 mg 
(84%) of 1b as a 1:1 mixture of two diastereomers. 1H NMR (MeOH-d4): δ 2.30 (s, 3H), 2.33 (s, 3H), 
2.61-3.18 (m, 5H), 4.51 and 4.83 (d, J = 3.5 and 6.0 Hz, 1H), 6.92-7.15 (m, 3H), 7.21-7.40 (m, 3H), 
7.49-7.63 (m, 1H). 13C NMR (MeOH-d4): δ 18.64, 20.02, 31.51, 35.25, 35.87, 43.08, 58.19, 125.44, 
125.73, 126.78, 127.33, 129.29, 129.96, 131.25, 134.43, 136.07, 136.21, 138.73, 143.83 (one 
diastereomer). 13C NMR (MeOH-d4): δ 17.38, 18.59, 31.51, 35.25, 35.87, 45.21, 60.52, 125.18, 
125.31, 127.48, 129.66, 131.27, 134.49, 136.27, 136.30, 137.94, 143.58 (other diastereomer). Anal. 
RP-HPLC Ia (total run time 30 min): tR = 12.89 min (purity 100%), IIb: tR = 11.79, 12.79 min (purity 
100%). HRMS (EI) m/z calcd for C18H21N: 251.1674; found: 251.1665. 
 2-(2,4-Dimethoxybenzyl)-2,3-dihydro-1H-inden-1-amine hydrochloride (1c). Yield: 539 g 
(17% yield over 5 steps) of 1c as a 1:1 mixture of two diastereomers. 1H NMR (MeOH-d4): δ 2.58-3.14 
(m, 5H), 3.78 and 3.79 (s, 3H), 3.81 and 3.82 (s, 3H), 4.43 and 4.69 (d, J = 4.1 and 5.8 Hz, 1H), 
6.45-6.57 (m, 2H), 7.02-7.52 (m, 5H). 13C NMR (MeOH-d4): δ 35.44, 35.79, 45.35, 54.82, 54.84, 
54.91, 57.98, 98.55, 104.89, 119.62, 125.36, 125.41, 127.24, 129.95, 131.31, 138.83, 144.09, 
158.89, 160.45 (one diastereomer). 13C NMR (MeOH-d4): δ 28.70, 32.75, 43.45, 54.82, 54.84, 54.91, 
60.26, 98.50, 104.61, 119.77, 124.92, 125.59, 127.32, 129.80, 130.80, 138.12, 143.62, 158.54, 
160.52 (other diastereomer). Anal. RP-HPLC Ia : tR = 8.47 and 9.81 min (purity 100%), IIIb: tR = 5.29 
and 5.61 min (purity 100%). HRMS (EI) m/z calcd for C18H21NO2: 283.1572; found: 283.1582. 
 2-(2-Methoxybenzyl)-2,3-dihydro-1H-inden-1-amine hydrochloride (1d). Yield: 439 mg 
(17% yield over 5 steps) of one diastereomer of 1d as a white solid. 1H NMR (MeOH-d4): δ 2.52-2.80 
(m, 2H), 2.85-3.15 (m, 3H), 3.85 (s, 3H), 4.71 (d, J = 5.9 Hz, 1H), 6.89-6.97 (m, 2H), 7.01-7.36 (m, 
5H), 7.50 (d, J = 6.6 Hz, 1H). 13C NMR (MeOH-d4): δ 30.37, 36.41, 44.21, 55.82, 59.00, 111.76, 
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121.82, 126.30, 126.43, 128.28, 128.54, 129.17, 131.01, 131.43, 139.80, 145.96, 158.71. RP-HPLC 
Ib: tR = 4.19 min (purity 100%), IIb: tR = 3.95 min (purity 100%). HRMS (EI) m/z calcd for C17H19NO: 
253.1467; found: 253.1476. 
 2-(4-Methoxybenzyl)-2,3-dihydro-1H-inden-1-amine hydrochloride (1e). Yield: 439 mg 
(19% yield over 5 steps) of 1e as a 1:1 mixture of two diastereomers. 1H NMR (MeOH-d4): δ 2.51-3.29 
(m, 5H), 3.77 (s, 3H), 3.79 (s, 3H), 4.49 and 4.77 (d, J = 3.9 and 6.2 Hz, 1H), 6.80-6.94 (m, 2H), 
7.08-7.52 (m, 6H). 13C NMR (MeOH-d4): δ 35.89, 38.28, 46.58, 54.73, 60.39, 114.14, 125.03, 125.67, 
127.44, 129.75, 130.06, 131.55, 137.93, 143.47, 158.92 (one diastereomer). 13C NMR (MeOH-d4): δ 
34.12, 35.33, 44.47, 54.73, 58.08, 114.11, 125.35, 125.46, 127.34, 129.92, 129.98, 131.49, 138.73, 
143.82, 158.92 (other diastereomer). RP-HPLC Ib: tR = 5.73 min (purity 100%), IIc: tR = 5.48 min 
(purity 96%). HRMS (EI) m/z calcd for C17H19NO: 253.1467; found: 253.1459. 
 2-(4-Methoxy-3-methylbenzyl)-2,3-dihydro-1H-inden-1-amine hydrochloride (1f). Yield: 
470 mg (20% yield over 5 steps) of one diastereomer of 1g as a white solid. 1H NMR (MeOH-d4): δ 2.42 
(s, 3H), 2.42-3.09 (m, 5H), 3.80 (s, 3H), 4.77 (d, J = 6.0 Hz, 1H) 6.82-7.54 (m, 7H). 13C NMR (MeOH-
d4): δ 15.35, 34.14, 35.37, 44.48, 54.84, 58.09, 110.21, 125.30, 125.46, 126.72, 131.04, 127.05, 
127.31, 129.96, 130.89, 138.78, 143.86, 156.94. Anal. RP-HPLC Ia: tR = 4.56 min (purity 100%), IIa: 
tR = 4.33 min (purity 99%). HRMS (EI) m/z calcd for C18H21NO: 267.1623; found: 267.1623. 
 2-(4-Methoxy-3-methylbenzyl)-N-(4-((1-amino-2,3-dihydro-1H-inden-2-yl)methyl)-
phenyl)acetamide (1g). Yield: 581 mg (23% yield over 5 steps) of 1f as a 1:5 mixture of two 
diastereomers. (MeOH-d4): δ 2.10 (s, 3H), 2.20-2.34 (m, 1H), 2.41-77 (m, 2H), 2.81-2.92 (m, 1H), 
3.00-3.15 (m, 1H), 3.98 and 4.28 (d, J = 7.6 and 7.8 Hz, 1H), 6.98-7.51 (m, 8H). 13C NMR (MeOH-d4): 
δ 22.73, 36.38, 38.92, 52.76, 61.76, 120.45, 123.50, 124.48, 126.56, 127.41, 129.28, 136.94, 
137.22, 141.91, 146.11, 170.55 (major diastereomer). 13C NMR (MeOH-d4): δ 22.73, 34.10, 35.19, 
46.63, 58.46, 120.32, 124.23, 124.65, 124.77, 127.63, 129.17, 136.82, 137.34, 141.91, 146.11, 
170.55 (minor diastereomer). RP-HPLC Id (total run time 30 min): tR = 10.42 min (minor 
diastereomer), 13.62 min (major diastereomer) (purity 100%), IId: tR = 5.21 min (minor 
diastereomer), 6.22 min (major diastereomer) (purity 100%). HRMS (EI) m/z calcd for C18H20N2O: 
280.1576; found: 280.1571.  
 2-Benzyl-2,3-dihydro-1H-inden-1-amine hydrochloride (1h). Yield: 350 mg (14% yield over 
5 steps) of one diastereomer of 1h as a white solid. 1H NMR (MeOH-d4): δ 2.52-2.66 (m, 1H), 2.70-
3.05 (m, 3H), 3.09-3.20 (m, 1H), 4.79 (d, J = 6.4 Hz, 1H), 7.25-7.55 (m, 9H). 13C NMR (MeOH-d4): δ 
35.03, 35.29, 44.29, 58.13, 125.29, 125.47, 125.61, 127.37, 128.73, 128.80, 130.02, 138.68, 139.59, 
143.77. RP-HPLC Ib: tR = 5.52 min (purity 100%), IIc: tR = 5.94 min (purity 97%), IIIa: tR = 3.37 min 
(purity 99%). HRMS (EI) m/z calcd for C16H17N: 223.1361; found: 223.1363. 
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 General method B for the synthesis of target compounds 1i-1n. 1-(2-(2,4-
Dichlorobenzyl)-2,3-dihydro-1H-inden-1-yl)piperidine (1k) (i) 2,4-Dichlorobenzaldehyde (17.5 g, 
100 mmol) and 1-indanone (13.2 g, 100 mmol) were added to a saturated solution of anhydrous K2CO3 
in EtOH (250 mL). The resulting reaction mixture was stirred vigorously for 18 h and 37% HCl (20 mL) 
was added. The precipitate was isolated by filtration, washed with water and dried under vacuum to 
give 25.8 g (89%) of 2-(2,4-dichlorobenzylidene)-2,3-dihydro-1H-inden-1-one as white crystals. 1H 
NMR (CDCl3): δ 3.92 (s, 2H), 7.12-7.66 (m, 5H), 7.80-7.99 (m, 2H). 
(ii) A suspension of 2-(2,4-dichlorobenzylidene)-2,3-dihydro-1H-inden-1-one (11.6 g, 40.1 mmol) and 
10% Pd/C (40 mg) in MeOH (100 mL) was hydrogenated with H2 (atmospheric pressure) for 6 h at a 
temperature of 50 °C. The reaction mixture was filtrated over Hyflo and the filtrate was evaporated in 
vacuo. Recrystallization from EtOH afforded 4.6 g (39%) of 2-(2,4-dichlorobenzyl)-2,3-dihydro-1H-
inden-1-one as white crystals. 1H NMR (CDCl3): δ 2.65-2.88 (m, 2H), 2.95-3.20 (m, 2H), 3.27-3.40 (m, 
1H), 7.06-7.20 (m, 2H), 7.26-7.40 (m, 3H), 7.56 (t, J = 7.4 Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H). 
(iii) A solution of 2-(2,4-dichorolbenzyl)-2,3-dihydro-1H-inden-1-one (1.86 g, 6.40 mmol) and NaBH4 
(0.17 g, 4.59 mmol) in MeOH (40 mL) was stirred for 3 h at room temperature. The reaction mixture 
was evaporated in vacuo, water was added (20 mL) and the water layer was extracted with EtOAc (3 x 
15 mL). The combined organic extracts were washed with water (3 x 25 mL) and brine (25 mL), dried 
over anhydrous Na2SO4, filtered and evaporated in vacuo to give 1.84 (98%) of 2-(2,4-dichlorobenzyl)-
2,3-dihydro-1H-inden-1-ol as a 1:1 mixture of two diastereomers. 1H NMR (CDCl3): δ 1.72 (br s, 1H), 
2.41-3.02 (m, 5H), 4.92 (br s, 1H), 7.16-7.38 (m, 7H). 
(iv) Thionyl chloride (0.75 mL, 10.3 mmol) was added to a solution of 2-(2,4-dichlorobenzyl)-2,3-
dihydro-1H-inden-1-ol (1.84 g, 6.28 mmol) in toluene (30 mL) at 0 °C. The reaction mixture was 
stirred at room temperature for 30 min, heated to 55 °C and stirred for 1 h. The solution was cooled to 
room temperature, washed with ice-water (2 x 15 mL), dried over anhydrous Na2SO4, filtered and 
evaporated in vacuo to give 1.88 g (96%) of 1-chloro-2-(2,4-dichlorobenzyl)-2,3-dihydro-1H-indene as 
a 1:1 mixture of two diastereomers. 1H NMR (CDCl3): δ 2.55-3.29 (m, 5H), 5.10 and 5.27 (d, J = 5.3 
and 4.8 Hz, 1H), 7.08-7.41 (m, 7H). 
(v) A solution of piperidine (70 µL, 0.71 mmol), NaI (75 mg, 0.50 mmol), and Na2CO3 (106 mg, 1.0 
mmol) in CH3CN (10 mL) was heated to reflux temperature and 1-chloro-2-(2,4-dichlorobenzyl)-2,3-
dihydro-1H-indene (0.16 g, 0.51 mmol) in CH3CN (1 mL) was added. The reaction mixture was refluxed 
overnight, the solvent was removed in vacuo and the residue was diluted with water (15 mL) followed 
by an extraction with DCM (3 x 10 mL). The combined organic layers were dried over anhydrous NaSO4, 
filtered, and evaporated in vacuo. Purification by flash chromatography (25% EtOAc in DCM) and 
recrystallization from EtOAc gave 90 mg (49%) of 1k as white crystals. 1H NMR (CDCl3): δ 1.29-1.51 
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(m, 6H), 2.29-2.70 (m, 6H), 2.76-2.99 (m, 3H), 3.95 (d, J = 3.4 Hz, 1H), 7.03-7.22 (m, 5H), 7.29-
7.41 (m, 3H). 13C (CDCl3): δ 24.61, 26.41, 37.00, 38.18, 38.80, 50.19, 76.04, 124.50, 125.88, 126.09, 
126.65, 127.38, 129.12, 131.78, 132.15, 134.78, 137.23, 142.58. Anal. RP-HPLC Ib (total run time 30 
min): tR = 19.88 min (purity 100%), IIb (total run time 30 min): tR = 13.77 min (purity 100%). HRMS 
(EI) m/z calcd for C21H23Cl2N: 359.1208; found: 359.1199. 
 4-(4-Chlorophenyl)-1-(2-(2,4-dichlorobenzyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,6-
tetrahydropyridine hydrochloride (1i). Yield: 50 mg (19%) of one diastereomer of 1i as a light 
brown solid. 1H NMR (MeOH-d4): δ 2.61-2.92 (m, 6H), 3.15-3.39 (m, 3H), 3.51-3.81 (m, 2H), 4.61-
4.69 (m, 1H), 6.01-6.07 (m, 1H), 7.31-7.54 (m, 10H), 7.67 (d, J = 7.1 Hz, 1H).13C (MeOH-d4): δ 
26.22, 37.74, 38.29, 40.69, 47.72, 47.83, 75.74, 118.08, 127.30, 127.70, 128.68, 128.96, 129.74, 
130.48, 132.14, 134.00, 134.59, 135.07, 135.83, 136.27, 136.78, 138.51, 146.52. Anal. RP-HPLC Ia 
(total run time 20 min): tR = 13.04 min (purity 99%), IIb: tR = 6.78 min (purity 96%). HRMS (EI) m/z 
calcd for C27H24Cl3N: 469.0945 (second isotope); found: 469.0931. 
 4-(4-Chlorophenyl)-1-(2-(2,4-dichlorobenzyl)-2,3-dihydro-1H-inden-1-yl)piperidin-4-ol 
hydrochloride (1j). Yield: 61 mg (23%) of one diastereomer of 1j as a white solid 1H NMR (MeOH-
d4): δ 1.81-1.92 (m, 4H), 2.50 (br s, 1H), 2.70-3.12 (m, 5H), 3.15-3.36 (4H), 4.41-4.47 (m, 1H), 7.15-
7.48 (m, 10H), 8.00 (s, 1H), 12.08 (br s, 1H). 13C (MeOH-d4): δ 35.03, 35.26, 37.25, 37.94, 38.73, 
44.31, 45.84, 46.37, 69.58, 75.31, 125.81, 126.00, 127.64, 127.97, 128.67, 128.76, 129.60, 131.01, 
132.58, 132.80, 133.54, 133.63, 134.80, 134.83, 144.42, 144.51. Anal. RP-HPLC Ia : tR = 6.19 min 
(purity 100%), IIa (total run time 30 min): tR = 13.45 min (purity 100%). HRMS (EI) m/z calcd for 
C27H26Cl3NO: 485.1080; found:485.1073. 
 1-(2-(2,4-Dichlorobenzyl)-2,3-dihydro-1H-inden-1-yl)-4-phenylpiperazine 
dihydrochloride (1l). Yield: 48 mg (22%) of of one diastereomer of 1l as a white solid. 1H NMR 
(MeOH-d4): δ 2.72-2.97 (m, 3H), 3.05-3.55 (m, 8H), 3.69-3.88 (m 2H), 4.64-4.72 (m, 1H), 6.88-7.08 
(m, 2H), 7.19-7.54 9m, 9H), 7.74 (d, J = 7.2 Hz, 1H). 13C (MeOH-d4): δ 37.56, 38.05, 40.90, 50.58, 
76.79, 118.22, 122.92, 127.46, 128.73, 128.78, 129.44, 130.41, 130.51, 132.52, 133.79, 134.00, 
134.66, 136.28, 136.55, 146.84, 150.63. Anal. RP-HPLC Ia: tR = 7.07 min (purity 100%), IIa: tR = 
4.13 min (purity 98%), IIb (total run time 30 min): tR = 19.11 min (purity 98%). HRMS (EI) m/z calcd 
for C26H26Cl2N2: 436.1473; found: 436.1471. 
 1-(2-(2,4-Dichlorobenzyl)-2,3-dihydro-1H-inden-1-yl)-4-methylpiperazine 
dihydrochloride (1m). Yield: 105 mg (46%) of one diastereomer of 1m as a light yellow solid. 1H 
NMR (MeOH-d4): δ 2.61-3.03 (m, 4H), 2.93 (s, 5H), 3.12-3.87 (m, 8H), 4.55-4.64 (m, 1H), 7.15-7.49 
(m, 6H), 7.72 (d, J = 7.1 Hz, 1H). 13C (MeOH-d4): δ 37.59, 38.05, 40.99, 43.36, 47.18, 51.93, 77.02, 
127.37, 128.72, 129.35, 130.46, 132.33, 133.98, 134.55, 136.27, 136.76, 146.61. Anal. RP-HPLC Ia 
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(total run time 20 min): tR = 12.99 min (purity 95%), IId: tR = 12.70 min (purity 96%). HRMS (EI) m/z 
calcd for  C21H24Cl2N2: 374.1317; found: 374.1311. 
 N-benzyl-2-(2,4-dichlorobenzyl)-2,3-dihydro-1H-inden-1-amine fumarate (1n). Yield: 20 
mg (8%) of one diastereomer of 1n as a white solid. 1H NMR (MeOH-d4): δ 2.69-2.79 (m, 2H), 2.89-
2.95 (m, 1H), 3.02-3.08 (m, 1H), 3.17-3.25 (m, 1H), 4.14-4.21 (m, 2H), 4.62 (d, J = 6.1 Hz, 1H), 
6.68 (s, 2H), 7.27-7.53 (m, 12H). 13C NMR (MeOH-d4): δ 32.41, 36.00, 44.64, 51.56, 65.52, 126.53, 
126.60, 127.91, 128.49, 129.71, 130.01, 130.30, 130.33, 130.51, 133.42, 134.08, 135.48, 135.89, 
136.00, 137.77, 144.58, 170.70. Anal. RP-HPLC Ia: tR = 8.22 min (purity 100%), IIa: tR = 12.37 min 
(purity 97%). HRMS (ESI) m/z calcd for C27H25Cl2NO4: 381.1051; found: 381.1046. 
 
Pharmacology 
[125I]CCL5 binding experiments and [3H]inositol phosphate accumulation assays were performed as 
previously described in the literature.25 
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Summary 
 
Design and synthesis of small nonpeptidergic ligands for the human 
cytomegalovirus-encoded receptor US28 
 
Several large DNA virus families, such as herpesviruses and poxviruses, have 
incorporated chemokine receptors from their hosts into their own viral genome 
to affect chemokine signaling for their own benefit. Only a few of these viral G 
protein-coupled receptors (GPCRs) have so far been demonstrated to be 
functional chemokine receptors with respect to signal transduction and 
chemokine binding properties. The genome of the β-herpesvirus human 
cytomegalovirus (HCMV) encodes several GPCRs, of which US28 is currently the 
most extensively characterized. Infection with HCMV has been linked to 
numerous pathological disorders, such as vascular diseases, transplant rejection, 
HIV, several inflammatory and autoimmune diseases, as well as cancer. 
Currently, the exact role of US28 in the pathogenesis of HCMV infection has not 
been completely elucidated yet, but the receptor has been suggested to play an 
important role in the development of e.g. vascular diseases, HIV and cancer.  
 
US28 is a constitutively active receptor, that signals in absence of any ligand. 
Blocking this viral-encoded GPCR, thereby inhibiting its constitutive signaling, 
could be a new strategy for the development of therapeutics against pathologies 
mediated by HCMV. The ligand-independent signaling of constitutively active 
receptors can be inhibited by inverse agonists, such as 5-(4-(4-chlorophenyl)-4-
hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile (VUF2274). This molecule has 
previously been identified as the very first small nonpeptidergic inverse agonist 
acting on US28.  
 
The work described in this thesis involves the design, synthesis and 
pharmacological characterization of small nonpeptidergic ligands for the HCMV-
encoded chemokine receptor US28. These novel ligands were used to elucidate 
the first structure-activity relationships on US28, resulting in a better 
understanding of the structural requirements that are important for ligand-
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receptor interactions. This was achieved using versatile medicinal chemistry 
approaches, which are addressed in the different chapters of this thesis.  
 
Chapter 1 gives a general introduction about the background and the context of 
this research. A clear survey of the potential roles of US28 is presented and we 
explain why we consider this receptor as a novel potential anti-viral drug target. 
Moreover, a detailed overview of all known US28 ligands and their structure-
activity relationships (SARs) is described followed by the aim of this thesis, 
which is defined at the end of this chapter. 
 
In Chapter 2 the synthesis and structure-activity relationships of the first 
nonpeptidergic inverse agonists for US28 are described. Starting from lead 
compound VUF2274, different structural 
modifications were introduced (see figure). 
Pharmacological evaluation of these ligands 
resulted in the very first structure-activity 
relationships of small nonpeptidergic ligands 
targeting a viral GPCR (US28) and 
demonstrated that a 4-phenylpiperidine moiety in the structure is essential for 
affinity and activity, while the nitrile group could be omitted.  
 
Chapter 3 describes a new series of VUF2274 analogues, in which the rigidity is 
increased by the introduction of conformationally restrained tricyclic ring 
systems or rigid fused and nonfused piperidine 
ring systems. Increasing the rigidity of the propyl 
linker between the diphenyl group and the 
piperidine moiety by introduction of a double bond 
led to a 3-fold improvement in binding affinity 
compared to the lead compound. However, 
replacement of the 4-hydroxy group with a methylamine group was even more 
favourable, as this modification gave a significant 6-fold increase in affinity.  
 
N
OH
Cl
CN
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N
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Although many changes were introduced in the structure of VUF2274, a more 
than 6-fold increase in binding affinity could not be achieved. This prompted the 
question whether more rigorous structural changes where needed to optimize 
US28 affinity. Chapter 4 describes our efforts to discover structurally diverse 
novel inverse agonists using molecular modelling techniques. Molecular 
modelling studies were initiated to design a focused virtual library around the 4-
(4-chlorophenyl)piperidin-4-ol scaffold of VUF2274. Drug-like descriptors were 
applied to calculate a diverse subset of 50 compounds. Parallel chemistry 
approaches were used to synthesize these compounds and 18 ligands could 
easily be isolated. Next to the pharmacological evaluation of these compounds, 
the protocols and limitations of this drug discovery approach were discussed in 
Chapter 4. Pharmacological evaluation of the synthesized compounds revealed 
one compound as as novel inverse agonists acting on US28. All other variations 
attached to 4-(4-chlorophenyl)piperidin-4-ol scaffold resulted in compounds with 
no activity at US28.  
 
Chapter 5 presents the results of our search for novel chemotypes targeting 
US28 by screening a selection of compounds from our in-house compound 
collection. We were aiming to discover new chemotypes for US28, because these 
molecules can provide new opportunities for the development of potent and 
selective ligands, eventually leading to promising therapeutics for clinical anti-
viral intervention. The compounds from our database were selected based on 
the molecular similarity to structures of known ligands acting on US28. This 
resulted in the identification of several interesting ligands, of which some were 
considered as new starting points for lead optimization programs. Moreover, 5-
(3-(4-methylpiperazin-1-yl)propyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine 
(A194) and 2-phenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine 
(B191) were disclosed as the very first small neutral antagonists acting on a 
viral-encoded receptor, providing us with new pharmacological tools to further 
investigate the pharmacological properties of US28. 
 
In Chapter 6, the lead optimization and structure-activity relationships of a 
selection of hits from the database screening is described. Interestingly, 
synthesis of a hybrid compound (VUF10000) containing important structural 
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features of inverse agonist VUF2274 and neutral antagonist A194 and 
subsequent pharmacological characterization of this compound showed that 
replacement of the N-
methylpiperazine group 
of A194 by the 4-(4-
chlorophenyl)piperidin-4-
ol moiety of VUF2274 
(see figure) led to the 
anticipated recovery of 
the inverse agonistic 
properties. Thus, we 
have determined the 
molecular features that 
are responsible for 
intrinsic activity, and in particular inverse agonism versus antagonism. 
Moreover, these structural modifications resulted in a significant 7-fold 
improvement of the binding affinity compared to VUF2274 and A194. These 
ligands give us a better understanding of the structural requirements that are 
necessary for inverse agonism and neutral antagonism. Besides, the possibility 
to modulate the functional activity of US28 can help us to investigate the 
significance of constitutive US28-signaling and the role of the receptor during 
HCMV infection. 
 
Screening of our in-house compound collection, as described in Chapter 5, 
rsulted in the identification of 2-(2,4-dichlorobenzyl)-2,3-dihydro-1H-inden-1-
amine (Z193) as a novel scaffold for inverse agonism on 
US28. Chapter 7 describes the hit optimization of this 
molecule by replacing the two chloro atoms by different 
substituents. Moreover, different cyclic ring systems and 
small groups were introduced at the amine group. The 
synthesis and pharmacological characterization of these compounds resulted in 
the first structure-activity relationships for the ligand-receptor interaction of 
these novel inverse agonists.  
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Taken together, this thesis describes the design and synthesis of small 
nonpeptidergic ligands acting on the HCMV-encoded receptor US28 by means of 
multidisciplinary approaches, such as lead optimization, library screening and 
molecular design techniques. In this study, novel scaffolds for both inverse 
agonism as well as neutral antagonism have been identified. These ligands have 
provided us with more insights in the structural requirements that are important 
for binding and functional activity to US28. Ultimately, this knowledge will help 
us to develop compounds with an improved activity and selectivity profile on 
US28. 
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Samenvatting 
 
Ontwerp en synthese van kleine liganden voor de door humaan 
cytomegalovirus gecodeerde receptor US28 
 
Verschillende DNA virussen, zoals herpesvirussen en pokkenvirussen, hebben 
chemokine receptoren van hun gastheer opgenomen in hun eigen virale genoom 
om het chemokine systeem van de gastheer te ondermijnen. Slechts een klein 
aantal van deze viraal-gecodeerde G-eiwit gekoppelde receptoren (GPCRs) zijn 
ook echt functionele chemokine receptoren, die in staat zijn om chemokines te 
binden en het ‘endogene’ signaal door te geven. Het genoom van het beta-
herpesvirus humaan cytomegalovirus (HCMV) codeert verschillende GPCRs, 
waarvan US28 op dit moment het best gekarakteriseerd is. Veel mensen (50-
90% van de volwassenen) zijn besmet met HCMV. Dit virus heeft alleen ernstige 
gevolgen voor mensen met een verzwakt immuun systeem. Onder die 
omstandigheden kan een infectie met het virus mogelijk bijdragen aan de 
ontwikkeling van hart- en vaatziektes, verschillende ontstekings- en auto-
immuunziektes, kanker en HIV. Op dit moment is de exacte rol van US28 tijdens 
HCMV infectie niet bekend. Wel laten de uitkomsten van verschillende 
farmacologische onderzoeken zien dat US28 een belangrijke rol speelt binnen de 
virale pathofysiologie, bijvoorbeeld in de ontwikkeling van atherosclerose, HIV 
en kanker.  
 
US28 is een constitutief actieve receptor, dat wil zeggen dat de receptor 
geactiveerd is in afwezigheid van chemokine liganden. Blokkeren van deze viraal 
gecodeerde receptor en het daarbij remmen van de constitutieve signalering zou 
een nieuwe strategie kunnen zijn voor de ontwikkeling van geneesmiddelen 
tegen de symptomen van HCMV infectie. De constitutieve signalering van GPCRs 
kan geremd worden door inverse agonisten, zoals 5-(4-(4-chlorophenyl)-4-
hydroxypiperidin-1-yl)-2,2-diphenylpentaannitrile (VUF2274). Dit molecuul is de 
eerste inverse agonist  dat beschreven is voor US28.  
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Het onderzoek dat beschreven is in dit proefschrift is gericht op het ontwerp, 
synthese en farmacologische karakterisatie van kleine niet-peptide liganden voor 
de HCMV gecodeerde chemokine receptor US28. Deze nieuwe liganden zijn 
gebruikt om de allereerste structuur-activiteitsrelaties voor US28 liganden te 
defineren. Deze informatie kan vervolgens gebruikt worden om een beter inzicht 
te krijgen in de moleculaire aspecten van de interactie tussen de liganden en de 
receptor.  
 
Hoofdstuk 1 geeft een algemene inleiding over de achtergronden en context 
waarop dit onderzoek is gebaseerd. Er wordt een overzicht van de mogelijke 
functies van US28 gegeven en er wordt uitgelegd waarom deze receptor 
beschouwd kan worden als een nieuw potentieel target voor anti-virale 
geneesmiddelen. Verder wordt een gedetaileerde beschrijving gegeven van alle 
bekende US28 liganden en hun structuur-activiteitsrelaties. Aan het einde van 
dit hoofdstuk wordt het doel van dit proefschrift beschreven. 
 
In hoofdstuk 2 wordt de synthese en structuur-activiteitsrelaties van de 
allereerste niet-peptide inverse agonisten voor US28 beschreven. Verschillende 
veranderingen werden aangebracht op diverse 
plaatsen in de moleculaire structuur van VUF2274. 
Farmacologische evaluatie van deze liganden 
resulteerde in de allereerste structuur-
activiteitsrelaties van niet-peptide liganden op een 
viraal gecodeerde GPCR (US28) en lieten zien dat 
een 4-phenyl piperidine groep in het moleuul belangrijk is voor affiniteit en 
activiteit, terwijl de nitril groep niet essentieel is.  
 
Hoofdstuk 3 geeft een uiteenzetting van een nieuwe serie van moleculen, waarin 
de rigiditeit van de propyl linker tussen de diphenyl groep en de piperidine ring 
werd verhoogd door het invoeren van een dubbele 
binding. Dit resulteerde in een 3 keer hogere 
bindings affiniteit dan leadverbinding VUF2274. 
Vervanging van de 4-hydroxy groep door een 
methylamine groep was zelfs nog gunstiger, en 
N
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leidde tot een 6 keer hogere affiniteit.  
 
Hoofdstuk 4 beschrijft onze pogingen om betere inverse agonisten met een 
verschillende structuur te identificeren met behulp van moleculaire modelling 
technieken. In hoofdstuk 2 en 3 worden vele derivaten van VUF2274 
beschreven. Geen van deze modificaties in de structuur resulteerde in een 
enorme sprong in affiniteit. Daarom werd besloten om meer rigoreuze 
veranderen aan te brengen in de structuur. Dit werd gedaan door een virtuele 
bibliotheek van verbindingen te ontwerpen met als basis het commercieel 
verkrijgbare 4-(4-chlorophenyl)piperidin-4-ol. Uitgaande van deze verbinding en 
commercieel verkrijgbare reagentia werden in silico alle eindproducten gemaakt. 
Van deze virtuele verbindingen werden vele fysisch chemische eigenschappen 
(descriptors) berekend. Aan de hand van de gegenereerde data werd onderzocht 
welke (sub)set van 50 verbindingen de grootste chemische diversiteit 
beschreven. De geselecteerde verbindingen moesten ook voldoen aan stricte 
eigenschappen waaraan medicijnen in het algemeen lijken te voldoen. 
Vervolgens werd deze set van verbindingen gesynthetiseerd via parallele 
synthese technieken. Dit resulteerde in de isolatie van 18 eindproducten. 
Farmacologische karakterisatie van deze verbindingen resulteerde in een nieuwe 
inverse agonist voor US28. Alle andere gesynthetiseerde verbindingen hadden 
geen affiniteit of activiteit op de receptor.  
 
In hoofdstuk 5 wordt onze zoektocht naar nieuwe chemotypes voortgezet door 
een database van verbindingen te screenen op US28. De moleculen werden 
geselecteerd op basis van de overeenkomsten die ze hebben met andere 
bekende US28-liganden. Het onderzoek in dit hoofdstuk leidde tot de 
identificatie van verschillende interessante liganden, waarvan enkelen werden 
gekozen als nieuw startpunt voor lead optimalisatie (zie hoofdstuk 6 en 7). 
Bovendien werden de twee allereerste neutrale antagonisten voor een viraal 
gecodeerde receptor (US28) ontdekt, namelijk 5-(3-(4-methylpiperazin-1-
yl)propyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine (A194) en 2-phenyl-
1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine (B191). Deze twee 
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moleculen dienen als nieuwe farmacologische tools om de eigenschappen van 
US28 verder te onderzoeken. 
 
Hoofdstuk 6 beschrijft de lead optimalisatie en structuur-activiteitsrelaties van 
een aantal verbindingen die als hits uit de database screening kwamen (zie 
hoofdstuk 5). Synthese van een hybride verbinding (VUF10000), die zowel 
belangrijke structuur 
eigenschappen van de 
inverse agonist VUF2274 
als van de neutrale 
antagonist A194 bevat (zie 
figuur), en de 
farmacologische evaluatie 
liet zien that het 
vervangen van de N-
methylpiperazine ring van 
A194 door de 4-(4-
chlorophenyl)-piperidin-4-
ol groep van VUF2274 leidde tot de voorziene herstel van de inverse 
agonistische eigenschappen. We hebben dus die moleculaire eigenschappen 
kunnen bepalen die verantwoordelijk zijn voor de intrinsieke activiteit, en dan 
voornamelijk voor inverse agonisme ten opzichte van antagonisme. Bovendien 
leidde deze aanpassing in de structuur tot de meest potente verbinding die ooit 
beschreven is op US28 met een 7 keer hogere bindingsaffiniteit dan VUF2274 en 
A194. Deze liganden geven een beter inzicht in de ligand-receptor interacties en 
de eisen waaraan de structuur van een molecuul moet voldoen voor neutraal 
antagonisme en inverse agonisme. Daarnaast kan de mogelijkheid om de 
functionele activiteit op US28 te reguleren ons helpen om het belang van de 
constitutieve signalering en de rol van US28 tijdens infectie met HCMV te 
onderzoeken. 
 
Screening van onze eigen bibliotheek van verbindingen, zoals beschreven in 
hoofdstuk 5, resulteerde in de identificatie van 2-(2,4-dichlorobenzyl)-2,3-
dihydro-1H-inden-1-amine (Z193) als een nieuwe inverse agonist voor US28. 
N
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Hoofdstuk 7 beschrijft de optimalisatie van dit molecuul door de twee 
chlooratomen te vervangen door andere substituenten. Daarnaast werden 
verschillende cyclische ring systemen en kleine groepen geïntroduceerd op het 
stikstofatoom. De synthese en farmacologische karakterisatie van deze 
verbindingen resulteerde in de eerste structuur-activiteitsrelaties van deze 
nieuwe groep van inverse agonisten. 
 
Dit proefschrift heeft een beschrijving gegeven van de ontwerp en synthese van 
kleine liganden liganden voor de viraal gecodeerde receptor US28 via 
multidisciplinaire benaderingen, zoals lead optimimalisatie, screening van een 
bibliotheek van verbindingen en moleculaire design technieken. In dit onderzoek 
zijn zowel nieuwe inverse agonisten als neutrale antagonisten geïdentificeerd, 
die ons meer inzicht hebben geven in de eigenschappen waaraan een molecuul 
moet voldoen voor binding en functionele activiteit op US28. Uiteindelijk zal 
deze kennis ons verder helpen om liganden met een hogere activiteit en betere 
selectiviteit te ontwikkelen. 
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met je eens, maar je enthousiasme en goede ideëen hebben mij vele malen 
geïnspireerd.  
 
Voor het beoordelen van dit proefschrift wil ik de leden van de leescommissie 
bedanken. Ook de leden van de STW gebruikerscommissie wil ik hierbij 
bedanken voor de bijdrage die ze hebben geleverd aan mijn onderzoek.  
 
Belangrijk zijn natuurlijk ook alle studenten die in meer of mindere mate hebben 
bijgedragen aan mijn proefschrift. Leena, thank you for the great time that we 
had. You were the one and only Grignard specialist, which resulted in a nice 
selection of compounds described in Chapter 2. Oscar en Sibel, met jullie komst 
was het gedaan met de rust op het lab en het was altijd heerlijk om jullie 
gekibbel aan te horen. Gelukkig ging dat niet ten koste van jullie werk en jullie 
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inzet heeft een belangrijke bijdrage geleverd aan hoofdstuk 3 en 4. Rana, jij 
nam niet alleen je enthousiasme en motivatie mee van de UvA, maar ook je hele 
hardrock CD selectie. Bedankt voor de vele discussies en interessante 
gesprekken die we hebben gevoerd. Jane, het caribische lachebekje met de 
mooie ballonnetjes, bedankt voor alle inspanningen die je hebt geleverd aan 
hoofdstuk 7. Door jou weet ik nu ook een snelle manier om een paar mooie 
mannen naar ons lab te lokken. Gewoon een TLC plaatje droogblazen onder de 
brandmelder en ze staan zo voor de deur!  
 
Daarnaast wil ik ook nog een aantal medewerkers bedanken. Henk, bedankt 
voor alle lunch besprekingen en de begeleiding aan het begin van mijn promotie 
onderzoek. Wiro, bedankt voor al je hulp toen ik als beginnende AIO op de 
afdeling kwam en voor alle keren daarna dat je even tijd voor me vrijmaakte als 
ik langskwam met een synthese- of ander probleem. Mark, bedankt voor alles 
wat je hebt bijgedragen aan mijn onderzoek. Je naam prijkt boven menig 
hoofdstuk en daarnaast heb je ook nog vele projecten gedaan die het niet tot dit 
proefschrift hebben gered. Bedankt ook voor de vele discussies die we hebben 
gevoerd, waarvan de meesten toch gingen over onze (zeer) uiteenlopende 
muzieksmaak. Dan maar weer Franky B, joepie! Henry, bedankt voor de goede 
samenwerking, die heeft geleid tot een bonte verzameling van presentaties, 
posters, artikelen en hoofdstukken. Ik zal jouw manier van communiceren, 
inclusief karatetrappen en bijnamen (Heeeeeeeey Wuppie), zeker missen. 
Bedankt ook dat je mijn paranimf wil zijn, een goed excuus om je voor een keer 
je pet af te laten zetten! Silvina en Saskia, thank you for all the pharmacological 
experiments that you did for me. Frans, bedankt voor de enorme hoeveelheid 
NMR metingen die je voor me hebt gedaan en alle hulp met de interpretatie van 
de spectra. Marek, thank you for doing all the HRMS measurements. Natuurlijk 
mag ik onze secretaresse ook niet vergeten. Laura, bedankt voor al je hulp, niet 
alleen tijdens mijn periode op de VU maar ook daarna tijdens het afronden van 
mijn proefschrift. Tenslotte hebben ook een aantal mensen buiten de VU 
bijgedragen aan dit proefschrift. David Lloyd, thank you for giving me the 
opportunity to learn molecular modelling at Trinity College. I would also like to 
thank the other members of his group for the nice time in Dublin.  
 
Dankwoord 
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Gelukkig was het niet alleen hard werken op de VU, maar was er ook genoeg 
afleiding tijdens de koffiepauzes, lunch-sessies, borrels en uitjes. Allereerst wil ik 
daarom al mijn collega’s van de synthese afdeling bedanken voor alle leuke 
momenten die we samen hebben gehad: Andrea, Bas-Jan, Edith, Erwin, 
Gerdien, Marinella, Stefania, Ruengwit, Maikel, Sjef, Elwin, Cindy, Rogier, Ewald 
en Janneke. Ik kon altijd bij jullie terecht met de meest onmogelijke vragen of 
gewoon om even mijn hart te luchten en/of een babbeltje te maken. Daarnaast 
wil ik ook een aantal andere collega’s bedanken die mijn verblijf op de VU tot 
een fantastische tijd hebben gemaakt: Aldo, Atilla, Carlos, Chris, Dennis, David, 
Gerold, Jane, Jeroen, Jib, Peter, Marcel, Marola, Martijn, Obbe, Richard en Rico. 
Alle andere collega’s van FAR, Altana, ACAS en OAC, bedankt voor jullie 
gezelligheid op de borrels en de leuke gesprekken op de gang. Daarnaast wil ik 
Joost en Arjen bedanken voor onze wekelijkse leuke en gezellige M1 lunch-
sessies.   
 
Atletiek was niet alleen de oorzaak dat ik vele malen kreupel over het lab 
strompelde, maar het gaf me ook de energie om alles van me af te zetten na 
een (frustrerende) lange werkdag. Vele mensen hebben ertoe bijgedragen dat ik 
elke keer weer met veel plezier naar de atletiekbaan ging, en daarvan mogen er 
een paar hier toch echt niet ontbreken. Anthony, door jouw positieve instelling 
heb ik de plezier in mijn sport teruggekregen en dat heeft me de motivatie 
gegeven om het (hinkstap)springen weer op te pakken. Angelina en Tony, 
bedankt voor alle goede gesprekken en jullie inspanningen op alle mogelijke 
fronten. Bram en Martien, het was heerlijk om na een lange werkdag met jullie 
slap te ouwehoeren en krom te liggen van het lachen.  
 
Tot slot wil ik mijn familie en vrienden bedanken. Allereerst wil ik natuurlijk mijn 
ouders en zusjes, Sijna, Tineke en Annie-Jo, bedanken voor simpelweg alles. 
Jullie hebben me altijd gesteund in alles waar ik mee bezig was en zonder jullie 
was ik nooit zover gekomen! Dennis en Davy, bedankt voor jullie gezelligheid 
tijdens alle familie aangelegenheden. Lieve Eline, je mama wilde geen Ram zoals 
tante Janneke, maar je was toen al zo eigenwijs dat je zelfs besloot geboren te 
worden op mijn verjaardag. Ik hoop dat we samen nog veel kattekwaad kunnen 
uithalen. 
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Moniek, jij kent me al bijna mijn hele leven en dat alleen is al bijzonder. Het 
maakt het nog specialer dat we nu al meer dan 25 jaar dikke vriendinnen zijn en 
als het aan mij ligt komen er nog vele jaren bij! Bedankt dat je mijn paranimf 
wil zijn en ik kijk al uit naar jouw promotie. Harold, bedankt voor je gezelligheid 
en al die keren dat je zo lekker voor me hebt gekookt. Oma Boot, bedankt voor 
de fantastische tijd die we hebben gehad op de boot en de leuke weekendjes en 
etentjes die we hebben gehad na het overlijden van Opa Boot. Ik hoop dat we 
nog lang van u kunnen genieten! Ingrid en Femke, mijn Guatemala vriendinnen, 
bedankt voor alle gezellige logeerpartijtjes, stapavonden, leuke gesprekken en 
de lol die we samen hebben gehad. Erik, Anu, Micaela, Sebastiaan, Nalan, Harry, 
Paola and Remko, thank you for all the nice dinners, drinks and the great trips 
to Istanbul, Brussels and Stockholm! 
 
Vati & Gloeske, Juliette en Oma Vuyk, bedankt voor jullie interesse en de 
gezellige etentjes die we samen hebben gehad. 
 
Lieve lieve Rogier, bedankt dat je er altijd voor me was, in goede en in slechte 
tijden. Je hebt me overal doorheen gesleept en me vele malen achter mijn 
laptop gezet als ik het even niet meer zag zitten. Zonder jou had ik het nooit 
gered! 
 
Met het afronden van mijn proefschrift is nu een nieuwe periode in mijn leven 
begonnen. Met veel voldoening zal ik terugkijken op mijn periode op de VU en 
vol goede moed en enthousiasme ga ik alle nieuwe uitdagingen aan die op me 
staan te wachten.  
 
  
  
